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Preface
The Swedish Criteria Group for Occupational Standards (SCG) of the Swedish
National Institute for Working Life (NIWL) has engaged Professor Staffan
Skerfving at the Department of Occupational and Environmental Medicine,
University Hospital, Lund, Sweden, to write this criteria document concerning
inorganic lead. Based on this document the Criteria Group will present a report to
be used as the scientific background material by the Swedish Work Environmet
Authority in their proposal for an occupational exposure limit.
Johan Högberg Johan Montelius
Chairman Secretary
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1Background
The literature on lead (Pb) is enormous. Pb is certainly the most extensively
studied toxic agent. A criteria document on inorganic Pb was written in 1991
(Skerfving 1992 and 1993). Since then, a wealth of new information has been
published. The intent of this update paper is to summarize this, mainly as a basis
for decisions on occupational exposure limits (OELs).
However, the review will not try to comprehensively cover all information;
rather it will focus on issues identified in the 1991 document to be critical for the
establishment of occupational exposure standards. In addition, some other new
information of importance for the risk assessment will be dwelt upon. The
documents covers information up to April 30, 2004.
Each section will start with a brief summary of the “state of the art 1991”, as
described in the criteria document (Skerfving 1992 and 1993). Then, new data
will be quoted and further treated in the section 10. Discussion and assessment.
Several reviews of the toxicology of inorganic Pb have occurred during the last
decade (eg, PIMs 1994; American Academy of Pediatrics 1995; Skerfving et al
1995; WHO/ICPS 1995 [contains references up to 1994]; Goyer 1996; US
ATSDR 1999; Landrigan et al 2000; WHO 2000b; US CDC 2002; RTECS 2003).
Concentrations will be given as presented in the papers, with one exception,
that blood-Pb concentrations (B-Pb) expressed in µg/dL (very common in the US)
have been changed to µg/L.
The number of decimals given for information on concentrations in the papers
have been kept, in spite of the fact that they are not always warranted by the
analytical technique. For bone-Pb, the negative values are sometimes obtained (ie,
lower than the standard) and reported in the papers (not to skew the distribution).
Also, the original number of decimals for effect estimates have been kept, in
spite of the sometimes large uncertainties.
21. Physical and chemical properties
Lead (Pb)
CAS registry number: 7439-92-1
Molecular weight: 207.19 (4 isotopes: 204, 206, 207 and 208).
Density: 11.3 g/cm3
Melting point: 327.5 °C
Boiling point: 1,740 °C
Valences: In its inorganic compounds, Pb usually has the oxidation
state +2, but +4 also occurs.
Conversions factors: 1 µg=0.004826 µmol. 1 µmol=207.2 µg.
Solubility: Metallic Pb is very insoluble, but will dissolve in nitric acid and
concentrated sulphuric acid. Most Pb (II) salts are difficult to dissolve (eg, Pb
sulphide and Pb oxides), with the exception for Pb nitrate, Pb chlorate, and – to
some extent – Pb sulphate and Pb chloride. In addition, some salts with organic
acids are insoluble, eg Pb oxalate.
Further information on physical and chemical properties of lead compounds
may be obtained in, eg, CRC Handbook of Chemistry and Physics (1989).
2. Exposure
2.1. State of the art 1991
In 1991 (Skerfving 1992 and 1993) it was noted, that the main origins of Pb is
occupational exposure, leaded gasoline, Pb paints, industrial Pb emissions, Pb
pipes and Pb solders in drinking water systems, cans with Pb-soldered side-seams,
Pb-glazed ceramic ware and hobby equipment.
In accordance with this, occupation, place of living, food, alcohol and smoking
habits and age, gender and socioeconomic status are determinants for the expo-
sure. Families of Pb workers are exposed in their homes through Pb uninten-
tionally brought home by the worker. Some exposure occurs through alcoholic
beverages and tobacco (including environmental tobacco smoke).
The main routes of Pb exposure in Sweden are food and - to a lesser extent - air.
In some other countries, ingestion of soil and dust by children are very important,
in some areas inhalation and ingestion of drinking water. Uptake of Pb occurs
through the gastrointestinal (GI) tract and inhalation.
It was estimated that an adult Swede, without occupational exposure, ingested
about 0.5 µg/kg/day (Skerfving 1992 and 1993). The “background” inhalation
exposure was far less. The exposure in modern man is two orders of magnitude
higher than in prehistoric subjects (Nubian skeletons).
32.2 Update
There seems to be some skin absorption of soluble Pb species (Stauber et al 1994).
Most of the information on exposure is based on measurements of the Pb
concentration in blood (B-Pb) (Skerfving et al 1993; WHO/ICPS 1995; WHO
1996). Hence, this will mainly be used as an index. The occupational exposure to
Pb in the Swedish work life decreased during the 1970s and 1980s. For example,
in a primary smelter the mean B-Pb in 1950 was 3.0 µmol/L, in 1987 1.6 µmol/L
(Lundström et al 1997). Further, in the register over legally prescribed surveys of
B-Pb in Pb-workers, the mean concentration was about 1.4 µmol/L in 1977, about
1 µmol/L in 1989 (Figure 1) (Swedish NBOSH 1993), although there may be a
sampling bias. In 1989, about 100 subjects in the four main exposing factories
were removed from exposure because of B-Pb ≥2.5 µmol/L (Järvholm 1996).
Unfortunately, after 1989, there is no national Swedish register.
After 1991, there has been a dramatic decrease of B-Pbs in the general Swedish
population (Strömberg et al 1995 and 2003; Bárány et al 2002b; Lundh et al 2002;
Wennberg et al, submitted), certainly mainly as a result of elimination of Pb from
gasoline. In accordance with this, the exposure gradient from the rural to urban
environment has decreased (Strömberg et al 2003).
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Figure 1. Blood lead levels 1977-89 in lead workers registered in the national Swedish
register (Swedish NBOSH 1993).
4Living close to a Swedish Pb-emitting industry (mining and smelting) may have
caused exposure in adults (Lagerkvist et al 1993; Hallén et al 1995) and children
(Strömberg et al 1995; Gerhardsson et al 1997a; Farago et al 1999), but it seems
that this has decreased (Berglund et al 1994 and 2000b; Strömberg et al 2003).
The impact of alcohol intake and smoking has been confirmed (Bensryd et al
1994; Micciolo et al 1994; Ehrlich et al 1998; Åkesson et al, submitted), including
that of environmental tobacco smoke (Willers et al 1992 and 1993; Osman et al
1998a; Berglund et al 2000b).
There has been an almost complete elimination of Pb-soldered side-seams in
food cans. As a curiosity, crystal glass may contaminate its liquid content (Nilsson
2002). Shooting at indoor firing ranges (Svensson et al 1992), as well as outdoor
hunting (Bensryd et al 1994) cause exposure to Pb. Gun bullet wounds may cause
a remarkable increase of B-Pb (Gerhardsson et al 2002).
Acid precipitation may cause an increase in the concentration of Pb in water
from private wells (Bensryd et al 1994; Gerhardsson et al 1997a; Rosborg et al
2003a and 2003b). However, there were no relationships between acidity of
drinking water or its Pb content, on the one hand, and B-Pb, on the other (Bensryd
et al 1994).
In 16 Swedish women having a mixed diet, the median fecal elimination of Pb
was 31 (range 14-118) µg/day (Vahter et al 1992). Since the GI absorption is low,
this should correspond to an ingestion of about 0.5 µg/kg body weight (bw)/day,
thus confirming the 1991 estimate. In other countries, food basket studies in the
1980s have indicated intakes up to 60 µg/kg bw/week (WHO 2000b). When there
were data for both children and adults, the former had a 2-3 times higher intake
than the latter.
A lot of the data on risks associated with Pb exposure relate to environmental
exposure in various other countries. Then, the exposure may be much higher. For
example, in Mexico City, the population of which has been studied frequently, the
exposure is high due to heavy traffic and high concentrations of Pb in the petrol
(Hernandez-Avila et al 1998) and consumption of foods cooked in Pb-glazed
pottery (Téllez-Rojo et al 2004). The exposure in some areas has decreased as a
result of reduction/elimination of Pb from gasoline (Thomas et al 1999; Ikeda et al
2000a and 2000b). Hence, the air concentration of Pb at selected monitoring sites
across the US decreased by 94% 1980-99 and by 60% 1990-99 (US EPA 1999;
US CDC 2003). In Sweden, the air-Pb now is a few ng/m3 (Nilsson 2003).
In areas, where the air levels of Pb were low, food is the dominating source
of Pb uptake, while high air concentration mean that half of the absorbed amount
originated from inhalation (Ikeda et al 2000a).
Pb plumbing (leaded water pipes and Pb-soldered joints) in the drinking-water
system may still be a problem (Potula et al 1999; Fertmann et al 2004), as may
living close to Pb-emitting industries (Bernard et al 1995; Osman et al 1998a;
Skerfving et al 1999; Counter et al 2000; Fischer et al 2003; Wasserman et al
2003). Also, dust and soil contaminated by deteriorating Pb-based paint is a major
concern (Elhelu et al 1995; Mielke & Reagan 1998; Manton et al 2000; Haynes et
al 2003). Pb-glazed low-temperature fired ceramic pottery is a problem in some
5countries (Brown et al 2000; Hernandez-Avila et al 1996). In the last decade,
heavy non-occupational exposure through cosmetics and herbal preparations in
some population strata have been stressed (Markowitz et al 1994). In 1979-1998
there were 200 deaths from Pb poisoning in the US (Kaufmann et al 2003). The
rate had decreased during the period. Ingestion of “moonshine” (illegally pro-
duced whiskey) and Pb paint (in children) and occupational poisoning were major
causes in 1979-1988 (Staes et al 1995).
“Background”/”reference”/”normal” concentrations for B-Pb are discussed
below (section 3.1. Blood lead).
2.3. Summary
In Sweden, the occupational exposure to Pb has decreased in the last decades, as
has exposure from leaded gasoline. The main route of Pb exposure in the general
population in Sweden is food. Alcohol beverages, smoking and drinking water are
other sources of background exposure. Acid precipitation increases Pb in well
water. Swedes ingest about 0.5 µg/kg bw/day, which is a low figure from an
international point of view.
In other geographical areas, occupation, industrial Pb emissions, dust from Pb-
paints, Pb pipes for drinking water, Pb-soldered cans and Pb-glazed ceramicware
are important sources.
3. Metabolism and biomonitoring
3.1. Blood lead
3.1.1. State of the art 1991
B-Pb is traditionally used for biomonitoring of Pb (Skerfving et al 1993). In 1991
(Skerfving 1992 and 1993), it was noted that other indices [urinary-Pb=U-Pb,
chelated Pb (sometimes called mobilized Pb=MPb) and bone-Pb] had been used,
but only to a limited extent. Serum/plasma-Pb (S-Pb/P-Pb) has some advantages
over B-Pb, but the analytical problems were great. As regards B-Pb, it was
stressed that: (1) The relationship between uptake and B-Pb is not rectilinear,
the relative increase of B-Pb decreases with rising exposure. This is probably the
reason why some effects (eg, on heme metabolism) display non-linear relation-
ships with B-Pb; it does not mean that there is a threshold. (2) There is a large
inter-individual variation in kinetics of B-Pb. (3) There also seemed to be a great
variation in the effects suffered by different individuals at the same B-Pb. There
were some indications that this might be due to variations in binding of Pb.
The “background” B-Pb in Swedish males in 1991 was assumed to be about
0.4 µmol/L, somewhat lower in females. In an international perspective, these
were low concentrations.
63.1.2. Update
3.1.2.1. Erythrocytes/whole blood
δ-Aminolevulinic acid dehydratase (ALAD; porphobilinogen synthase=PBGS;
EC 4.2.1.24) is an enzyme present in all cells, including the erythrocytes (review:
Kelada et al 2001). It is the second enzyme in the heme pathway, promoting the
asymmetric addition of two molecules of δ-aminolevulinic acid (ALA) to form
the monopyrrole porphobilinogen. ALAD is a 250 kDa homo-octameric enzyme,
containing four active sites, reactive cysteines, and two different types of zinc
(Zn)-binding sites (Jaffe et al 2000). Pb can replace some of the Zn (Jaffe et al
2001); the binding of Pb is about 20 times tighter than for Zn (Simons 1995).
The association of Pb causes slow-acting inhibition of the enzyme activity.
In the red cells, ALAD binds about 80% of the Pb (Bergdahl et al 1996 and
1998b; Bergdahl 1998). However, the binding capacity is limited. This is the
explanation of the well-known non-rectilinearity of the relationship between
B-Pb and exposure (Skerfving et al 1993). Other proteins in the erythrocyte also
bind Pb, though to a much lesser extent (Bergdahl et al 1998b). Hence, a 45-kDa
protein carries only about 20% of the B-Pb and a <10 kDa one <1%, while no
binding to hemoglobin was found.
In northern Sweden, the range of Pb in erythrocytes (Ery-Pb) in adults (age
25-74) in the period 1990-1999 was 11-750 µg/L; the median in males was 63,
in females 45 µg/L (Lundh et al 2002; Wennberg et al, submitted). The highest
median concentration (71 µg/L) was seen among males in the age stratum 45-54
years. If one assumes a 45% packed cell volume, this corresponds to a B-Pb of
29 µg/L. The Ery-Pb was higher in men than in women (maximum median
52 µg/L at age 55-64).
In 176 men and 248 women from central Sweden, the B-Pb was lower at 50
than at 70 years of age; after 70, there was an increase, probably because of higher
exposure 10-30 years ago, which had been retained in the skeleton (Baecklund et
al 1999). In 730 women aged 53-64 years from the south of Sweden sampled in
1997, the median B-Pb was 22 (range 7-81) µg/L (Åkesson et al, submitted).
Further, in 762 elderly (age above 75, mean 88.2±4.9 years), subjects from
Stockholm city, the average B-Pb was 0.18  ±0.11 (range 0.01-1.41) µmol/L
(Nordberg et al 2000). Men had higher B-Pb than women (0.22 vs. 0.17 µmol/L,
respectively).
In 314 15-year-old adolescents from Central Sweden (Uppsala and Trollhättan),
the median B-Pb 1993/94 was 16 (range 3.5-170) µg/L (Bárány et al 2002a;
Bárány & Oskarsson 2002). Boys had higher B-Pb than girls (medians 20 vs 15
µg/L) (Bárány et al 2002b). In 7-year-old children sampled in southern Sweden
1995-2001, the geometric mean B-Pb was 21 (range 6-80) µg/L (Strömberg et al
2003).
B-Pbs have decreased in many countries during the last decades (Skerfving et al
1999; Thomas et al 1999; Meyer et al 2003b). Hence in Sweden, the decrease has
been about 6% per year in both children in the south (Strömberg et al 1995 and
72003), see Figure 2, and adults in the north (Lundh 2002; Wennberg et al,
submitted); there was also a decrease in adolescents (Bárány et al 2000b). The
decrease is parallel to the elimination of leaded gasoline (Strömberg et al 1995
and 2003). Decays of B-Pb have also been reported in Germany (Meyer et al
2003a), Poland (Jarosinska & Rogan 2003) and the United Kingdom (UK)
(Delves et al 1996) and the US (Pirkle et al 1998). In some areas, it has been
shown, that the decrease reflects air-Pb concentrations (Thomas et al 1999).
Figure 2. Blood lead levels (geometric means and ranges, which have been truncated
at 83 µg/L) in 3,306 Swedish children 1978-2003 (Landskrona=squares, Trelleborg=
triangles) (Strömberg et al 2003 and to be published).
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8Table 1. Blood lead concentrations in urban children and adults (B-Pb, in different areas,
WHO regions) (Fewtrell et al 2004).
         B-Pb (µg/L)
Area
WHO
region
Surveyed
countries Children    Adults
Africa D Nigeria 111 116
E South Africa 98 104
Americas A Canada, USA 22 17
B Argentina, Brazil, Chile, Jamaica,
Mexico, Uruguay, Venezuela
70 85
D Ecuador, Nicaragua, Peru 90 108
B Saudi Arabia 68 68Eastern
Mediterranean D Egypt, Morocco, Pakistan 154 154
Europe A Denmark, France, Germany,
Greece, Israel, Sweden
35 37
B Turkey, Yugoslavia 58 92
C Hungary, Russia 67 67
B Indonesia, Thailand 74 74South East
Asia D Bangladesh, India 74 98
A Australia, Japan, New Zealand,
Singapore
27 27Western
Pacific
B China, Philippines, Korea 66 36
In a review of B-Pbs measured in different regions, there was a remarkable
variation, with one order of magnitude (Fewtrell et al 2004), see Table 1.
However, in many countries, the B-Pbs are still high. Some examples: Even in
the Baltic area, there are considerable variations (Skerfving et al 1999). Hence, in
some geographical areas, the B-Pbs are high: In the Katowice area, Poland, the
median B-Pb in children was 0.27 (range 0.09-1.9) µmol/L (Osman et al 1998a).
In some areas of Kosovo, the median B-Pb in children is 120 (range 42-260) µg/L
(Gerhardsson et al 2001). In Montevideo, Uruguay, the mean B-Pb was 96 (range
47-191) µg/L (Schütz et al 1997). In the Ecuadorian Andes, B-Pbs up to 1,100
µg/L were encountered in children in families engaged in tile production (Counter
et al 1997; Vahter et al 1997).
In samples obtained 1999-2000 (National Health and Nutrition Examination
Survey III=NHANES III) in adult US males, the median B-Pb was 18 and in
females 13 µg/L (US CDC 2003). In US children aged 1-5 years, the median was
27 µg/L; however, 4.4% had ≥100 µg/L (Pirkle et al 1998). There was a gradient
from non-hispanic whites, over Mexican Americans to non-hispanic blacks. High
levels occur in urban settings, old buildings, lower socioeconomic groups, immi-
grants and refugees. (Kaufmann et al 2000). In many areas, the fraction of child-
ren with B-Pb ≥100 µg/L is high. Hence, in New Orleans, Louisiana, USA, 29%
had such concentrations (Rabito et al 2003), in Wuxi City 27% (Gao et al 2001),
9in Johannesburg, South Africa 78% (Mathee et al 2002) and in Dhaka,
Bangladesh, 87% (Kaiser et al 2001).
Guidelines for sampling (Cornelis et al 1996) and presentation of “normal”
values for toxic metals in blood and urine (Vesterberg et al 1992) have been
published, as well as reference values for B-Pb (Gerhardsson et al 1996; Ewers et
al 1999; Herber 1999). However, it was not possible to establish generally valid
reference values for B-Pb. The B-Pbs are widely distributed within any popula-
tion, and generally appear to have a log-normal distribution, which is skewed
towards higher concentrations. As a result, many people are exposed to high
concentrations of Pb, even when the mean is low.
There is some diurnal variation in B-Pb, with the lowest values in the night
(Yokoyama et al 2000; Soldin et al 2003). In children, season of sampling for
B-Pb seems to be of importance (higher in summer) (Mielke & Reagan 1998;
Gulson et al 2000a; Kaufmann et al 2000), probably mainly because the varying
fraction of time they spend outside.
B-Pbs were associated with the serum level of selenium (Se) (Osman et al
1998b; Bárány et al 2002c), as well as with glutathion peroxidase and seleno-
protein P in serum (Osman et al 1998b). This may indicate an effect of Se on Pb
metabolism, which may be of particular interest in Sweden, since it is a Se-
deficient area.
The relationship between B-Pb and skeletal Pb is discussed below (Section 3.2.
Skeletal/bone lead).
3.1.2.2. Plasma/serum
Pb is present in blood plasma and serum (P-Pb/S-Pb). The P-Pb makes up only
about 1% of the total B-Pb (Schütz et al 1996; Bergdahl et al 1998b and 1999;
Skerfving et al 1998; Smith et al 1998; Hernandez-Avila et al 1998; Bárány et al
2002c; Bergdahl 2002; Smith et al 2002).
In plasma, most of the Pb has been claimed to be present in a low molecular
weight fraction, supposed to represent an ionic form (Sakai et al 1998). Possibly,
some of the Pb is bound to cystein, which is in accordance with in vitro binding
(Al-Modhefer et al 1991). Also, there is some binding to a high molecular weight
protein, which is neither globulin, nor albumin, in spite of in vitro binding to the
latter.
Serum/plasma is readily transported to target organs and may thus constitute
the majority of the bioavailable Pb in the circulation. This should make S-Pb/P-Pb
optimal measures of exposure and risk. However, because of the low concentra-
tions, determination of Pb in plasma/serum has long been analytically compli-
cated.
However, the development of inductively-induced plasma mass spectrometry
(ICP-MS) has made determinations sensitive (detection limit about 0.01 µg/L),
accurate and relatively simple (Schütz 1993; Schütz et al 1996; Bárány et al 1997;
Smith et al 1998). For example, in 43 Swedish Pb-smelter workers, the median P-
Pb was 1.2 (range 0.3-3.6) µg/L, while the B-Pb was 281 (60-530) µg/L. In seven
unexposed controls, the corresponding values were 0.15 (0.1-0.3) and 40 (24-59)
10
µg/L, respectively (Schütz et al 1996). Contamination at sampling or analysis
is no major problem. However, severe hemolysis may cause spuriously high
concentrations (Smith et al 1998; Bergdahl et al, submitted). There was no swift
variation from day-to-day depending on the variations in exposure.
As said above, because of the saturation of ALAD binding, the relationship
between B-Pb and P-Pb is non-rectilinear (Bergdahl et al 1997c; Smith et al
2002). Possibly, the B-Pb/P-Pb relationship varies between individuals (Hedmer
et al 2001; Smith et al 2002; Bergdahl et al, submitted).
P-Pb after chelation has been proposed as an index of body burden (Sakai et al
1998), but has only occasionally been used.
3.1.3. Summary
Traditionally, B-Pb is used for biomonitoring of Pb. A major advantage of B-Pb is
the wealth of information. However, it has problems: (1) The relationship between
uptake (and effects) and B-Pb is not rectilinear. (2) There is a large inter-individ-
ual variation in kinetics of B-Pb.
There has been a dramatic decrease of B-Pb during the last decades. The “back-
ground” average B-Pb in adult Swedish males is now about 0.15 µmol/L, lower in
females, adolescents and children. In an international perspective, these are low
concentrations.
In the erythrocytes, Pb is mainly bound to the enzyme ALAD. The binding
capacity is limited, which is the explanation of the non-linear behaviour of B-Pb.
Serum/plasma-Pb (S-Pb/P-Pb) amount to only 1% of the B-Pb. They have some
advantages over B-Pb (closer relation to target tissue concentration). The analyti-
cal problems are no longer unsurpassable. However, there is still limited
information. Hence, we have to rely on B-Pb.
3.2. Skeletal/bone lead
3.2.1. State of the art 1991
In 1991 (Skerfving 1992 and 1993), it was concluded, that Pb accumulates in the
skeleton, which contains several Pb pools; trabecular bone has a faster turnover
than cortical. Pb is released from the skeleton, whereby it may cause endogenous
exposure, which may go on for decades after end of occupational exposure, and
may be responsible for a major fraction of B-Pb. The bone-Pb might constitute a
risk of poisoning, if rapidly released. Thus, skeletal accumulation should be
avoided, especially in girls and fertile women, since it will cause exposure of the
fetus and breast-fed infant. Also, there were indications of a mobilization of Pb
from the skeleton at menopause.
3.2.2. Update
Methods for in vivo measurement of Pb by K-shell X-ray fluorescence (XRF) in
fingerbone (Skerfving & Nilsson 1992; Nilsson & Skerfving 1993; Mattsson et al
2002), cortical tibia (Erkkilä et al 1992; Todd & Chettle 1994), as well as the
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mainly trabecular bones, calcaneus (Erkkilä et al 1992; Todd & Chettle 1994),
and patella (Hu et al 1991, 1996c and 1998; Watanabe et al 1994) have been
extensively used in the last decade. Occasionally, determinations have been
reported for ulna and sternum, but the measurements were less precise (Erkkilä et
al 1992). There is a reasonably good correlation between the different bone sites
(Gerhardsson et al 1992; Erkkilä et al 1992; Tell et al 1992). The concentrations
in tibia and calcaneus may be used to calculate the total bone Pb burden, which
averaged about 100 mg in Pb workers and 8 mg in occupationally unexposed
subjects (Erkkilä et al 1992). Measurements by L-shell XRF have been used
only occasionally, because of its inability to assess deep parts of the bone.
A long series of studies of bone-Pb in Pb workers have been published in
the last decade (eg, Erkkilä et al 1992; Gerhardsson et al 1992, 1993 and 1998;
Börjesson et al 1997a and 1997b; Olsson et al 2000; Schütz et al, submitted).
Their levels are much higher than in occupationally unexposed subjects. Usually,
the highest concentrations have been recorded in retired workers, as compared to
active ones (Gerhardsson et al 1993), due to longer exposure duration and higher
exposure intensity (and the slow elimination of Pb from bone, see below!).
Also, many studies of bone-Pb in the general population have appeared (eg,
Gamblin et al 1994; Kosnett et al 1994; Hoppin et al 1995, 1997 and 2000; Hu et
al 1996b; Kim et al 1997; Roy et al 1997; Aro et al 2000; Wasserman et al 2003;
Lin et al 2004). Determinations are possible for tibia, calcaneus and patella, at
least in populations with a relatively high exposure. However, for fingerbone, the
sensitivity is not sufficient. The tibia-Pb in Canada was higher than in northern
Sweden and Finland, similar to southern Sweden, but lower than in England
(Roy et al 1997). There is an increase in bone-Pb with age (Kosnett et al 1994;
Watanabe et al 1994; Hu et al 1996b; Lin et al 2004).
There are associations between bone-Pb, on the one hand, and both B-Pb
(Erkkilä et al 1992; Börjesson et al 1997a and 1997b; Gerhardsson et al 1998;
Wasserman et al 2003) and S-Pb/P-Pb (Bergdahl et al 1998a; Gerhardsson et al
1998; Hernandez-Avila et al 1998), on the other. Women immigrating to
Australia, from areas where the exposure was to Pb of a different 206Pb/204Pb
ratio than that in Australia, have been studied for changes in the B-Pb isotopic
ratios (Gulson et al 1995). This confirmed that release from bone made up a
significant fraction (45-70%) of total B-Pb. Similar data have been published for
the US general population (Smith et al 1996). In Pb workers, about 1.7 µg/L per
µg/g bm in tibia seemed to originate from endogenous exposure (Bleecker et al
1995). The association between bone-Pb and B-Pb is particularly close in retired
workers, but less in active ones, in whom the current exposure is superimposed
on the endogenous one from bone (Erkkilä et al 1992; Gerhardsson et al 1992 and
1998; Börjesson et al 1997a and 1997b). It has been estimated, that a constant
occupational exposure corresponding to a B-Pb of 2.4 µmol/L for 38-63 years
would result in a B-Pb of 1 µmol/L after retirement (Erkkilä et al 1992).
Pb is lost from the bone by diffusion (heteroionic exchange), as well as by
resorption. The trabecular (spongy, eg, in calcaneus, patella and vertebrae) bone-
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Pb has a more rapid turnover than the cortical (Hu et al 1991 and 1998; Kim et al
1997). From relationships between tibia-Pb and calcaneus-Pb, on the one hand,
and time-integrated B-Pb, on the other, it was estimated that the half-times were
13 and 12 years, respectively. In a similar approach, the corresponding half-times
were 16 and 27 years (Gerhardsson et al 1992). In a recent study, the tibia-Pb half-
time was estimated to 15 (95% confidence interval=CI 9-55) years (Brito et al
2000). There are indications that young subjects have a shorter half-time than
older ones, and that high exposure means a slower turnover than a low (Brito et al
2000 and 2001). For fingerbone-Pb, the half-time was estimated to 5.2 (range 3.3-
13.3) (Börjesson et al 1997a) and 14 (Börjesson et al 1997b) years.
By direct, long-term measurement of finger-bone-Pb by XRF in Pb-workers for
up to 18 years after end of exposure, the half-time was 16 (95% confidence
interval=CI 12-23) years (Nilsson et al 1991). The corresponding decline of B-Pb
could be described by a three-exponential model, with half-times of 34 (29-41)
days, 1.2 (0.9-1.8) years and 13 (10-18) years, respectively, Figure 3 (Skerfving et
al 1993 and 1998) and Figure 4 (Skerfving et al, to be published). The fast
Exposure
Chelatable lead ∼2 % of BB
∼0.4 % of ΒΒ
t∼1 mo
∼8 % of ΒΒ
t∼1 mo
∼0.001 % of ΒΒ
∼23 % of ΒΒ
t∼min
t∼1 y
Blood
cells
Soft
tissues
Trabecular
bone
Cortical
(compact)
bone
∼69 % of ΒΒ
t∼decades
Urine Bile etc.
Excretion
Plasma
Figure 3. Metabolic compartment model for lead in an adult man (Skerfving et al 1995).
The figures shown for the percentage of body burden in different compartments are those
corresponding to approximately steady state conditions (ie, the situation after regular
exposure during long time). The areas of the boxes are not proportional to the sizes of the
compartments. “Chelatable lead” denotes the amount available for binding to a chelating
agent in a mobilization test. BB=total body burden; t=biological half time; y=year;
mo=month; min=minute.
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component definitely reflects soft tissues, the second probably trabecular bone
and the last one cortical bone.
In particular, evidence suggests mobilization of Pb from the skeleton during
bone demineralisation. Women loose as much as half of the trabecular bone and
a third of cortical peak bone mass during their later lifetime. Estrogen supplemen-
tation may decrease the Pb mobilization (Webber et al 1995; Korrick et al 2002;
Latorre et al 2003). Increased B-Pb has been observed during pregnancy and
lactation (section 8. Reproduction and effects in infants/small children), meno-
pause (Grandjean et al 1992; Lagerqvist et al 1993; Symanski et al 1995; Nielsen
et al 1998; Berglund et al 2000a; Hernandez-Avila et al 2000; Korrick et al 2002;
Latorre et al 2003), old age (Webber et al 1995; Tsaih et al 2001), thyreotoxicosis
(Goldman et al 1994) and primary hyperparathyroidism (Osterloh & Clark 1993).
Other bone disease may also increase the bone-Pb (Berlin et al 1995; Adachi et
al 1998).
There is a strong interaction between season and bone-Pb (patella) on B-Pb;
hence, the bone-Pb exerted an almost two-fold greater influence on B-Pb during
the winter months than in the summer (Oliviera et al 2002). The explanation was
supposed to be enhanced bone resorption, because of decreased exposure to
sunlight, resulting in lower levels of activated vitamin D.
Because of its slow turnover, bone-Pb reflects long-term Pb exposure (and
total body burden), which may be of importance for chronic toxicity. Hence, in
Pb workers, there were close correlations between tibial and calcaneal Pb, on the
one hand, and duration of exposure to inorganic (Todd et al 2001) and organic
(Swchwartz et al 1999) Pb and time-integrated B-Pb in workers exposed to
inorganic Pb (Bergdahl et al 1998a), on the other.
The relationships between exposure time, B-Pb and bone-Pb are described in
Figure 5. They are non-rectilinear (Fleming et al 1997; Brito et al 2002). When
recent exposure has been low, meaning a relatively low current B-Pb, a high bone-
Pb may indicate previous higher exposure, which may affect the relationship
between effects and B-Pb in the direction of an underestimate of risk.
In a study of bone-Pb, Cake et al (1996) found a somewhat stronger correlation
with S-Pb than with B-Pb. In accordance with this, among Mexicans, bone-Pb (in
particular trabecular) had a B-Pb-independent effect on P-Pb (Hernandez-Avila et
al 1998). Further, in pregnant women, estimated P-Pb varied independently of B-
Pb, and was assumed to be affected mainly by maternal bone-Pb (Chuang et al
2001).
On the basis of such observations, it has been speculated, that the endogenous
Pb from bone may cause a constant inflow of Pb into serum/plasma, which may
elevate the S-Pb/P-Pb continuously over extended periods of time, thus leading to
a great transfer of Pb into target organs and high P-Pb/B-Pb ratio (Cake et al 1996;
Hu et al 1998). In contrast, Pb from exogenous sources (ingested or inhaled),
which may enter the circulation in a discontinuous fashion, depending on the
exposure pattern, was believed to cause a lower target organ exposure and P-
Pb/B-Pb ratio. Similar conclusions were made on basis of studies of U-Pb,
which was used as a proxy for P-Pb (Tsaih et al 1999).
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Figure 5. Relation between bone (Bone-Pb) and blood (B-Pb) lead concentration,
assuming that the worker´s exposure is constant over time. It is assumed that the exposure
starts at age 17 years and that the B-Pb in an occupationally unexposed subject is 0.3
µmol/L (Börjesson et al 1997b).
However, no support for a preferential effect of bone-Pb on P-Pb was found,
neither in a study of B-Pb, P-Pb and bone-Pb among Swedish active and retired
smelter workers (Bergdahl & Skerfving 1997), nor in studies of Pb-isotope ratios
in pregnant and lactating women (Gulson et al 1998b, 2000b and 2003). This is
also in accordance with the rapid equilibrium between plasma and erythrocytes
(Simons 1993).
The above-mentioned observations, that S-Pb or P-Pb may reflect bone-Pb
better than B-Pb, or at least contribute in models of bone-Pb and B-Pb, have
a much simpler explanation in the fact that they are all inter-correlated. Any
exchange between bone and blood occurs via plasma. Therefore, in modelling
of bone-Pb, B-Pb is merely a proxy for P-Pb. Bearing in mind that P-Pb, at the
same B-Pb, can vary by a factor 2-3, it is natural that P-Pb contributes
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significantly in models of B-Pb and bone-Pb. Moreover, the curved relation
between B-Pb and P-Pb might be paralleled by a similarly non-rectilinear one
between B-Pb and bone-Pb (Brito et al 2002), which would invalid the linear
regression model. Hence, there is no evidence that the endogenous exposure
from bone-Pb should pose a threat different from the external one.
Deciduous tooth-Pb in children predicts bone-Pb decades later (Kim et al
1996a). Of course, the turnover is slow (Gulson and Gillings 1997). There was an
association between B-Pb and dental caries (Moss et al 1999; Gemmel et al 2002).
This might be because of Pb-modified enamel is more susceptible, but there are
several other possibilities, including residual confounding by socioeconomic
factors.
3.2.3. Summary
Pb accumulates in the skeleton, which contains about 95% of the body burden,
and which has several Pb pools; trabecular bone has a faster turnover (half-time
about one year) than cortical (half-time decades). Pb is released from the skeleton,
whereby it may cause endogenous exposure, which may go on for decades after
end of occupational exposure, and may be responsible for a major fraction of B-
Pb. It has been claimed, that P-Pb is particularly affected by this release; however,
this is far from well founded.
The bone-Pb might constitute a risk of poisoning, if rapidly released. Thus, Pb
accumulated in the skeleton of girls and fertile women, will cause considerable
exposure of fetuses and breast-fed infants. Also, there is mobilization of Pb from
the skeleton at menopause.
Skeletal Pb may be measured by in vivo XRF. There is a lot of information on
tibial, calcaneal and patellar Pb levels in Pb workers and general populations. The
bone-Pb reflects the long-term B-Pb pattern (time-integrated or cumulated B-Pb).
3.3. Urinary lead and chelatable lead
U-Pb has sometimes been used as a proxy for biomonitoring of exposure and risk
of Pb (Skerfving 1992 and 1993).
In a study of 646 women aged 52-63 years from the south of Sweden, there was
a relatively close association between B-Pb (median 22, range 11-46 µg/L) and U-
Pb (rS=0.67; p<0.0001) (Åkesson et al, submitted). However, the variation is too
large (Erkikilä et al 1992; Skerfving et al 1993; Bergdahl et al 1997c; Börjesson et
al 1997a and 1997b; Gulson et al 1998a; Paschal et al 1998; Fukui et al 1999;
Higashikawa et al 2000; Shimbo et al 2000), to allow a prediction on an individual
B-Pb from U-Pb. Also, the association, due to the above-mentioned saturation of
B-Pb, is non-linear (Fukui et al 1999; Tsaih et al 1999). Further, the necessary
adjustment for variations in dilution of spot samples is difficult to manage (Sata et
al 1995; Sata & Araki 1996); eg, the creatinine excretion, which is often used, is
dependent upon muscle mass. Also, there is some diurnal variation in the excre-
tion, with the lowest concentrations in the night, due to some diurnal variations
in P-Pb and in glomerular filtration rate (GFR) (Yokoyama et al 2000). Since
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creatinine excretion also varies in parallel, creatinine-adjusted U-Pb concentra-
tions vary less.
In contrast to B-Pb, P-Pb seems to be rectilinearly related to “basal” U-Pb
(Hirata et al 1995; Bergdahl et al 1997c; Gerhardsson et al 1998), as well as to
the urinary excretion of Pb after chelation (Gerhardsson et al 1999).
Urinary excretion of Pb after administration of a chelating agent has often been
used as an index of risk and total body burden. After administration of calcium
disodium ethylenediamine tetraacetic acid (EDTA), the P-Pb increases, because
of the presence of a Pb-EDTA complex, which is filtrated into urine (mobilized
Pb=M-U-Pb; chelatable Pb/chelated Pb/mobilized Pb) (Sakai et al 1998). After
such chelation there is only a marginal (6%) decrease of erythrocyte Pb (and thus
of B-Pb). The Pb excretions after the major chelating agents (EDTA and
dimercaptosuccinic acid (DMSA) differ (Lee et al 1995).
Chelatable Pb (Figure 3) has been used as an index of the total body burden.
However, it is not a good measure. It mainly reflects Pb concentrations in blood
and soft tissues (Tell et al 1992; Gerhardsson et al 1998; Schwartz et al 1999), and
possibly trabecular bone (Tell et al 1992), while it is not a good index of total
body burden, and thus not of long-term accumulation, which mainly occurs in
cortical bone. Accordingly, chelation did not cause any decrease of neither tibia-
Pb, nor calcaneus-Pb (Tell et al 1992). The bone-Pb available for chelation seems
to decrease with increasing age (Schwartz et al 1999; Todd et al 2001).
In summary, U-Pb has only been used to a limited extent, partly because of the
problems with adjustment for diuresis. However, U-Pb after administration of
chelating agents (chelatable Pb) has been fairly widely used as an index of risk
and the body burden. However, it does not reflect the bone-Pb, which is the major
pool. Further, the major advantage of chelation lies in the fact that it increases the
concentration of Pb in urine, which makes the Pb determination easier. However,
with modern analytical methods, this is no longer as important. Further, renal
impairment may decrease the excretion of the complex.
3.4. Other indices
Pb is excreted in the saliva, which is probably the explanation of the gingival Pb
seam sometimes seen in Pb workers (Skerfving 1992 and 1993). In Singaporean
Pb workers ,the mean B-Pb was 266 µg/L, while the saliva-Pb was only 0.77
µg/L; there was a non-rectilinear relationship, reflecting the saturation of B-Pb at
high exposure (Koh et al 2003). The authors conclude that saliva Pb should not be
used for biomonitoring. Pb is also excreted into sweat; there is a correlation with
B-Pb, although - as always in the case of B-Pb - non-rectilinear (Omokhodion &
Crockford 1991).
Pb grows out into hair (Skerfving 1992 and 1993). In Pb workers in Singapore
(GM B-Pb 341 µg/L), the GM hair-Pb was 641 µg/g (Foo et al 1993). There was
a correlation between hair-Pb and B-Pb, though non-linear. However, due to the
risk of external contamination, hair-Pb is not a reliable index of the internal dose.
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3.5. Toxicokinetics
3.5.1. State of the art 1991
In 1991 (Skerfving 1992 and 1993), it was noted, that there was a good deal of
data on the metabolism of Pb.
Of particular importance is the relationship between exposure and B-Pb,
as most of the information on exposure-response relationships relate to B-Pb.
Generally, in industry, there had been poor correlations between air-Pb measure-
ments and B-Pb, probably because: (1) Limited data on air-Pb concentrations.
(2) Most of the sampling had been of the area mode, not personal sampling in
the breathing zone of the worker. (3) Variations in particle sizes and solubility of
the Pb species. (4) The “background” Pb exposure (through food, water and air)
may vary. (5) Exposure through alcoholic beverages and tobacco had not been
accounted for. (6) Inter-individual variation in Pb metabolism had not been
considered. (7) The endogenous exposure from the skeletal Pb pool may be
of importance. (8) The curvilinear relationship between B-Pb and Pb exposure
(saturation of B-Pb at high exposures). Hence, other sources of information were
used. Then, a B-Pb of 1.5 µmol/L was estimated to correspond to an uptake of
700 µg/week.
As said above, the “background” B-Pb in Swedish males was assumed, at that
time, to be about 0.4 µmol/L, somewhat lower in females. The Swedish “back-
ground” uptake – mainly from foods, to some extent also from water, air and
tobacco – was about 35 µg/week. In other parts of the world, the “background” is
much higher. If 1.5 µmol/L should not be exceeded, the uptake from occupational
exposure should be ≤670 µg/week. If an occupational exposure was entirely
through inhalation, the particle size ≤1 µm (Pb fume), the pulmonary deposition
40% (which was assumed to be fully absorbed) and 60% of the Pb was cleared to
the GI tract (where 15% was absorbed), then the inhaled amount should be ≤1,370
µg/week. At an inhalation at work of 50 m3 per week (10 m3 per day in males),
this corresponds to about 30 µg/m3, and a B-Pb of 0.75 µmol/L to about 15 µg/m3.
The uncertainty of these estimates was stressed.
3.5.2. Update
3.5.2.1. Models
Since 1991, several advanced metabolic models have been presented - two
physiologically based pharmacokinetic (PBPK) models (Legett 1993; O´Flaherty
1993) and one classical compartment (US EPA 1994 and 2002) one. A simple
compartment model is presented in Figure 3.
The Legett (1993) model is an expansion of an International Commission on
Radiation Protection (ICRP 1993) age-specific one. It will not be discussed here.
In 1994, US Environmental Protection Agency published an “Integrated
Exposure Uptake Biokinetic Model for Lead in Children” (IEUBK), a detailed,
classical compartment model (US EPA 1994 and 2002; White et al 1998). In a
four-step process, it mathematically and statistically links several sources (soil,
house dust, drinking water, air and food) of environmental Pb exposure to B-Pb
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in children, 0-84 months of age. It takes into account indoor and outdoor air-Pb,
time spent outdoors, ventilation rate and lung absorption. The drinking-water data
includes the fraction of total water intake consumed as first draw and Pb concen-
tration in that, as well as flushed water, and the fraction consumed from fountains
and concentration in that. The GI bioavailability is expressed in relation to Pb
acetate in pigs. Also, the in utero transfer is estimated from maternal B-Pb. The
body compartments are lungs, GI tract, plasma/extracellular fluid, red blood cells,
kidney, liver, other soft tissues and trabecular and cortical bone. The elimination
occurs through urine, feces and skin/hair/nails. The transfer rates were based in
part on kinetic data in baboons. Certain non-linearities, specifically capacity-
limited binding in the red cell and absorption from the GI tract, are built into the
model.
The accuracy of the model in prediction of B-Pb has been verified (Choudhury
et al 1992). Further, a probabilistic (of exposure parameters) version has been
developed (Goodrum et al 1996). A key input in the model is the assumption of
the variability of B-Pb (expressed as geometric standard deviation) in populations
of children (Griffin et al 1999). The use of a high absorption rate (40-50%, even at
age 7), has been criticized (Gulson et al 1997a).
A PBPK model of Pb kinetics has been developed and validated for adults with
a wide range of exposures from a variety of sources (O´Flaherty 1993). It has been
supplemented with a Monte Carlo probabilistic module (Beck et al 2001). The
model has also been tested and calibrated for B-Pb in children (O´Flaherty 1995),
as well as bone-Pb in Pb workers (Fleming et al 1999). Both B-Pb and bone-Pb
are very labile in early childhood; they respond rapidly to increases in exposure,
and decrease almost as rapidly to near-preexposure concentrations, when exposure
returns to background levels (O´Flaherty 1995). From the peak in adolescence and
into early adulthood, the rate of bone turnover drops dramatically and, hence, the
ability to reverse bone-Pb accumulation relatively rapidly is lost.
Despite some qualitative and quantitative differences in Pb uptake, the
O´Flaherty and IEUBK models give predicted B-Pbs that are not greatly
dissimilar (O´Flaherty 1998). This is not unexpected, since both models were
calibrated against the same types of data for B-Pb in US urban children.
3.5.2.2. Relationship between lead concentrations in air and blood
In a series of studies, the relationship between B-Pb and air-Pb concentrations
have been scrutinized. Most studies show the well-established non-rectilinear
relationship, with a saturation of B-Pb at rising air-Pb (Figure 6). It is also obvious
that the curves vary between the studies. It seems that workers in Pb-battery
factories, where the exposure is to soluble Pb oxide and sulphate, have higher B-
Pb than crystal-glass industry-workers, where the Pb is less soluble. Most studies
entailed high air-Pb levels. However, US (Ulenbelt et al 1990; Hodgkins et al
1992) and Italian (Masci et al 1998) workers exposed at low intensities also fit. In
a study of 20 Spanish smelter workers, the slope of the curve is in accordance
with the figures in the low range (De Medinilla & Espigares 1991).
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When using the relationships specifically for Swedish occupational condi-
tions, one must consider the background exposure outside work, which is low in
Sweden, as compared to many other countries (Skerfving et al 1999). Also, the
endogenous exposure from the skeleton, caused by the Pb-exposure history,
affects the air-Pb/B-Pb relationship (Schwartz et al 1994 and 1995). Further,
the hygienic standard of the worker (in particular eating and smoking at work)
influences the B-Pb (Hodgkins et al 1992; Far et al 1993; Maheswaren et al 1993;
Chuang et al 1999). Hence, there may be a wide variation in the same factory of
B-Pb on air-Pb.
3.5.3. Summary
Several metabolic models for Pb have been designed and tested, both compart-
ment and physiologically-based ones. They allow prediction of concentrations
in biomarkers at varying exposure.
The models, as well as studies of occupationally exposed workers, show a non-
rectilinear relationship between air concentrations and B-Pb. This means that, at
the low air-Pbs relevant for the present Swedish exposure within and without
workplaces, even a minor increase in the exposure will cause a substantial
increase of B-Pb.
They also indicate a wide variation in the relationship, which is probably
mainly due to variations in particle sizes and solubility of the Pb species, exposure
through contaminated food and tobacco, as well as varying “background” expo-
sure. Also, there is an inter-individual variation in Pb metabolism. Because of the
accumulation of Pb in the skeleton, endogenous exposure from that pool will
differ between workers with varying exposure history.
The present “background” B-Pb in Swedish males is about 0.15 µmol/L, lower
in females, adolescents and children (Section 3.1. Blood lead). It seems that the
average Swedish worker would just not reach a B-Pb of 1.5 µmol/L if he is
exposed to 200 µg/m3 of Pb with low solubility (sulphide, dust from crystal glass,
etc) or to about 30 µg/m3 with high (sulphate, nitrate, etc), assuming small particle
sizes. However, there is a wide inter-interindividual variation of B-Pb at a certain
air-Pb.
3.6. Gene-environment interaction
3.6.1. State of the art 1991
In 1991 (Skerfving 1992 and 1993), it was noted that, in addition to the age-
and sex-related variations in vulnerability, there was a large inter-individual
differences in sensitivity to Pb, but the basis of this was largely unknown.
3.6.2. Update
Since 1991, a wealth of new information has been published on ALAD, which is
encoded by a single gene on chromosome 9q34. Human ALAD is a polymorphic
enzyme. Eight ALAD variants have been described. The allele contains a site-
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directed mutagenesis, a G→C transversion at position 177 of the coding region,
resulting in the substitution of asparagine for lysine at amino acid 59 (proteins
K59 and N59, respectively). These amino acids have different charges, and
electrophoretic separation may be used to identify the polymorphism, and the
phenotype of individuals. However, genotyping has mostly been employed. The
human ALAD gene was cloned and sequenced more than 20 years ago. The
enzymatic specific activity of K59 was twice that of N59 (Jaffe et al 2000).
The enzyme is codominant, in that both these alleles are expressed if a copy is
present. Hence, there are three distinct isoenzyme phenotypes: K59-K59 (ALAD
1-1), K59-N59 (ALAD 1-2) and N59-N59 (ALAD 2-2). Below, the first one will
be denoted as ALAD1, and the latter two as ALAD2. In Caucasian populations,
approximately 80% of the individuals have ALAD 1-1, 19% ALAD 1-2 and 1%
ALAD 2-2 (Bergdahl et al 1997b; Kelada et al 2001). Asian and African popu-
lations have lower frequencies of ALAD2.
As said above, ALAD is the major binding site for Pb in red cells (Bergdahl et
al 1996, 1997b and 1998b). Experimentally, there was neither differential
displacement of Zn by Pb for K59 relative to N59, nor inhibition of activity by Pb
(Jaffe et al 2000). However, in erythrocytes, the ALAD2 gene product seemed to
bind Pb more tightly than the ALAD1 one (Bergdahl et al 1997c). Hence, genetic
polymorphism in ALAD may affect the metabolism of Pb.
Among 1,051 environmentally exposed individuals (primarily children) in New
York City, ALAD2 subjects had higher B-Pb than ALAD1 ones (Wetmur et al 1991;
Wetmur 1994). However, the design of the study has been challenged. In a popu-
lation-based study of 660 Taiwanese subjects, ALAD2 subjects had higher B-Pb
than ALAD1 ones (78.3 vs 59.5 µg/L), but the difference was not statistically
significant (Hsieh et al 2000). This may be because of the relatively low B-Pb
and the few ALAD2 subjects.
In 202 German Pb-exposed workers, the ALAD2 subjects had higher B-Pb than
the ALAD1 ones (means 470 vs 384 µg/L) (Wetmur et al 1991). In accordance with
this, in 134 smelter workers, there was a (statistically non-significant) difference
in B-Pb between ALAD1 and ALAD2 subjects (means 231 vs 284 µg/L) (Alexander
et al 1998). Also, in 381 Canadian smelter workers, ALAD2 subjects had higher B-
Pb (means 251.8 vs 228.5 µg/L) and S-Pb than ALAD1 ones (Fleming et al 1998).
In another Korean battery plant (308 currently exposed workers), ALAD2 subjects
more often had high B-Pb, and they were 2.3 times more likely to have worked for
more than 6 years and, accordingly, they were over-represented in the workforce
(Schwartz et al 1995). The finding was confirmed in a study of 798 Korean Pb
workers and 135 unexposed controls (Schwartz et al 2000c).
However, the information is not consistent. Hence, in 726 middle-age and
elderly US men, ALAD2 subjects (mean B-Pb 62 µg/L) did not differ from ALAD1
ones (Hu et al 2001). Moreover, in 691 US construction workers (mean B-Pb only
77.8 µg/L), there was no difference in B-Pb (Smith et al 1995a). Further, in
another study, of Japanese Pb workers (N=192; 125 controls), there was no
ALAD-genotype dependent difference in B-Pb (Sakai et al 2000). Moreover,
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in 201 Japanese porcelain paint workers, there was no statistically significant
difference in B-Pb between ALAD2 and ALAD1 subjects (means 89, range 18-307
vs 78, range 14-270 µg/L) (Zhang et al 1998). Also, among 72 Turkish battery
workers, the 29.2% who were ALAD2 did not differ in B-Pb from ALAD1 ones
(means 349 vs 344 µg/L) (Süzen et al 2003). However, in the ALAD1 subjects,
the U-Pb was higher in relation to B-Pb, as compared to ALAD2 ones (means 78.5
vs 80.6 µg/g crea), though the difference was not statistically significant.
Any effect of ALAD genotype on Pb metabolism, might explain ethnic differ-
ences noted in B-Pb in a study of battery workers (Chia et al 1991). However,
there are other possible explanations. Further, gene-environment interactions, as
described above, may – at least partly - explain the association between B-Pbs
seen in women (but not in men) in a Swedish study of mono- and dizygotic twins
(Björkman et al 2000). The genetic influence was as high as 58%.
It has been hypothesized, that one link is via genetics of bone metabolism
(Vahter et al 2002). The ALAD genotype seems to affect the Pb kinetics in
calcified tissues. In US children, there were indications that ALAD2 subjects had
lower dentine-Pb (Bellinger et al 1994a). They also were less likely to have high
tibia-Pb. This is in accordance with a study of US middle-aged and elderly men,
in whom it also seemed that ALAD2 subjects had lower patella-Pb (but not tibia-
Pb) (Hu et al 2001). In accordance with this, in US cases of amyotrophic lateral
sclerosis (ALS; motor neuron disease) and referents, ALAD2 subjects had lower
patella-Pb and tibia-Pb (but did not differ in B-Pb) (Kamel et al 2003). Also,
another ALAD polymorphism was associated with low bone-Pb. In 122 US
construction workers, there were no ALAD-dependent differences in patella- or
tibia-Pbs (Smith et al 1995a). Also, in 89 Swedish Pb-smelter workers, there
was no polymorphism-dependent difference in B-Pb or bone-Pb (Bergdahl et al
1997a). Neither did, among 381 Canadian smelter workers ALAD genotype affect
tibia- or calcaneus-Pbs (Fleming et al 1998 and 1999). However, ALAD2 subjects
seemed to have a lower increase of bone-Pb on cumulated B-Pb. Hence, the
results differ between studied populations. This may be because the selection may
vary, depending on the exposure and health surveillance systems. Also, the effect
seems to be exposure-dependent.
In 57 Korean battery workers, the ALAD1 individuals had a higher urinary
excretion of Pb after DMSA-chelation (Schwartz et al 1997a). Studies in US
former organo-Pb workers (Schwartz et al 1997b) and Swedish smelter workers
(Gerhardsson et al 1999) corroborated this. Intriguingly, Schwartz et al (1997b)
claimed that creatinine clearance was an important predictor of the excretion and
that the ALAD genotype modified this interaction; ALAD2 subjects had larger
increase of chelated Pb with rising creatinine clearance.
There is a rare hereditary ALAD deficiency (for some reason denoted
plumboporphyria by some authors), which may constitute an inborn error of Pb
metabolism, making the subject vulnerable, and predispose for severe toxic effects
at relatively low exposure (and low B-Pb) (Dyer et al 1993).
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Among 57 Korean battery workers, ALAD1 subjects had higher hemoglobin A1
levels, which, in turn, was associated with high DMSA-chelatable Pb (Schwartz et
al 1997a). The authors concluded that hemoglobin A1 (in addition to ALAD)
binds Pb. However, as said above, Bergdahl et al (1998b) found no binding of Pb
to hemoglobin.
Calcium (Ca) status affects Pb absorption; this is mediated through Ca-binding
proteins, which are, in turn, affected by the blood-borne form of vitamin D
(calcitrol), which binds to the vitamin D receptor (VDR). In 781 Korean battery
workers, there was a difference in B-Pb between VDR genotypes (Lee et al
2001b). Also, there was a non-significant difference in bone-Pb. Interestingly, the
authors found an association between VDR and ALAD genotypes, which varied by
exposure status (but with no interaction). This may indicate a genotype selection.
Among 504 US former organo-Pb workers, the VDR genotype also modified the
kinetics of bone-Pb (Schwartz et al 2000a). However, in US cases of ALS and
referents, VDR polymorphism did not affect bone-Pb (Kamel et al 2003).
In 275 2-year old US children, there was an interaction between B-Pb and
polymorphism in the VDR-Fok1 gene; in those with the FF genotype, B-Pb
increased more with rising floor-dust Pb, than in Ff individuals; the ff subjects
were too few to allow firm conclusions (Haynes et al 2003). The authors thought
that the effect was due to Pb´s mimicry of Ca, and a more efficient Ca absorption
in FF subjects. B-Pb was inversely associated with B-Pb, but there was no
significant modification of this relationship by VDR genotype.
Low iron status increases the GI absorption of Pb. Hence, there is an inverse
relationship between iron intake (Cheng et al 1998b), serum ferritin (the iron-
transport protein) (Berglund et al 1994; Osman et al 1998b; Lundh et al 2002;
Wennberg et al, submitted; Bárány et al, submitted), and red cell mean corpus-
cular volume (Wrigth et al 1999 and 2003), on the one hand, and B-Pb, on the
other.
Subjects who were homozygous for the mutation which induces hereditary
hemochromatosis, with increased absorption of iron (and iron overload), had
increased B-Pb (homozygous 56, heterozygous 41 and wild-type 36 µg/L,
respectively) (Barton et al 1994). However, this finding was not corroborated
in a Swedish study; however, the B-Pbs were lower (Åkesson et al 2000).
3.6.3. Summary
For centuries it has been known, that there is a large inter-individual variation
in sensitivity to Pb, but the basis for this has been largely unknown. Possible
explanation of – at least some – this variation has now been revealed. ALAD,
which is a major binding site for Pb, is polymorphic. Two genotypes have been
focussed upon: ALAD1 (80% in the Swedish population) and ALAD2 (20%). It
seems that the gene product of ALAD2 binds Pb tighter than ALAD1, and that the
former subjects have higher B-Pb than the latter at the same exposure, at least at
high exposure intensities, and lower chelatable Pb. The tendency to reach higher
B-Pb may lead to an selection by a surveillance system based on B-Pb checks;
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workers with some ALAD genotypes may leave Pb-exposing workplaces. It is
likely, that the genotype affects the Pb accumulation pattern of the skeleton;
ALAD2 subjects accumulate less.
There are some indications of an interaction between polymorphism in the
VDR gene and B-Pb.
Subjects with iron deficiency (mainly women) absorb a larger fraction of
ingested Pb.
4. Organ effects
4.1. Nervous system
4.1.1. State of the art 1991
In 1991 (Skerfving 1992 and 1993), it was noted, that very severe Pb toxicity,
with clinical encephalopathy, may occur in some adults at B-Pbs about 4 µmol/L.
There was evidence of slight effects on the central nervous system (CNS; symp-
toms and neurobehavioural testing at exposures corresponding to B-Pbs of 2.5
µmol/L; limited data indicated effects already at 1.5 µmol/L). Infants are probably
more sensitive than adults. The health impacts of slight CNS effects were not fully
clear; however, it seems reasonable to consider them adverse.
Severe Pb exposure causes peripheral neuropathy with axonopathy. Slight
peripheral nerve dysfunction (reduced nerve conduction velocities at neuro-
physiological examination, but no signs or symptoms) may occur in adult
subjects; limited information indicated that this may occur at B-Pbs as low as
1.5 µmol/L. It was not known whether the reduced conduction velocities are really
subclinical signs of the clinical neuropathy - it might be that they signify a more
harmless disturbance of the ion transport over the cell membrane of the nerve cell.
Also, there were some indications of reversibility. However, in light of the severe
neuropathy that may affect heavily Pb exposed subjects, the conduction velocity
disturbances were considered adverse. Effect on the autonomic nerve system had
been recorded at similar B-Pbs.
4.1.2. Update
A wealth of new information has occurred since 1991. Several reviews have been
published (Spurgeon 1994; Balbus-Kornfeld et al 1995; Albers & Bromberg 1995;
Araki et al 2000; Meyer-Baron & Seeber 2000; Goodman et al 2001; Seeber et al
2002; Lidsky & Schneider 2003).
4.1.2.1. Central nervous system
Neuropsychological tests
Occupational exposure
A long series of studies of neurobehavioural CNS effects in Pb workers have been
published.
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Ehle and McKee (1990) reviewed 14 studies published 1978-86. The authors
concluded, that the data suggested that Pb-exposed workers, even at B-Pbs <600
µg/L, have more difficulty performing tasks that require: (1) attention/concentra-
tion/memory; (2) visuospatial and visuomotor skills; (3) speed of learning and
problem-solving ability; and that deficits appear to be associated with degree of
exposure. Further, it was considered possible, that increased irritability, fatigue,
tension, depressed mood and interpersonal problems were effects of Pb exposure.
As to psychomotor and psychophysiological testing (critical flicker fusion, eye
movements, reaction time and psychomotor performance), there was unsufficient
support of associations.
In 17 Japanes gun metal foundry workers (median B-Pb 400, range 300-640
µg/L) and 10 controls (B-Pb 120 µg/L), there was an association between B-Pb
and impaired performance in one out of a series of psychological tests (Yokoyama
et al 1988). At a second examination, 2 years later, when an exhaust ventilation
system had been introduced, and the B-Pb had decreased among the 11 most
heavily exposed workers (medians 460 to 380 µg/L), their performance in that test
had improved, while the others had not changed. This was claimed to indicate
reversibility.
When 70 UK male Pb workers (battery and printing industries; median B-Pb
about 300, range <20-800 µg/L) were followed for 8 months, those with B-Pb
in the range 410-800 µg/L performed less than the lower ones in sensory motor
reaction time and some cognitive tests and they had more difficulties in remem-
bering incidental information (Stollery et al 1991).
In 98 Belgian battery factory workers (mean 510, range 400-750 µg/L) and 85
“controls” (B-Pb 209, range 44-390 µg/L), there was no statistically significant
difference in flicker fusion (Gennart et al 1992a).
In 43 Venezuelian Pb smelter (mean B-Pb 2 µmol/L) and 45 “unexposed”
(B-Pb 0.73 µmol/L) workers, there were associations between current B-Pb (less
so with peak B-Pb or time-weighted B-Pb) and some aspects of a mood scale
(tension-anxiety, hostility, depression, difficulties in concentrating) and joint pain
(adjusted for age, education, alcohol intake, solvent exposure and exposed/unex-
posed status, which might have caused an over-adjustment), while a series of
neurobehavioural tests did not reveal clear associations (Maizlish et al 1995).
Among Canadian current (N=11) and former (N=30) smelter workers (mean
time-weighted B-Pb during an average of 52.51 months was 527.5, range 300-660
µg/L) and 37 “non-smelter workers” (B-Pb not given) there was no obvious
association between exposure, on the one hand, and cognitive and motor
functions, on the other (Braun & Daigneault 1991). However, most tests were
made after end of exposure, and there was a heavy selection of the examined
subjects.
In 109 German copper-smelter workers there was an association between
time-weighted averages of B-Pb (range about 190-570 µg/L) and air-Pb (average
0.14±0.11, range about 0.025-0.45 mg/m3) (Pfister et al 1994). At neuropsycho-
logical examination, there were no clear differences between the performance
in these workers (median B-Pb at time of examination 312, range about 90-590
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µg/L; median during the last 5 years 238±104 µg/L) and 27 unexposed workers
(assumed B-Pb about 50 µg/L). Possibly, the most heavily exposed workers
(average B-Pb >350 µg/L) performed less, but there was a selection.
Twenty-six German non-ferrous smelter workers (partly the same as above?;
mean B-Pb 377±71 µg/L; mean air-Pb 0.13±0.05 mg/m3) differed from 48
“unexposed controls” as regards psychoneurovegetative, neurologic, irritability
and concentration symptoms (Pfister et al 1999). Also, there was an association
between individual estimates of air-Pbs and symptoms. In neurobehavioural test
batteries, concentration and IQ differed (but not other tests); however, there were
indications of a pre-exposure difference in IQ.
In a study of 467 male current and former Canadian Pb workers, who were
employed in a Pb smelter, which had operated for 26 years, and in which, due
to hygienic measures and personal protection, the exposure had decreased
significantly 12 years ago, there were no associations between the current B-Pb
(mean 275, SD 84; range not given) µg/L or time-weighted average (TWA) B-Pb
and 13 neuropsychological tests (Lindgren et al 1996). However, the time-
integrated B-Pb (mean 7,652, range 6-16,257 µg/L x year) was associated with
impairment of five tests (visuomotor skill, psychomotor speed and dexterity
and verbal memory) after adjustment for age, education, alcohol use, and – less
obviously why - time of employment and depressive symptoms. The authors
suppose that the effect was due to previous high exposure. They do not give any
estimate of the corresponding B-Pb, but it seems that it should have been about
600 µg/L in average.
In a study of 80 of current Canadian smelter workers (partly the same?), there
were significant adjusted associations between B-Pb (mean 264, range 130-430
µg/L), TWA B-Pb, cumulated B-Pb and tibia-Pb (mean 41, range –12 to 90 µg/g
bm), on the one hand, and one to four out of five neuropsychological tests (verbal
and visuomotoric abilities), on the other (Bleecker et al 1997a). It seemed, that
young workers were less susceptible than older (ages 44-64) ones (effect at tibia-
Pb >20 µg/g bm).
In a Finnish study of 54 storage battery workers with well known exposure
to Pb (mean recent B-Pb 1.3±0.4 µmol/L; tibia-Pb 19.8±13.7, calcaneus-Pb
78.6±62.4 µg/g bone mineral=bm), those who had never exceeded 2.4 µmol/L
still had a decrement in visuospatial and visuomotor function, attention and verbal
comprehension (Hanninen et al 1998).
Several critical reviews of studies up to 1999 have been published. In a survey
of 21 studies of neurobehavioural testing in Pb-exposed, it was concluded, that the
best three ones indicated a greater effect of recent exposure (B-Pb) than of time-
integrated exposure (Balbus-Kornfeld et al 1995). In a summary of two meta-
analyses (including studies by Braun et al 1991; Bolla et al 1995; Lindgren et al
1996; Chia et al 1997; Maizlish et al 1995; Hanninen et al 1998; Pfister et al 1999;
quoted here), the authors concluded that “These test results provide evidence for
subtle deficits being associated with average blood lead levels between 370 and
520 µg/L.” (Seeber et al 2002). Critics were published (Goodman et al 2001). As
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a consequence, a third meta-analysis was made; the authors withheld their
conclusion (Seeber et al 2002).
In another review, about 140 studies were scrutinized, and 22 ones with B-Pb
<700 (B-Pb means 240-630 in exposed subjects, <280 in “unexposed” ones) µg/L
and 22 tests were selected on basis of strict criteria (information on potential
confounders, ia age, education and alcohol use) for a meta-analysis (Goodman et
al 2002). Only two of the tests showed unequivocal significant difference between
exposed and control groups. The results were sensitive to selection of studies,
inclusion or exclusion of tests, adjustment for reliability and choice of statistical
analysis. A problem was lack of control of the wide inter-personal variability (pre-
exposure capacity). Prospective studies were thus urged. This review has attracted
several comments, it has, eg, been accused of bias because of industrial funding
(Seeber & Meyer-Baron 2003; Schwartz et al 2002). In response to the critics the
authors made new approaches, but stayed with their conclusion (Goodman et al
2003).
Contrary, in another meta-analysis, which evaluated 12 tests, using similar
selection criteria, but with a different analytical approach, three of the tests
showed significant effects (Meyer-Baron & Seeber 2000). The authors concluded
that “The evidence of neurobehavioural deficits at a current blood lead concentra-
tion of ∼40 µg/100 ml is obvious”. The controversy well illustrates the problems
associated with evaluation of this kind of studies.
In a study of 50 Chinese Pb battery plant workers (geometric mean=GM B-Pb
371, range 132-646 µg/L) and 97 referents (B-Pb 61, range 24-124 µg/L), the
former had poorer performance in neurobehavioural tests (manual dexterity,
perceptual motor speed and motor steadiness in the WHO Neurobehavioural Core
Test Battery) (Chia et al 1997). The cumulated B-Pb correlated better than current
B-Pb with tests of perceptual and motor skill.
In a Swedish study, 38 male workers at a secondary smelter were divided into
a high (median fingerbone-Pb 32, range 17-101 µg/g; B-Pb 1.8, range 0.9-2.4
µmol/L) and a low (median fingerbone-Pb 16, range –7 to 49 µg/g; B-Pb 1.6,
range 0.8-2.6 µmol/L) bone-Pb group (Österberg et al 1997). Also, 19 referents
were studied (median fingerbone-Pb 4, range –4 to 18 µg/g; B-Pb 0.18, range
0.07-0.34 µmol/L). There were no association between the Pb exposure (including
time-integrated B-Pb) and results in a neuropsychological test battery.
In a study of 803 Korean workers (mean B-Pb 320±150 µg/L; tibia-Pb
37.1±40.3 µg/g bm) and 135 controls (mean B-Pb 53±18 µg/L; tibia-Pb 5.8±7.0
µg/g bm), there were associations between B-Pb and DMSA-chelatable Pb, on the
one hand, and some of the WHO neurobehavioural core battery tests, on the other
(Schwartz et al 2001). Tibia-Pb did not show such associations. In a fraction of
the workers, erythrocyte protein kinase C (PKC) activity modified the relation
between neurobehavioural test results and B-Pb (Hwang et al 2001). Further,
tibia-Pb (but not B-Pb) was associated with PKC (Hwang et al 2002).
47 German male battery plant workers (current mean B-Pb 308, range 106-621
µg/L, time-integrated B-Pb 4,6135, range 110-213,300 µg/L x year) differed in
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several neurobehavioural tests from 53 referents (steel workers; B-Pb 43.2, range
16-126 µg/L) (Barth et al 2002). There were associations between current B-Pb
and the cognitive tests, but not with time-integrated B-Pb.
General population
In adult middle-aged and elderly US general population men (mean B-Pb 55
µg/L, patella-Pb 31.7 and tibia-Pb 22.5 µg/g bm) men with higher B-Pb were
less good in cognitive tests than those with low (Payton et al 1998).
Stokes et al (1998) examined 281 young (age 19-29), who had from 9 months
to 9 years lived near a US Pb smelter, and 287 referents. Their current mean B-Pb
was 29 and 16 µg/L, respectively, tibia-Pb 4.6 vs. 0.6 µg/g bm. A fraction of the
exposed subjects had an average of 493 µg/L as infants/children. Almost all
adjusted results of a long series of tests of CNS function and symptoms were
poorer in the exposed than in the control group. However, there was a conside-
rable selection, and no significant associations with tiba-Pbs, which the authors
think is because of lack of precision in the tibia-Pb determinations, or to a lack of
correlation with the actual historical exposure.
In 762 elderly (age above 75, mean 88.2±4.9 years), subjects from Stockholm
city, there was no association between B-Pb (mean 0.18±0.11, range 0.01-1.41
µmol/L) and adjusted cognitive function (Mini-Mental State Examination=
MMSE) (Nordberg et al 2000).
In a construction carpenter, clinically severely Pb-poisoned through cutting
of steel while dismantling a bridge, EDTA-chelation therapy 2 years later was
claimed to improve neuropsychological tests and postural sway test performance
(Linz et al 1992). However, the causal relationship is doubtful.
Other effects
In a study of 60 Finnish Pb-battery workers, alpha and beta activities of the
electroencephalogram (EEG) were more abundant in subjects with higher long-
term exposure (Kovala et al 1997). Their mean current B-Pb was 1.3 (range 0.5-
2.2) µmol/L, time-integrated B-Pb 26 µmol/L x years, exposure time 16 years,
long-term B-Pb 1.6 µmol/L and maximum B-Pb 2.5 µmol/L. Their mean tibia-Pb
was 26, and calcaneus-Pb 88 µg/g bm.
In a kind of population-based case-referent study in the US, there were
associations between work with Pb and Cu, and Pb and iron (mainly electricians,
vehicle mechanics and machine operators), as recorded in an occupational-
hygienist administered questionnaire, and clinically well-defined Parkinson´s
disease (Gorell et al 1999). However, the exposure is ill-defined.
Similarities between the primary motor neuropathy caused by Pb, and ALS
have been noted. In a US case-referent study of ALS, the risk was associated with
self-reported occupational exposure to Pb (odds ratio=OR 1.9, CI 1.3-3.3) (Kamel
et al 2002). Further, among 107 cases and 41 referents, a risk was associated with
B-Pb (range <10-140, median about 40 µg/L; OR 1.9, CI 1.4-2.6 per 10 µg/L
increase). Such an effect may be spurious, because low physical activity may
mobilize bone-Pb to the blood. However, the risk was also related to patella-Pb
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and tibia-Pb (<4-107 and <7-61 µg/g bm, respectively). But the matter may
be complicated since there were indications that two different ALAD poly-
morphisms were associated with decreased bone-Pbs, and - at the same time -
with non-significantly either increased or decreased ALS risks (Kamel et al 2003).
4.1.2.2. Autonomous nervous system
Among 172 Japanese Pb storage battery-factory and Pb-refinery workers mean
B-Pb 360, range 50-760 µg/L), there was an association between electrocardio-
graphic (ECG) heart rate variability (HRV) and B-Pb, which was obvious at B-
Pbs >300 µg/L, but probably also present at >200 µg/L (Teruya et al 1991).
The workers were exposed to antimony, arsenic (As) and tin at “negligible
concentrations”. The data indicate an effect of Pb on parasympathetic nerve
function.
Between 98 Belgian battery-factory workers (mean 510, range 400-750 µg/L)
and 85 “controls” (B-Pb 209, range 44-390 µg/L), there were no statistically
significant differences in HRV (Gennart et al 1992a). Neither was there any
association with B-Pb.
In the above-mentioned 16 gun-metal foundry workers (mean B-Pb 340, range
160-600 µg/L), a study of the autonomous nervous system, revealed that the HRV
at deep breath was significantly depressed, as compared to 16 unexposed workers
(B-Pb not given), indicating an effect of Pb on parasympathetic activity (Murata et
al 1991). In 22 gun-metal foundry workers (partly the same?; median B-Pb 300,
range 120-590 µg/L), the HRV was also significantly depressed, as compared to
14 unexposed workers (Murata et al 1993).
Between 36 female Chinese glass (mean B-Pb 556, range 258-793 µg/L) and
15 control (B-Pb 63 µg/L) workers, there were significant differences in HRV,
indicating effects on the sympathetic and parasympathetic (less) nervous systems,
possibly on the brain-stem level (Murata et al 1995). However, the exposed
workers had more subjective symptoms than the unexposed ones.
4.1.2.3. Peripheral nervous system
Nerve conduction
Among 31 Taiwanese battery workers (mean B-Pb 630, range 170-1,860 µg/L),
25 had mild distal extensor weakness of the upper limb, prolonged motor latency
of the median nerve and signs of denervation in the electromyogram (EMG), as
compared to 31 referents (B-Pbs not given!) (Yeh et al 1995). There were also
neurophysiological effects in the tibial and sural nerves, which correlated with
the cumulative (but not current) B-Pb.
In a study of 16 male Japanese gun-metal foundry workers (mean B-Pb 340,
range 160-600 µg/L), both the motor and sensory nerve conduction velocities in
the distal median nerve were significantly slowed, as compared to 16 “unexposed”
controls (B-Pb not given) (Murata et al 1991). In accordance with this, in 22 gun-
metal foundry workers (median B-Pb 300, range 120-590 µg/L), both the motor
and sensory nerve conduction velocities in both the distal radial and median
nerves were significantly slowed, as compared to 14 “unexposed” controls (B-Pb
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not given) (Murata et al 1993). There were some indications that Zn and Cu
antagonized the subclinical neurotoxic effects of Pb (Arakai et al 1993). It seems
that fast sensory fibers are more sensitive to Pb than slow ones (Sata et al 1993;
Fujimura et al 1998).
In 41 Japanes Pb workers (production of Pb-glass based colors, Pb pipes and
electrode platers and Pb-bronze; mean B-Pb 433, range 130-700 µg/L; air-Pb
<2.69 mg/m3) and 39 unexposed workers (B-Pb not given!), there was a B-Pb
associated, adjusted effect on radial nerve motor and sensory conduction
velocities (Hirata & Kosaka 1993).
In Israel, 21 battery-factory workers (mean B-Pb 285±52 to 525±52 µg/L in
subgroups) had longer visual event-related potentials than 40 unexposed controls
(77 µg/L), did not differ in sensory nerve conduction velocities (Solliway et al
1994).
In 72 Chinese battery workers (mean current B-Pb 369, range 73-685 µg/L) and
82 referents (B-Pb 105, range 44-198 µg/L), there were significant differences in
sensory and motor conduction velocities, distal latency and amplitudes of the
median nerve, while in the radial nerve only distal latency were affected (Chia et
al 1996b). The findings correlated with cumulative B-Pb. However, workers with
cumulative B-Pbs <400 µg/L x year did not differ from the referents. Similar
findings were made during a follow-up each 6 months during 3 years (Chia et al
1996c).
Further, in the above-mentioned study of 60 Finnish Pb-battery workers,
peripheral sensory thresholds and - to a lesser degree - motor conduction
velocities, showed negative correlations with time-integrated B-Pb and exposure
time (Kovala et al 1997). Vibration threshold in the arms were related to the
recent exposure, in the leg to the long-term one. The mean current B-Pb was
1.3 (range 0.5-2.2) µmol/L, long-term B-Pb 1.6 µmol/L and maximum B-Pb
2.5 µmol/L. Their mean tibia-Pb was 26, and calcaneus-Pb 88 µg/g bm.
On the other hand, in a study of 80 of current Canadian smelter workers, there
were no significant associations between B-Pb (mean 264, range 130-430 µg/L),
TWA B-Pb, cumulated B-Pb or tibia-Pb (mean 41, range –12 to 90 µg/g bm), on
the one hand, and current perception thresholds in fingers or toes, on the other
(Bleecker et al 1997a). In the same workers, there was a non-linear, U-shaped
relationship between adjusted, simple reaction time and B-Pb (Bleecker et al
1997b). The authors believe that Pb causes activation. They further claim that
the B-Pb originating from endogenous exposure from the skeleton has less effect
than that from recent uptake; however, that conclusion seems doubtful, due to
imprecise estimates and low levels.
In 17 male Japanese gun-metal workers (mean B-Pb 402, range 220-590 µg/L),
studied twice at a 1-year interval, there was a decrease in sensory nerve conduc-
tion velocity of large fibers in the median nerve, parallel to an increase of EDTA-
chelated Pb (but no association with change of B-Pb) (Yokoyama et al 1998).
These workers differed from non-exposed referents.
In a study of 95 Korean Pb workers (smelting, polyvinyl chloride and battery
production; mean B-Pb 446, range 214-784 µg/L) and 13 controls (B-Pb 59, range
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40-72 µg/L), there were associations between B-Pb and DMSA-chelatable Pb, on
the one hand, and subjective symptoms (tingling or numbness in arms or legs and
muscle pain), on the other (Lee et al 2000).
Other
Among 151 Latvian battery workers, 46 subjects with symptoms and signs of
peripheral neuropathy (mainly sensory, with paresthesiae, pain and impaired
sensitivity to pain and vibration) had higher mean B-Pb (639 µg/L) than the others
(B-Pb 492 µg/L) (Rubens et al 2001). In accordance with this, the neuropathy
group had “abnormal” sensory nerve neurophysiology, while motor conduction
velocities were within the “normal” range; there were no correlations with B-Pbs.
In a study of 803 Korean workers (mean B-Pb 320±150 µg/L; tibia-Pb
37.1±40.3 µg/g bm) and 135 controls (mean B-Pb 53±18 µg/L; tibia-Pb 5.8±7.0
µg/g bm), there were associations between B-Pb and DMSA-chelatable Pb, on the
one hand, and peripheral motor strength (pinch and grip strength), on the other
(Schwartz et al 2001). Tibia-Pb did not show such associations.
Moreover, in 206 Taiwanese Pb-battery workers (current average B-Pb
283±127 µg/L), there were associations between the vibration perception
threshold in the feet (but not the hands) and the average B-Pb during the last
5 years; there seemed to be a threshold at 310 µg/L (Chuang et al 2000).
In a Japanese vinyl chloride resin factory, which had used Pb-stearate stabilizer,
in one worker, who had severe Pb poisoning (B-Pb 1,000 µg/L), with advanced
motor neuropathy, including hand muscle atrophy, chelation with EDTA for one
year caused a significant clinical and neurophysiological improvement (Kajiyama
et al 1993).
No data on gene-environment interaction as regards neurotoxicity in adults have
been published.
4.1.2.4. Other effects
Evoked potentials
In a series of studies, evoked potentials have been assessed in relation to Pb
exposure. Disturbances on evoked potentials may mean effects in different areas
of the nervous system. Hence, visual evoked potentials involve both the visual
nerve and the cerebral cortex, auditory brainstem evoked potentials the auditory
nerve, the brain stem and the cortex, and somatosensory evoked potentials the
afferent sensory nerves of the PNS, the plexus, the brain stem and the cortex.
Auditory or visual event-related evoked potentials also assess cognitive functions.
In 49 Pb-exposed Italian workers (battery factory workers, ceramic industries
and miscellaneous; four of them exposed through consumption of Pb-contami-
nated wine!; mean B-Pb 546 µg/L) and 49 controls (B-Pb not given), there were
differences in auditory brainstem evoked potentials (Discalzi et al 1992). Workers
who had a mean B-Pb <500 µg/L during he last 3 years differed from those
>500 µg/L.
In 22 male Japanese gun-metal foundry workers exposed to Pb, Zn and copper
(Cu; median B-Pb 300, range 120-590 µg/L), latencies of auditory event-related
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and somatosensory and auditory evoked potentials were associated with B-Pb,
as compared to 14 unexposed workers (Araki et al 1992; Murata et al 1993).
In the 41 above-mentioned Japanese Pb workers (production of Pb-glass-based
colors, Pb pipes and electrode platers and Pb-bronze; mean B-Pb 433, range 130-
700 µg/L; air-Pb <2.69 mg/m3) and 39 unexposed workers (B-Pb not given!),
there was a B-Pb-associated, adjusted effect on visual evoked and short-latency
somatosensory evoked potentials and auditory brainstem response, but not on the
electroretinogram (Hirata & Kosaka 1993). The authors claim that the effect is
greater on the PNS component of somatosensory and auditory pathways than on
CNS, while the opposite is true for the visual pathway.
In 36 female Chinese glass (mean B-Pb 556, range 258-793 µg/L) and 15
control (B-Pb 63 µg/L) workers, there were no effects on visual or brainstem
auditory evoked potentials (Murata et al 1995).
In Israel, 21 battery-factory workers (mean B-Pb 285±52 to 525±52 µg/L in
subgroups) had longer visual event-related potentials than 40 unexposed controls
(77 µg/L) (Solliway et al 1994). Among the Pb workers, the effect correlated with
B-Pb. In a second study, visual event-related potentials while performing a target
detection, as well as memory scanning tasks, differed between 31 Pb workers (B-
Pb 414, range 230-530 µg/L) and 56 non-exposed controls (B-Pb 78, range 10-
130 µg/L) (Solliway et al 1995a and 1995b). The findings correlated with U-
ALA; the authors suspected that this was due to ALA-induced inhibition of
gamma-aminobutyric acid (GABA) release, or competitive binding of ALA
to GABA receptors, which has been shown experimentally.
In 300 Italian males, there was an association between B-Pb and visual evoked
potentials (Abbate et al 1995). The effect seemed to appear already in a group
with a mean B-Pb of 295±38.9 µg/L. It is not clear how the subjects were re-
cruited, or how they were exposed. However, since the highest sub-group had a
mean B-Pb of 557 µg/L, they must reasonably have been exposed occupationally.
In a study of seven Ecuadorian children with extremely high Pb exposure (B-Pb
648-833 µg/L), auditory brainstem evoked potentials were “normal” (Counter et
al 1997).
In a study of 155 children aged 4-14 in the Katowice area in Poland, some
aspects of the auditory brainstem evoked potential differed between children with
B-Pbs above and below 100 µg/L (0.48 µmol/L) (Osman et al 1999a).
Postural stability
Postural stability is a complex function. It involves exteroceptors and proprio-
ceptors, sensory nerves of the PNS, the spinal medulla, the brain stem, the visual
nerves, the cerebellum and the cerebral cortex.
In 60 Chinese Pb-battery workers (B-Pb mean 360, range 64-645 µg/L) and
60 controls (B-Pb 63±2.4 µg/L), there was an increased postural sway (Chia et al
1994c). In the Pb workers, the postural sway parameters were not significantly
correlated with current B-Pb or total cumulated B-Pb (Chia et al 1996a). This
indicates reversibility, though the interpretation is complicated by the fact that B-
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Pb had decreased over time. However, the cumulated B-Pb during the latest
2 years was associated with all parameters.
Twenty-nine Chinese female glass workers (B-Pb mean 557, range 260-790
µg/L) differed in posturography in relation to 14 unexposed referents (B-Pb mean
61, range 50-90 µg/L) (Yokoyama et al 2002a). In the Pb workers, there was a
relationship between the effect and B-Pb.
In 49 male Japanese workers exposed to Pb stearate in a chemical factory
(current mean B-Pb 180, range 70-360 µg/L; past B-Pb 477, range 110-1,100
µg/L), differed from unexposed controls (B-Pbs not given!) as to different
parameters of posturography (Yokoyama et al 1997 and 2002b). These findings
indicated an effect on the anterior cerebellar lobe and the vestibulo-cerebellar
and spinocerebellar afferent systems.
In 109 6-year-old children, there were a statistically significant association
between postural sway and B-Pb during the first five years of life (GM 119±15
µg/L) (Bhattacharya et al 1993).
Other
Effects of Pb on auditory and visual functions have been reviewed (Otto & Fox
1993).
In a study of 155 children aged 4-14 in the Katowice area in Poland (median
B-Pb 72, range 19-281 µg/L=0.34, range 0.09-1.4 µmol/L), the hearing threshold
increased with rising B-Pb, even below 100 µg/L (0.48 µmol/L) (Osman et al
1999a). Above that B-Pb, there was also a change of brainstem auditory-evoked
potential.
In Pb-workers and referents, there was an association between impaired visual
contrast and B-Pb (median 280, range 60-610 µg/L and 70, 20-210 µg/L, respec-
tively) (Lucchini et al 2000). This was considered to be a sensitive indicator of
neurotoxicity.
In an audiometry study of Ecuadorian children with high environmental Pb
exposure (median B-Pb 526, range 99-1,100 µg/L) and a referent group of 14 (B-
Pb 64, range 39-120 µg/L), there were no Pb-associated effects (Counter et al
1997). However, the testing facilities may not have been optimal.
In a recent review of 102 papers on neurotoxic effects in Pb workers, it was
concluded, that, on a group basis, effects on peripheral nerve conduction velocity,
event-related evoked EEG potential, postural balance and HRV occurred at group
mean B-Pbs of 300-400 µg/L, on somato-sensory, visual and brainstem auditory
evoked EEG potentials, as well as on distribution of nerve conduction velocities,
at 400-500 µg/L (Araki et al 2000).
4.1.2.5. Organolead
In a study of US current organo-Pb (tetramethyl and tetraethyl Pb, which are
rapidly dealkylated in the body) workers (exposed to a mixture of organic and
inorganic Pb; “lifetime” mean B-Pb 261 µg/L), there were plenty of neurological
findings (Mitchell et al 1996); however, the group was selected. Among 222
workers (air-Pb: inorganic 4-119, organic 1-56 µg/m3; weighted average B-Pb 240
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µg/L), manual dexterity and verbal memory/learning (Schwartz et al 1993) and
simple visual reaction time (Schwartz et al 1995) were related to the exposure
intensity (and U-Pb). Among the Pb workers, 42.6% had “subnormal” scores in a
symptoms questionnaire, vs 7.6% in a referent group of unexposed workers from
the same factory (B-Pbs not given) (Bolla et al 1995). The neurobehavioural and
symptoms pictures were similar to that in workers exposed to organic solvents
(Schwartz et al 1993; Bolla et al 1995).
In 543 US former (average 17.8 years since last exposure) organo-Pb workers,
there were associations between current (mean 14.4, range –1.6 to 52.0 µg/g bm)
and peak (calculated concentrations at the end of occupational exposure, assuming
a half-time of 27 years; mean 23.7, range –2.2 to 105.9 µg/g bm) tibia-Pb, on
the one hand, and adjusted performance in a series of neuropsychological tests
(particularly in the domains manual dexterity, executive ability and verbal
intelligence and memory), on the other (Stewart et al 1999). The associations
were somewhat closer with peak levels than with current ones. There was almost
no correlation with cumulated occupational exposure (µg/m3; data not given) or
current DMSA-chelated Pb. The authors claim that the results indicate a
cumulative and persistent effect. However, the selection of workers was great.
Further, the back-calculation did not take into account the current “background”.
B-Pbs were not given, but in a sub-population, the current average concentration
was 46 µg/L (Tassler et al 2001).
Interestingly, the Apolipoprotein E genotype (which has associations with
Alzheimer´s disease) interacted with tibia-Pb to explain findings (Schwartz et al
2002). The authors argue, that the tibia-Pb after end of exposure (ie, through
endogenous exposure) may be of importance (Links et al 2001).
Also, they followed the workers for up to 4 years (Schwartz et al 2000b). Then,
there was a decline of function in some tests, which was proportional to “peak”
tibia-Pb. The authors claim that earlier external exposure may cause a progressive
decline in cognitive functions. Contrary, sensory and motor tests in the hands did
not deviate (Schwartz et al 2001). These important findings have some limitations,
though, because the workers had been exposed to organo-Pb (though the tibia
accumulates and releases inorganic); further, there is a multiple inference
problem.
In 490 of the US former (average 16 years since last exposure) organo-Pb
workers, there were no associations between current B-Pb (mean 46 µg/L)
and DMSA-chelated Pb and current (mean 14.7 µg/g bm) and peak (calculated
concentrations at the end of occupational exposure, assuming a half-time of 27
years; mean 24.1 µg/g bm) tibia-Pb, on the one hand, and peripheral nervous
function in hands (sensory pressure threshold in index fingers) and pinch and grip
strengths), on the other (Tassler et al 2001). The only exceptions were (for unclear
reasons) associations with pressure threshold in the little finger.
Effects on cognitive and behavioural effects in infants and children are
discussed in section 8. Reproduction and effects in infants/small children.
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4.1.3. Mechanisms
The mechanism behind Pb-induced neurotoxicity is not clear (Rice & Silbergeld
1996). However, several possibilities have been proposed. Hence, Pb interferes
with heme synthesis, which may impair the energy metabolism in the nervous
system. Further, ALA is neurotoxic.
Also, Pb interferes with Ca-dependent processes, ia, such related to neuronal
signalling and intracellular signal transduction (Rice & Silbergeld 1996). Pb
perturbs intracellular Ca cycling, altering releasability of organelle stores, such as
endoplasmic reticulum and mitochondria. In some cases, Pb inhibits Ca-dependent
events, such, including Ca-dependent release of several neurotransmitters and
receptor-coupled ionophores in glutamateric neurons; in other cases, Pb appears to
augment Ca-dependent events, such as protein kinase C and calmodulin.
Experimentally, Pb can induce significant function impairment in vivo in the
nervous system at doses below those associated with cytotoxicity (Rice &
Silbergeld 1996). For instance, exposures that significantly and persistently alter
both neurochemical parameters and behaviour, are associated with little
quantitative changes in brain weight, size, regional cytoarchitecture or markers of
neural or glial numbers.
4.1.4. Summary
Heavy Pb exposure (B-Pb ≥4 µmol/L) to inorganic Pb may cause clinical
encephalopathia, which is to a large extent reversible if adequately treated (Table
2, see page 80). Slight CNS symptoms have been reported in groups of workers
with mean B-Pb of about 1.5-2 µmol/L, or higher.
Neurobehavioural effects may occur at B-Pbs of 1.5-2.0 µmol/L (tibia-Pb
40 µg/g bm), or higher (Table 2). There are many problems associated with the
interpretation of these data: For example, several indices of exposure and a wide
variety of tests have been used; only some in each study have been positive, which
may lead to a bias of multiple inference. Also, the reference groups had often
relatively high B-Pbs, in the same range that has, on basis of limited data, been
claimed to cause disturbances of neurobehavioural tests in the general population.
There are some reports of associations between occupational Pb exposure, on
the one hand, and Parkinson´s Disease and ALS, on the other.
Severe Pb exposure causes peripheral neuropathy, which is reversible, if
adequately handled. Slight sensory symptoms and signs of decreased strength
have been noted at mean B-Pbs about 1.5 µmol/L, or higher (Table 2).
Neurophysiological disturbances of motor and sensory nerve conduction
velocities and of vibrations sense have repeatedly been associated with mean
B-Pbs of about 1.5 µmol/L (tibia-Pb 30-40 µg/g bm), or higher.
Subclinical effects on vision and hearing, as well as on visual and auditory
evoked potentials, have been reported at mean B-Pbs of 1.5 µmol/L, or higher,
and at even lower B-Pbs in children (Table 2). Subclinical effects on postural
stability have been recorded at B-Pbs of 1.5 µmol/L, or higher. All these effects
may be due to disturbances of different parts of the nervous system.
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Several studies indicate effects on the autonomous nervous system (mainly
HRV) at mean B-Pbs of about 1.5 µmol/L, or higher (Table 2).
For all these effects, it is not clear whether they are mainly dependent upon
recent or long-term exposure (reflected by time-integrated B-Pb or bone-Pb).
However, there is some evidence that some of these effects may be reversible
at a reduction of exposure.
4.2. Blood and blood-forming organs
4.2.1. State of the art 1991
In 1991 (Skerfving 1992 and 1993), it was recognized, that heavy Pb exposure
may cause anemia. Such is usually associated with B-Pbs of 3 µmol/L. The main
mechanism is inhibition of several enzymes in the heme (ALAD and heme
chelatase, the inhibition of which causes a rise of zinc protoporphyrin [ZPP]
in blood) and hemolysis. There was limited data indicating an effect on the
hemoglobin concentration at a mean of 2.5 µmol/L.
Further, the nucleic acid metabolism in erythrocytes is Pb sensitive. Hence,
pyrimidin-5´-nucleotidase (P5N) activity is inhibited. An advantage with P5N
over ALAD determinations was that it is less sensitive as to time after sampling.
There is slight enzyme inhibition in the bone marrow/red cells at low B-Pbs.
Probably, effects on the enzymes ALAD and P5N in red cells are proportional to
the B-Pb, right down to the B-Pbs in subjects without particular Pb exposure, even
at the low B-Pbs seen in Sweden at that time (mean B-Pb about 0.3 µmol/L). At
B-Pbs about 1.0 µmol/L, the ALA concentrations in plasma and urine and ZPP
in erythrocytes start to increase. Disturbance of heme metabolism is more
pronounced in women than in males.
However, it was not known whether such slight effects have health cones-
quences. Neither was it known whether corresponding inhibition of heme
synthesis occurs in other tissues at similarly low exposure. However, considering
the central position of heme in the energy metabolism (CNS inclusive) and in
handling of organic xenobiotics by the tissues, the effect was considered to be
potentially important. However, there was not sufficient evidence for classifying
such effects as definitely adverse.
There were some indications that subjects with certain types of inborn errors
of metabolism (porphyria) are particularly sensitive to Pb, and that hemoglobin
disorders could predispose.
4.2.2. Update
4.2.2.1. Heme metabolism
Determination of ALAD activity has considerable method problems (Jaffe et al
1991). ALAD activity (especially the fraction of the activity restored by Zn or
dithiothreitol) is more sensitive than disturbances in ALA concentrations (Sakai
& Morita 1996).
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In Pb workers, ALA increases earlier in plasma (P-ALA; but not in red cells)
than in urine; there is an exponential increase of P-ALA with rising B-Pb (Morita
et al 1994; Sakai & Morita 1996; Sakai et al 1998), which is most likely due to the
saturation of the Pb binding in the red cells.
P-Pb without (Hirata et al 1995) and after (Sakai et al 1998) chelation is
associated with ALA concentrations in plasma and urine and coproporhyrin in
urine; it displays closer correlations than B-Pb. In Israeli battery workers, smokers
had higher U-ALA than nonsmokers, in spite of the fact that B-Pbs did not differ
(Solliway et al 1996). The authors argue (without data), that creatinine adjustment
of U-ALA is not valid, since ALA excretion is dependent upon the pH of the
urine.
In Japanese workers with B-Pb <400 µg/L, the “benchmark dose” (excess risk
5%) was calculated to B-Pbs of 27 µg/L for Ery-ALAD, 33 µg/L for P-ALA and
88 µg/L for U-ALA (Murata et al 2003).
By cytometry, ZPP may be determined in individual red cells, which may be an
advantage when evaluating the time pattern of Pb poisoning, as it reflects the B-
Pb at the time of formation of the cell (Markowitz et al 1994). B-ZPP is less
sensitive to Pb exposure than P-ALA (Sakai & Morita 1996).
There are indications of gene-environment interaction: In Japanese Pb workers,
there was no genotype-associated difference in basic B-ALAD activity, but
restoration of activity by chelator was less efficient in ALAD2 subjects than in
ALAD1 ones (Sakai 2000), which may be a result of the tighter binding of Pb.
However, contrary to what might be expected from the higher affinity of Pb to
ALAD2 than to ALAD1, elevated P-ALA was shown in Korean (Schwartz et al
1997b), Thai (Sithisarankul et al 1997) and Japanese (Sakai et al 2000) Pb
workers with homozygous ALAD1 genotype, as compared to ALAD2 subjects.
Moreover, among 72 Turkish battery workers, the ALAD1 subjects had higher
U-ALA than the ALAD2 ones (29.2%), especially at B-Pbs >500 µg/L (Süzen et
al 2003).
Since there seems to be no clear genotype-dependent difference in basic
ALAD activity in erythrocytes (Zhang et al 1998; Sakai et al 2000; Süzen et al
2003), the above-mentioned rise of P-ALA may be caused by an induction of
ALA synthetase, caused by negative feed-back regulation due to lack of heme,
which is a result of inhibition of ferrochelatase-mediated incorporation of Fe3+
into heme in the mitochondria, because Pb is not as efficiently sequestered by
the ALAD protein in ALAD1 subjects, as compared to ALAD2 ones.
Moreover, among the above-mentioned Korean, Thai and Japanese Pb workers,
those with ALAD1 had higher ZPP, when controlling for B-Pb (Schwartz et al
1995; Sakai et al 2000). The same finding was claimed to be present in 119
Canadian smelter workers (Alexander et al 1998).
However, the picture is not clear: In 201 Japanese porcelain paint workers,
there was no statistically significant difference in U-ALA between ALAD2 and
ALAD1 subjects, though the latter had higher values numerically (Zhang et al
1998). Further, in 798 Korean Pb workers (mean B-Pb 320, range 40-860 µg/L;
tibia-Pb 37.2, range –7 to 338 µg/g bm) and 135 controls (mean B-Pb 53, range
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20-100 µg/L; tibia-Pb 5.8, range –11 to 27 µg/g bm), there was no clear effect
modification of ALAD (nor VDR) genotype of the effect of Pb (B-Pb and DMSA-
chelatable Pb) on neither ALA, nor ZPP metabolism (Lee et al 2001b).
4.2.2.2. Nucleotide metabolism
The enzyme P5N is present in the cytosol of erythrocytes. It catalyzes, as a step
in degradation of ribosomal RNA, hydrolytic dephosphorylation of pyrimidine-5´-
monophosphates, but is ineffective on purine nucleotides, which are kept as a
source of ATP.
Hence, inhibition of P5N leads to accumulation of pyrimidine nucleotides in red
cells (Ichiba et al 1992; Kim et al 1995a), which is believed to shorten the life
span of the cells. However, the inhibitory effect of Pb on ALAD is higher than on
P5N (Kim et al 1995a). Nicotinamide adenine dinucleotide synthetase (NADS)
activity is also inhibited by Pb (Morita et al 1997), but has only occasionally been
used for monitoring.
4.2.2.3. Hemoglobin/anemia
Hu (1991a) studied 21 US adults in the general population (mean current B-Pb
0.29 µmol/L), who had 1930-1942 suffered from Pb-poisoning as children, and
matched referents (B-Pb 0.36 µmol/L). The cases still had lower blood hemo-
globin levels.
It has been claimed, that reserve capacity for new blood formation is a more
sensitive index of toxic effect than the hemoglobin level (Grandjean 1991).
In 98 Belgian battery factory workers (mean 510, range 400-750 µg/L) and
85 “controls” (B-Pb 209, range 44-390 µg/L), there were associations between
hemoglobin concentration and hematocrit, on the one hand, and B-Pb, on the
other, although only 6% of the variance was explained (Gennart et al 1992a).
In a study of 31 Israelian Pb workers (B-Pb 414, range 230-530 µg/L) and 56
non-exposed controls (B-Pb 78, range 10-130 µg/L), the latter had lower, and
weakly B-Pb associated, red blood cell count, while the haemoglobin concentra-
tions did not differ (Solliway et al 1996). Also, there was an exposure-dependent
elevation of glutathione peroxidase activity, which the authors attributed to
reticulocytosis (not assessed) and Pb-induced free radical formation, with lipid
peroxidation. Acetyl-cholinesterase activity in blood cells did not differ.
In the above-mentioned 798 Korean Pb workers (mean B-Pb 320, range 40-860
µg/L; tibia-Pb 37.2, range –7 to 338 µg/g bm) and 135 controls (mean B-Pb 53,
range 20-100 µg/L; tibia-Pb 5.8, range –11 to 27 µg/g bm), tibia-Pb (but neither
B-Pb, nor chelatable Pb) was associated with lower hemoglobin/ (packed cell
volume), although the explained variance was small (<1%) (Lee et al 2001b).
The authors suppose, that while the effect on ALA and ZPP depends on recent
exposure, the effect on hemoglobin is a long-term one.
In a study of US construction workers without particular exposure to Pb (mean
B-Pb 0.40 µmol/L=83 µg/L), the patella-Pb (but neither B-Pb, nor tibia-Pb) was
associated with a decrease of hemoglobin and hematocrit (Hu et al 1994). The
authors assumed that this indicated an effect on hematopoesis (direct on the bone
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marrow?). However, there was no effect modification by ALAD genotype (Smith
et al 1995b).
In a study from Brazil (of Caucasians and mulattoes), 60 subjects exposed to Pb
in a pottery manufacturing plant (mean B-Pb 534±12.1 µg/L), as compared to 30
controls (police preparatory school students; B-Pb 63±2.3), besides increased U-
ALA, had higher fraction of blood methemoglobin and urinary chemilumini-
scence, as well as activity of superoxide dismutase (SOD) in blood (Costa et al
1997). The latter finding correlated with B-Pb, the first two ones with U-ALA.
The authors believe, that the effects were due to a pro-oxidant effect of ALA,
causing oxidative stress with production of reactive oxygene species (ROS),
resulting lipid peroxidation, leading to excretion of chemofluorescents and
induction of the antioxidant defence, which is in agreement with experimental
findings (including decrease of glutathione). However, they do not account for
age, or smoking and alcohol habits, which may confound the results.
In 13 Pb-smelter workers, there was inverse relationship between hemoglobin
level and P-Pb (median 1.4, range 0.9-3.0 µg/L), which may indicate the inhi-
bition of the heme synthesis (Bergdahl et al, submitted). The dose-response
relationship of such an effect may be blurred if B-Pb (median 390, range 320-
450 µg/L) is used, because of reverse causation (Pb induces a decrease of the
red cell volume, which binds Pb).
4.2.3. Summary
Heavy Pb exposure (about 3.0 µmol/L, or more) may cause clinical anemia,
caused by inhibition of heme synthesis and hemolysis (Table 2).
Slight effects on blood hemoglobin concentrations and hematokrit have
been reported at mean B-Pbs of 2.0-2.5 µmol/L (Table 2). However, B-Pb has
particular limitations as an index of exposure when effects on the blood are
assessed, since a reduced voume of red cells will limit the possibilities of Pb
binding in blood. P-Pb may have advantages, but the information is yet scanty.
Further, there are some data, indicating that bone-Pb may be more closely
associated with blood effects than is B-Pb, perhaps through a local effect on
the bone marrow. Any effect on the hemoglobin concentration is adverse.
The main target in the heme synthesis is ALAD, the activity of which seems to
be inhibited at B-Pb right down to those in general populations with low exposure
(about 0.10 µmol/L; Table 2). This results in increases of ALA concentrations in
plasma (documented at about 0.15 µmol/L) and urine (about 0.4 µmol/L). At
higher B-Pbs, there is inhibition of heme syntethase, resulting in an increase of
blood ZPP, and of P5N of the nucleotide metabolism. The relations between all
these effects and B-Pb are exponential, because of the saturation of the erythro-
cytes at high exposure. Disturbance of heme metabolism is more pronounced in
women than in males.
It is not known whether such slight effects on heme synthesis and nucleic acid
metabolism have health consequences. Neither is it known whether corresponding
inhibition occurs in other tissues at similarly low exposure. However, considering
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the central position of heme in the energy metabolism (CNS inclusive), and in
handling of organic xenobiotics by the tissues, the effect on the heme metabolism
is potentially adverse. Also, it must be considered that ALA is neurotoxic and
induces formation of free radicals.
There are indications of a gene-environment interaction, in that one of the
ALAD genotypes (ALAD1) is associated with a greater effect on the heme
metabolism (than in ALAD2 subjects). Subjects with certain types of inborn
errors of metabolism (porphyrias) may be particularly sensitive to Pb, and that
some hemoglobin disorders may predispose.
4.3. Kidneys
4.3.1. State of the art 1991
In 1991 (Skerfving 1992 and 1993), it was concluded, that Pb may induce kidney
damage, with interstitial nephritis, often combined with hypertension, hyper-
uricemia and gout. Since there was no evidence of overproduction of uric acid,
it was assumed that there was an impairment of the tubular secretion of urate.
The information on exposure-response was incomplete. However, severe effect
were assumed to occur mainly a long time after high exposures, though there was
evidence, that slight effects on the tubular epithelium, with enzymuria, occurs at
considerably lower exposures, probably already at B-Pbs of about 1.5-2.0 µmol/L.
The health effects of slight enzymuria were not known; there was some infor-
mation indicating reversibility after end of exposure. However, considering the
severe kidney effects that Pb-exposed individuals may suffer, the subclinical
findings were considered adverse. Pb also affects vitamin D and Ca metabolisms.
In children, such disturbances had been documented already in the B-Pb range
0.75-1 µmol/L. However, adults seem to be less sensitive.
4.3.2. Update
Since 1991, a lot of new data have been published (reviews: Nolan & Shaikh
1992; Batuman 1993; WHO/ICPS 1995; Loghman-Adham 1997). In one review,
the proofs for the existence of Pb-induced nephropathy in man was questioned
and considered to be, at best, circumstantial (Nuyts et al 1991). Hence, it was
claimed, that the morphological picture is unspecific and the temporal relationship
between exposure and onset of disease obscure (exposure history often not
reported). Further, it was suspected, that Pb merely aggravates a pre-existing
kidney disease. Also, a healthy worker selection (before employment, or during
exposure, because of the medical survey system or selective quitting because of
disease) probably exists. However, these conditions would rather cause a bias
towards the null. Moreover, the risk of counfounding, from cadmium (Cd) and
mercury (Hg) nephrotoxicity, as well as socioeconomic factors, was stressed,
which is a true problem. However, organic solvents, which were also mentioned
as a potential confounder, only seldom occur in the same occupational settings.
Further, the health importance of microproteinuri and enzymuria was challenged.
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Since 1991, more evidence from animal experiments has been published,
again showing nephropathy with nuclear inclusion bodies in proximal tubuli,
microproteinuria and enzymuria and - finally - tubular atrophy and interstitial
fibrosis (Khalil-Manesh et al 1992a and 1992b).
4.3.2.1. Occupational exposure
Kidney function
In 98 battery factory workers (mean 510, range 400-750 µg/L) and 85 “controls”
(B-Pb 209, range 44-390 µg/L), there were no statistically significant differences
in serum concentrations of creatinine or β2-microglobulin (ß2-MG), predicted
creatinine clearance (calculated from serum creatinine, sex, age, and body size)
or urinary excertion of albumin, ß2-MG, retinol-binding protein (RBP) or the
lyzosomal enzyme N-acetyl-ß-D-glucosaminidase (NAG; age-adjusted) (Gennart
et al 1992a). Neither was there any association with the B-Pb. There was no
difference in U-Cd. However, the Pb exposure in the “controls” was remarkable.
In 70 current (median B-Pb 1.54, range 0.24-2.29 µmol/L; tibia-Pb 48.6 µg/g
bm) and 20 retired (B-Pb 0.48 µmol/L; tibia–Pb 100.2 µg/g) Swedish smelter
workers and 41 referents (B-Pb 0.2 µmol/L; tibia-Pb about 20 µg/g), there was no
difference as regards plasma creatinine, creatinine clearance, or urinary excretion
of albumin, ß2-MG or NAG (Gerhardsson et al 1992).
In 87 active and 16 former battery plant workers, 38 clerks at the factory and
26 unexposed referents, there were no correlations between parameters reflecting
short- (mean B-Pb 0.18-1.45 µmol/L in the four groups) or long-term (time-
integrated B-Pb; tibia-Pb –3.5 to 21.1; calcaneal-Pb 1.2 to 76.6 µg/g bm) Pb
exposure, on the one hand, and urinary activity of NAG or concentration of RBP,
on the other (Erkkilä et al 1992), although the reporting of data was very brief.
When a battery of 22 potential markers of renal changes were applied to a
cohort of 41 Belgian smelter workers, moderately exposed to Pb (mean B-Pb 480,
range 360-650 µg/L; exposure ≥1 year), and 41 controls (average B-Pb 167, range
63-343 µg/L), the only effect observed were associations between urinary
excretion of eicosanoids (lower 6-keto-prostaglandin F1 and higher tromboxane
B2) and B-Pb, which was considered to reflect a disturbance of their synthesis in
the kidney (Cárdenas et al 1993). The urinary excretion of some tubular antigens
was associated with duration of Pb exposure (but not B-Pb). There was no
correlation between Pb exposure, on the one hand, and markers of glomerular
(including albumin), proximal (including ß2-MG, RBP and NAG) and distal
tubular, and collecting duct/interstitial markers, on the other. The Pb-exposed
workers also had some Cd retention, as compared to the controls (mean U-Cd 0.88
vs 0.40 µg/g creatinine=crea), while they had lower U-Hg (1.7 vs 2.3 µg/g crea).
Eicosanoid disturbances may affect the renal hemodynamics. Accordingly, in
76 Belgian smelter workers (GM B-Pb 430, range 259-679 µg/L; tibia-Pb 66,
range <15-69 µg/g bm), and 76 referents (B-Pb 141 µg/L; tibia-Pb 21 µg/g),
there was a slight positive association between creatinine clearance after protein
challenge and tibia-Pb (Roels et al 1994). The authors hypothesize, that Pb
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induces a slight hyperfiltration (as has also been seen in experimental animals)
(Khalil-Manesh et al 1992a and 1992b). The Pb-workers excreted more NAG,
but this was associated with a slight difference in U-Cd (1.04 vs 0.53 µg/g crea).
There were no other differences in kidney function (urinary albumin, transferrin,
β2-MG or RBP).
In 99 Japanese Pb-solder and Pb-smelter workers (B-Pb 39-1,077 µg/L),
subjects with high B-Pb (means 276 µg/L and higher) had increased urinary
excretion of α1-microglobulin= α1-MG; adjusted for age, but not for Cd), while
serum concentration of α1-MG was not affected (Endo et al 1993).
Among 166 Spanish Pb-battery workers (median B-Pb 368 µg/L) there was a
clear increase of urinary NAG (but not of the brush-border enzymes alanine-
aminopeptidase and γ-glutamyl-transpeptidase=γ-GT, albumin or total protein), as
compared to 60 controls (B-Pb 116 µg/L) (Santos et al 1994). In the whole group,
B-Pb correlated with U-NAG.
In an interesting study of 128 workers exposed to Pb oxide and stearate in a Pb-
stabilizer factory and 152 controls, there was no difference in total urinary NAG
(Chia et al 1994b). Further, there was no association between NAG and current
(median B-Pb 296, range 39-666 vs 87, range 32-164 µg/L) or time-integrated B-
Pb. However, the relative (but not absolute) change of B-Pb during the last 6
months was correlated to NAG. Moreover, when the two species of NAG - NAG-
A and NAG-B - were studied separately, the association was only with the latter,
which is heat stable, linked to the lysosomal membrane of the proximal tubular
cell and excreted at epithelial turnover, as a result of necrosis, cell breakdown
or loss of brush-border vesicles, while the intralysosomal NAG-A is excreted
through exocytosis. Hence, the data indicate that there is damage, dependent
upon recent exposure, which indicates reversibility. Also, there were indications
of a difference between Chinese and Malays.
In another report on 128 (partly the same?) Pb-workers (mean current B-Pb
326, range 76-662 µg/L) and 93 controls (B-Pb 90, range 32-67 µg/L), there was
a significant difference in urinary α1-MG (Chia et al 1995a). Also, that tubular
protein was associated with B-Pb, but more strongly with time-integrated B-Pb,
and in particular with B-Pb peaks >600 µg/L. Similar - but less definite - increases
were seen for serum β2-MG and urinary albumin, while urinary β2-MG and RBP
only correlated with the time-integrated B-Pb. There was no effect of recent
changes of B-Pb. Interestingly, there was an effect-modification by age; the effect
was more pronounced in workers employed >30 years. Importantly, there was no
effect of U-Cd (1.21, range 0.05-2.07 µg/g crea in the exposed group).
In a study of 154 mainly Malayan and Indian workers (partly the same?) in a
Pb-stabilizer factory, there were associations between the urinary excretion of a
proximal tubuli brush-border antigen, on the one hand, and time-integrated B-Pb,
number of peaks >400 µg/L and relative change of B-Pb during the last 6 months,
on the other; current B-Pb also correlated, but less (Chia et al 1994a). Further, the
brush border protein excretion was associated with – in order of association -
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urinary α1-MG, NAG-B, β2-MG and RBP, which strongly supports a toxic effect
on the proximal tubuli.
In 137 Pb-exposed mainly Malayan and Indian workers (partly the same?) in
a Pb-stabilizer factory and 153 postal workers (current B-Pbs not given!), the Pb
workers had higher serum α
 1-MG and urinary albumin, while there was no
difference in serum creatinine or creatinine clearance (Chia et al 1995b). It is
difficult to follow the data treatment. However, it seems, that Pb workers >30
years of age more often had abnormally (not defined) high serum β2-MG. Also,
the time-integrated (but not current) B-Pb correlated with serum α1-MG,
irrespective of age and with abnormal serum creatinine and β2-MG and urinary
albumin at >30 years; for the latter two markers, the number of B-Pb peaks above
>600 and >400 µg/L seemed to be of importance. The findings may indicate a
decrease of GFR and tubular protein reabsorption. The Cd retention (B-Cd ≤1.92
and ≤2.0 µg/L in the exposed and unexposed groups, respectively; U-Cd ≤2.07
and ≤1.2 µg/g crea) did not seem to confound.
In 22 Indian automechanics (mean B-Pb 409, range 300-690 µg/L), urinary
NAG and β2-MG were increased, as compared to 27 referents (B-Pb 232±98
µg/L) (Kumar & Krishnaswamy 1995). Further, there was a significant
association between B-Pb and NAG (but not β2-MG). There was a marginal
impairment of 4-h creatinine clearance, but not statistically significant.
In 382 South African Pb battery plant workers (mainly coloured; current
mean B-Pb 535, range 23-1,100 µg/L), there was no association between blood
pressures and B-Pb (Ehrlich et al 1998). In 40 subjects studied (later), the median
tibia-Pb was 60.9, range 22.6-179.4 µg/g bm.
In 80 active (median B-Pb 1.6, range 0.7-2.8 µmol/L; tibia-PB 25, range –5 to
193 µg/g bm) and 73 retired (B-Pb 0.9, range 0.4-1.6 µmol/L; tibia-Pb 75, range
17-169 µg/g bm) Swedish Pb-smelter workers and 24 referents (median B-Pb 0.2,
range 0.1-0.7 µmol/L; tibia-Pb –6 to 36 µg/g bm), there was an increased
excretion of urinary NAG in the active subjects, and a correlation between NAG
and tibia-Pb; no such associations were seen in the retired individuals (Tell et al
1998). The groups did not differ in U-Cd. There were no differences in excretion
of albumin or β2-MG.
Out of 22 Swedish smelter workers (11 active, 11 retired; median B-Pb 1.2,
range 0.37-2.4 µmol/L; fingerbone-Pb 48, 20-99 µg/g ww) and 11 referents (B-Pb
0.20, 0.10-0.34 µmol/L; fingerbone-Pb 2, -2 to 16 µg/g ww), one active and five
retired showed signs of kidney dysfunction (urinary NAG, protein HC, β2-MG
and/or albumin above the upper reference limits) (Gerhardsson et al 1998).
However, there was a concomitant low exposure to Cd (Pb-workers: B-Cd 8.6,
1.9-53 nmol/L, kidney-Cd 24, 5-61 µg/g; referents: B-Cd 2.6, 0.9-16 nmol/L,
kidney-Cd 10, 3-28 µg/g), although this was considered to be of less importance.
In 382 South African Pb battery plant workers (mainly coloured; current mean
B-Pb 535, range 23-1,100; historical B-Pb 573, range 140-963 µg/L), there was an
association between serum creatinine and urate (but not urinary NAG, RBP,
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alkaline phosphatases, Tamm-Horsfall glycoprotein, epidermal growth factor or
albumin), on the one hand, and current and historical B-Pb exposure, on the other
(Ehrlich et al 1998). In 40 subjects studied (later), the median tibia-Pb was 60.9,
range 22.6-179.4 µg/g bm, in 56 was the median B-Cd <0.5, range up to 1.2 µg/L.
In 803 Korean Pb workers (mean B-Pb 320±150 µg/L; tibia-Pb 37.2±40.4 µg/g
bm) and 135 controls, there were associations between some aspects of impaired
kidney function, and the biomarkers of Pb exposure (Weaver et al 2003), although
the picture was not coherent. The effect was modified by age (worse in old
workers). Interestingly, the blood urea nitrogen (BUN) and serum creatinine
decreased, and measured and estimated creatinine clearances increased, with
rising Pb markers. U-Cd (mean 1.1 µg/g crea) was associated with U-NAG.
However, tibia-Pb (but not the other Pb biomarkers) was correlated with U-NAG
after adjustment for Cd; a 0.5 µg/g crea increase in U-Cd had the same effect as
a 66.9 µg/g bm rise of tibia-Pb.
Deaths
In a study of 1,900 US smelter workers (average duration of Pb exposure 9.9
years), there was an increase of deaths from chronic kidney disease, which was
most pronounced in those with long-time exposure (standardized mortality
ratio=SMR=2.79, 95% confidence interval=CI 0.75-7.15) (Steenland et al 1992).
However, the work had entailed a certain exposure to Cd as well.
In a study of mortality 1950-1992 among 1,388 workers and laborers in an
Italian primary Pb smelter (air-Pb in 1977-78; GM 47.6, range 1-1,650 µg/m3),
there was no increase of all causes (SMR=89; CI=82-95; national rates) (Cocco
et al 1997). Regional rates were higher, but were only available from 1965 on
(SMR=105; CI=97-114). There was an increase of deaths from “saturnism”
(among those exposed for >20 years RR=38.5; CI=4.4-340; mostly among
maintenance workers and labourers), and of deaths from geneto-urinary system
diseases (SMR=126; CI=78-192 and SMR=135; CI=74-227, respectively; all
among workers employed before 1946; 52% from renal failure). The latter risk
was associated with duration of exposure (>20 years RR=6.6; CI=1.7-26.1;
adjusted for calender year and age). There was concurrent exposure to Cd (28%
of air samples >10 µg/m3).
4.3.2.2. General population
Adults
In a cross-sectional study in Belgium (random samples from two areas with
substantial environmental Cd exposure, and two with lower; 965 men and 1,016
women; the Cadmibel study), measured and estimated creatinine clearances were
slightly and inversely related to B-Pb (males: mean 114, range 23-725 µg/L;
females: 75, range 17-603 µg/L) (Staessen et al 1992 and 1996). Importantly,
the relation was neither altered by adjustment for Cd levels in blood or urine, nor
hypertension. Further, a 10-fold increase of B-Pb was associated by a raised risk
of substantially reduced GFR (<52 mL/min in males, <43 mL/min in females;
OR=3.76, CI=1.37-10.4). There were associations between B-Pb and B-ZPP,
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on the one hand, and urinary β2-MG, on the other, while γ-GT displayed no such
associations. B-Pb was increased in subjects who reported heavy metals at work.
In a cross-sectional study of 744 Caucasian middle-aged and elderly US men
out of the general population, with an average B-Pb of 81 (range <40-260) µg/L,
there was (after adjustment for a series of potential confounders, including blood
pressure and smoking) a significant negative association between creatinine
clearance (measured or estimated) and B-Pb (Payton et al 1994). A 100 µg/L
increase of B-Pb was associated with a 10.4 mL/min decrease in logarithm of
creatinine clearance. There was also an association between patella-Pb (mean
32.1±19.5 µg/g bm) and estimated creatinine clearance (Wu et al 2003a).
In a follow-up of 777 middle-age and elderly men from the general US
population, the association between patella-Pb and serum urate was confirmed
(Shadick et al 2000). Gouty arthritis had been diagnosed in 6.7%; however,
neither B-Pb, nor bone-Pb predicted this diagnosis. Further, in a 6-year follow-up
of 448 of the men, longitudinal, adjusted increases in serum creatinine were non-
significantly associated with baseline B-Pb (mean 65±42 µg/L), patella-Pb
(32.4±20.5 µg/g bm) and tibia-Pb (21.5±13.5 µg/g bm) (Tsaih et al 2004). The
rise of serum creatinine was dependent upon a statistically significant interaction
between baseline tibia-Pb and hypertensive status. An interaction was also present
between B-Pb and bone-Pb, on the one hand, and diabetes, on the other (a change
from the lest to the highest tibia-Pb was associated with a 17.6 times higher
increase in diabetics, as compared to non-diabetics).
Further, in a longitudinal (1979-1994) study in the above-mentioned
population (459 US men), there was an association between concurrent serum
creatinine and B-Pb, even at B-Pbs ≤0.48 µmol/L (<100 µg/L) (Kim et al 1996b).
The creatinine/B-Pb relationship was curvilinear, with a steeper slope in the low
B-Pb range. An increase of B-Pb by 1 µmol/L meant an average rise of serum
creatinine by 2.89 µmol/L. The effect was greater in older age strata. A tenfold
increase of B-Pb meant a serum-creatinine increase corresponding to 20 years of
aging. More important, there was a relationship between the B-Pb at one point in
time and the change in serum creatinine until next sampling, although this was
only borderline statistically significant. There was no significant impact of
hypertension.
In a study of 64 Spanish patients with chronic renal failure (mean±SEM
creatinine clearance 41.4±3.7 mL/min), hypertension and gout, but without known
Pb exposure, B-Pb was somewhat higher than in 30 control subjects (mean B-Pb
211 vs 167 µg/L), but 56.1 vs 0% had a high urinary Pb excretion after EDTA
administration (Sánches-Fructuoso et al 1996). In the latter, there was an asso-
ciation between chelatable Pb and serum creatinine. Comment: Since the EDTA-
Pb complex is excreted through glomerular filtration, any such association would
be partly obscured. In those subjects, there was also a correlation to transiliac
bone-Pb (mean 27.8 µg/g ww). No associations with Pb biomarkers were seen
for other cases of chronic renal failure. The selection of patients is not clear.
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Within the US NAHNES III cross-sectional survey (15,211 adult subjects),
there were, among hypertensives (but not normotensives), associations between
B-Pb (mean 42.1 µg/L), on the one hand, and serum creatinine (adjusted OR
between the highest and lowest B-Pb quartiles 2.41) and chronic kidney disease
(GFR <60 mL/min/1.73 m2 estimated from the serum creatinine; OR=2.60), on
the other (Muntner et al 2003). However, the association was only present among
non-smokers. There was an indication of an interaction with diabetes. The
relationship was curvilinear, with the greatest effect at low B-Pbs.
In a study of the population around a battery factory in Taiwan, there was a
decreasing gradient of B-Pb from the plant and outwards (means 163.3, 134.5 and
74.8 µg/L) (Lin et al 1993). Between the most and least exposed groups, there was
a significant difference in urinary NAG. However, within the most exposed group,
there was no clear association between NAG and chelatable Pb.
In a study of 820 women aged 52-63 years from the south of Sweden, there
were significant associations between B-Pb (median 22, range 11-46 µg/L), on the
one hand, and serum concentrations of creatinine and cystatin C (indices of GFR),
as well as urinary Ca (index of tubular function), on the other (Åkesson et al,
submitted). Further, U-Pb was associated with urinary levels of α1-MG, NAG and
Ca. However, there was a correlation between biomarkers of Pb and Cd. Thus,
when adjustment was made, only cystatin C remained as significantly associated
with B-Pb.
In a series of Taiwanese papers, effects of Pb mobilization (elimination) on
kidney function has been addressed: In one of these studies, the progression of
chronic renal insufficiency (serum creatinine 15-39 mg/L; GFR 12.7-72.7
mL/min/1.73 m2 ) of varying etiology (mainly glomerulonephritis and hyper-
tension) during 24 months was to some (limited) extent dependent upon the “body
lead burden” (or rather, EDTA-chelatable Pb; mean 104 µg) in subjects who had a
mean B-Pb of 53 µg/L (0.26 µmol/L) (Lin et al 2003). During 27 months, half of
64 patients with high “body lead burdens” (80-530 µg) were treated with EDTA
(1 g weekly). Then, the “body lead burden” decreased (from 151 to 43 µg; B-Pb
from 61 to 39 µg/L) and the GFR increased by 11.9%, while GFR decreased by
3.6% in the non-treated controls. After end of the chelation, the “body lead
burden” and B-Pb increased again, most probably because of “refilling” of
endogenous Pb from the bone pool. This may indicate a potentiating effect of Pb
on renal disease of other basal etiology. However, the mechanism is not known.
One obvious possibility is the decrease of Pb, but another one is scavering by
EDTA of ROS. A third one (less probable) is chelation of Cd, and a fourth
confounding via alcohol intake and consumption of analgetics (Elinder 2003;
Elinder & Alvestrand 2003). The same research group has published other papers
on the same issue, with fewer patients and shorter chelation and follow-up times
(Lin et al 1999 and 2001b). It is not clear whether the patients were the same.
In another study (different material?), of 101 patients with chronic renal
insuffiency (again mainly because of chronic glomerulonephritis and hyper-
tension), there were significant correlations between “body lead stores” (but not
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significantly with hemoglobin-adjusted B-Pb, which was 52-545 µg/L), on the
one hand, and serum urate and urate clearance, on the other (Lin et al 2001a). In
accordance with this, 67 patients with a history of gouty arthritis had higher levels
than the 34 others (means: serum urate 99 vs 86 mg/L; B-Pb 536 vs 43.9 µg/L;
“body lead store” 138.1 vs 64.2 µg). Similar results have been reported earlier in
smaller patient materials (partially the same?). In the first one, it was shown that
subjects with essential hypertension and renal insufficiency had increased “body
lead burden” (Lin & Lim 1994), in the second one relations between urate
metabolism and this burden (Lin & Huang 1994). Moreover, EDTA-chelation
therapy weekly during one month in a random half of 30 gout patients with “high
body lead stores”, markedly increased the urate clearance. The mechanism was
probably Pb elimination (Lin et al 2001a).
Chelation therapy by DMSA improved the renal function in Pb-treated
experimental animals (Khalil-Manesh et al 1992b).
Children
Some recent papers have reported data on Pb and kidney effects in children: A
Pb-associated increase of urinary RBP was seen in a group of children from the
Czech Republic with B-Pbs ranging 123-354 µg/L (Bernard et al 1995). Further,
urinary NAG was increased in Romanian children with a mean B-Pb of 342 µg/L
(Verberk et al 1996).
In 162 Polish children (age 4-14), there were statistically significant associa-
tions between decreasing estimated creatinine clearance, and increasing serum
cystatin C and urinary α1-MG, on the one hand, and B-Pb (median 0.35, range
0.09-1.36 µmol/L), on the other (Osman et al 1999b). These associations were
present even in subjects with B-Pbs <0.7 µmol/L. Cd and Hg levels in blood
were not associated with the kidney markers.
A very detailed study of 62 children in a contaminated Polish area (mean B-Pb
133 µg/L, previously 210 µg/L) and 50 controls (B-Pb 39 µg/L), the former had
higher (and B-Pb associated) urinary excretions of glomerular (transferrin, prosta-
glandins and thromboxane B, but not albumin), proximal (ß2-MG and Clara cell
protein, but not α1-MG or NAG) and distal (epidermal growth factor) tubular, as
well as collecting duct/interstitial cell (prostaglandin) markers (Fels et al 1998). In
total, no less than 29 markers were studied. The urinary Cd levels were 0.88 and
0.43 µg/g crea, respectively.
In an Australian study among subjects with no reported history of heavy Pb
exposure, there were no differences in B-Pb in those with normal renal function,
or mild or severe renal dysfunction (Emmerson 1991). In contrast, B-Pbs were
higher among adults with renal failure and a history of childhood Pb poisoning.
Hu (1991a) studied 21 US adults (mean B-Pb 0.29 µmol/L), who had 1930-
1942 suffered from Pb-poisoning as children, and carefully matched referents (B-
Pb 0.36 µmol/L). Surprisingly, the plumbism cases had increased mean adjusted
creatinine clearances and low serum creatinine concentrations.
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In 62 adult US subjects with severe childhood Pb poisoning (mean initial B-Pb
1,503±771, range 1,000-4,701 µg/L) and 19 aged-matched siblings, studied 17-23
years (mean B-Pbs in both groups 74 µg/L) after chelation therapy, there were no
differences in renal function parameters, including serum creatinine and urinary
ß2-MG clearance (Moel & Sachs 1992). In a follow-up study of 454 US children,
who had been hospitalized for Pb poisoning in the period 1923-1966, there were
(up to 1991) no increase in deaths from chronic nephritis (McDonald & Potter
1996).
4.3.2.3. Gene-environment interaction
An important issue is, whether ALAD genotype may interact with Pb as regards
nephrotoxic effects. In 691 US construction workers (mean B-Pb 77.8 µg/L),
there was an association between BUN and B-Pb; subjects with ALAD2 had higher
(sic!) BUN than the ALAD1 ones (Smith et al 1995a). They also had a tendency of
higher serum urate concentration, but there was no difference in serum creatinine.
In a study of 89 smelter workers and 32 referents, serum creatinine was slightly
higher in ALAD2 individuals, but the difference was not statistically significant
(Bergdahl et al 1997a). They also excreted more Ca, but there were no differences
as regards excretion of β2-MG or NAG.
In a recent update of 709 subjects in one of the above-mentioned surveys
of middle age and elderly Caucasian US men (Payton et al 1994), serum urate
concentration were, as mentioned above, associated with patella-Pb, but more
clearly in ALAD2 genotype individuals (already at >15 µg/g bm) than in ALAD1
ones (only at >101 µg/g bm). There also seemed to be an interaction between
tibia-Pb and the ALAD2 genotype as regards serum creatinine concentration.
In a small study of smelter workers from northern Sweden, there was no
interaction between Pb and ALAD genotype as regards GFR or serum creatinine
(Gerhardsson et al, to be published).
4.3.3. Summary
Heavy Pb exposure may cause renal dysfunction characterized by glomerular
and tubulointerstitial changes, resulting in chronic renal failure, hypertension,
hyperuricemia and gout. There are indications that a fraction of such patients, at
least in some areas, have an occult Pb exposure, and that elimination of Pb by
chelation therapy may be beneficial.
At low-level Pb-exposure, there are associations between B-Pb and bone-Pb,
on the one hand, and increased serum levels of urate and urinary excretion low
molecular weight proteins and lysosomal enzymes, on the other. This indicates an
effect on the proximal tubuli (although hyperuricemia may also reflect oxidative
stress) (Waring et al 2001). The effect on α1-MG is more evident than on ß2-MG,
which may be due to the problem by destruction of the latter at low urinary pH, as
well as the fact that it has a lower molecular weight, which might make it less
sensitive to inefficient reabsorption in the proximal tubuli.
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Such effects have been seen in occupational groups with mean B-Pb of about
1.5 µmol/L, or higher (Table 2). In a few studies changes have been seen in
workers with mean bone-Pbs of about 40 µg/g bm, or higher.
Limited data indicate that corresponding effects may occur in general popu-
lations of children with B-Pb of about 0.5 µmol/L, or higher; in one study even
lower.
However, these slight effects are sensitive to confounding. Then, a particular
problem is Cd, which is well known to cause proximal tubular effects, even at low
exposures. Hence, smelter workers – one of the most frequently studied categories
- are often exposed to both Pb and Cd. This may cause a bias – overestimation of
any Pb effect. Also, there is a possibility of a Pb/Cd interaction/sum effect. On the
other hand, effects have been seen in workers in occupational setting (mainly
battery factories) with less likelihood of Cd exposure.
As to glomerular effects, the picture is less clear. There were also associations
between B-Pb, on the one hand, and serum concentrations of creatinine, BUN,
cystatin C and urate and estimated and measured creatinine clearance, on the
other. Such effects have been reported in adult general populations with mean B-
Pb of 0.5 µmol/L, or higher; in a couple of studies even lower (Table 2). There are
limited indications of interactions between Pb exposure, on the one hand, and
diabetics and hypertensive status, on the other.
This may indicate an effect on the GFR. However, since urate and creatinine are
excreted by tubular secretion, this may – at least partly – also be due to tubular
damage. Also, there is a possibility that a decrease of GFR may result in an
accumulation of B-Pb (reverse causality). This possibility has not been
conclusively addressed. There are no data indicating Pb-induced albuminuria.
Glomerular effects have only to a limited extent been studied in workers, and
have then sometimes indicated hyperfiltration.
There are some indications, that the ALAD2 genotype is particularly associated
with Pb-associated increase of serum creatinine.
A problem in the interpretation of data from the occupational studies is the
health surveillance that Pb workers are often subject to, meaning that subjects
with history or signs of kidney disorder or hypertension are selected before and
during employment, which would cause an underestimate of the risk, in particular
if the role of Pb is aggravation of other kidney disease.
It is not known whether recent or long-term (continuous or peaks) Pb exposure
is the most relevant determinant of risk. Further, the relationship between the
sensitive urinary tests and later clinical chronic renal disease is not clear. There is
limited evidence of increased mortality from kidney disease in Pb workers, but Cd
confounding precludes firm conclusions.
4.4. Cardiovascular system
Relationships between Pb and blood pressure in pregnant women will be
discussed in section 8. Reproduction and effects in infants/small children.
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4.4.1. State of the art 1991
In 1991 (Skerfving 1992 and 1993), it was noted, that Pb causes an increase of
blood pressure in experimental animals. The exposure-response relationship is
unusual: The effect is probably more pronounced at low exposures than at high
ones. Also, several studies of samples from the general population indicated that a
similar effect may occur in man. Then, it seemed that the slope of the B-Pb/blood
pressure curve is steepest at low B-Pbs, levelling off at higher ones. In the B-Pb
range of the general population in many countries, there was an increase of
systolic and diastolic blood pressure by 1-2 mm Hg (0.133-0.266 kPa) for each
doubling of B-Pb. This is a rather small effect from an individual risk point of
view.
However, from a population health point of view, it might be important, since
an effect on the blood pressure may have impacts on the cardiovascular system,
mainly cerebrovascular disease and coronary heart disease (CHD). Hence, each
mm Hg rise is associated with an increase of ischemic heart disease by about 1%.
It has been proposed that Pb is the background of the association in the general
population between soft drinking water and CHD. However, Pb is certainly not a
major contributor to risk of cardiovascular disease. Thus, any association between
Pb exposure in the general population and risk of cardiovascular disease had not
been empirically demonstrated. Moreover, the available information did not allow
firm conclusions on whether the association between B-Pb and blood pressure in
man is causal; there might be methodological problems (reverse causality and
residual confounding).
It was also concluded, that several studies indicated a blood-pressure effect in
heavily exposed Pb workers. It is possible that these effects are associated with
kidney damage, and different from the effect at lower exposures, which may
mainly be due to effects on vascular reactivity. Increased risk of cerebrovascular
(perhaps also CHD) had been reported in some studies of Pb workers.
4.4.2. Update
4.4.2.1. Blood pressure
In particular, the inconsistencies between studies of occupationally Pb-exposed
populations and general populations have attracted several reviews and provoked
controversy regarding the effect (Hertz-Picciotto & Croft 1993; Staessen et al
1994, 1995 and 1996; Nawrot et al 2002; Den Hond et al 2003).
Occupational exposure
In 410 male US textile workers exposed to carbon disulphide (CS2) and – to some
extent – Pb at soldering during maintenance operations, there were associations
between B-Pb and logarithms of systolic (0.63 mm Hg per 100 µg/L; adjusted for
ia alcohol intake) and diastolic blood pressures (Egeland et al 1992). A problem in
the interpretation is an association between B-Pb and the CS2-exposure. The B-
Pbs were low (means 0.44-0.82 µmol/L in various CS2-exposure groups).
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In 809 UK Pb-battery workers (mean B-Pb 316 µg/L), there was a significant
association between systolic (but not diastolic) blood pressure and B-Pb, which,
however, disappeared after adjustment for confounders (Maheswaran et al 1993).
Between 166 Brazilian battery-factory workers (median B-Pb 368 µg/L) and 60
controls (116 µg/L), there was a difference in diastolic (but not systolic) blood
pressure (Santos et al 1994). Further, in multivariate models (adjusted for age
and body mass), there were associations between systolic and diastolic blood
pressures, on the one hand, and B-Pb, on the other.
However, in 382 South African battery-plant workers (mean historical B-Pb
573, range 140-963 µg/L), there was no association between blood pressure and
Pb exposure (Ehrlich et al 1998).
In a study of 543 male former (≥18 years since last exposure) US workers in an
organo-Pb plant, there was an association between adjusted systolic and diastolic
blood pressures and B-Pb (mean 46, range 10-200 µg/L, explained variance
1.3%); the authors claim that an association was present down to 50 µg/L
(Schwartz & Stewart 2000), but this seems doubtful. Tibia-Pb displayed no
such association. In a prospective follow-up during 4 years of 496 of the former
workers (mean B-Pb 46±26 µg/L; tibia-Pb 14.7±9.4 µg/g bm), there was an
increase of systolic blood pressure, which was dependent upon the Pb biomarkers
(0.64 and 0.73 mm Hg for each standard deviation increase for B-Pb and tibia-Pb,
respectively (Glenn et al 2003). In 220 of the subjects, the gene for the alpha 2
subunit of Na(+)-K(+)ATPase seemed to modify the relation between B-Pb and
blood pressure (Glenn et al 2001). There was a great difference in genotype
prevalence between African Americans and Caucasians.
General populations
Most of the recent studies have been made in general populations: Møller &
Kristensen (1992) found, in 1,052 Danes, a rise of systolic blood pressure by 1.86
(cross-sectional) or 0.90 (longitudinal) mm Hg at a rise of B-Pb by 100 µg/L (B-
Pb means 1976: men: 136, range 50-600; women 96, 40-390 µg/L). In a German
population, there were also statistically significant associations between B-Pb
(median 83 µg/L in 1,703 men, and 60 µg/L in 1,661 women) and systolic (1.45
mm Hg per 100 µg/L; adjusted for, ia, alcohol intake and hematocrit) and
diastolic blood pressures (Hense et al 1993).
In the cross-sectional Belgian CadmiBel study (2,327 subjects), there was
no evidence of an association between B-Pb and blood pressure or hypertension
(Dolenc et al 1993; Staeseen et al 1996). In a prospective follow-up of the
population, which had a mean B-Pb of 87 µg/L in 1985-1989, and 29 µg/L after
an average follow-up time of 5.2 years, there was no consistent association
between changes of blood pressure and of B-Pb (Staessen et al 1996). Neither
the baseline B-Pb, nor ZPP predicted the development of hypertension during
the follow-up.
In 254 male and 271 female Italians, there was a correlation between B-Pb
and hypertension (Apostoli et al 1992). Further, in 630 Italian males (patients at
general practitioners and blood donors; mean B-Pb 148, range 43-469 µg/L), there
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were univariate associations with systolic and diastolic blood pressures and with
hypertension, but when potential confounders (age, BMI and alcohol intake) were
adjusted for, these were lost (Micciolo et al 1994). However, it is not obvious that
this is not an over-adjustment.
In a study of 507 male Austrian law-enforcement officers (policemen, prisons
officers, etc) without significant occupational exposure to Pb (mean B-Pb 80±35
µg/L), there was a significant effect of B-Pb on diastolic (but not systolic) blood
pressure, even when the potential confounders alcohol intake and erythrocyte
count were taken into account (Wolf et al 1995).
In 798 middle-aged and elderly US men (median B-Pb 56, range 5-350 µg/L),
an increase of 27 µg/L (sic!) was associated with rise of adjusted diastolic blood
pressure by 1.2 mm Hg (Proctor et al 1996). Also, there was, in addition, an
association between blood pressure, on the one hand, and patella-Pb and tibia-Pb,
on the other (Hu et al 1996a). In a third study of the same basic population
(N=519), there was no association between B-Pb and blood pressure, but
there was one between blood pressure and patella-Pb (Cheng et al 2001).
In middle-aged women from the same US area, there was also an association
between patella-Pb (mean 13.3 µg/g bm) and risk of hypertension, but no such
associations for B-Pb (mean 0.15 µmol/L) or tibia-Pb (Korrick et al 1999).
In 762 elderly (age above 75, mean 88.2±4.9 years), subjects from Stockholm
city, there was no association between B-Pb (mean 0.18±0.11, range 0.01-1.41
µmol/L), on the one hand, and adjusted (age and BMI) systolic or diastolic blood
pressure, on the other (Nordberg et al 2000).
In a Croatian population (N=154), B-Pb (median 57, range 25-254 µg/L) was
associated with adjusted both systolic and diastolic blood pressures (Telisman et
al 2001).
Nash et al (2003) in 2,165 perimenopausal women from the general US popu-
lation (NHANES III), found that an increase of B-Pb from 10 to 64 µg/L was
associated with a rise of systolic blood pressure by 1.7 mm Hg, and of diastolic
blood pressure by 1.4 mm Hg. Also, there were relationships with systolic and
diastolic (odds ration 8.1, 95% confidence interval 2.6-25) hypertension. The
effects were most evident in postmenopausal women. The Pb effect was much
more prominent in black men and women than in white subjects (Vuppituuri et al
2003). Hence, there seemed to be an effect modification by race, the reason of
which is unclear. However, in another analysis of the NHANES III data, no
association between B-Pb and blood pressure was found (Den Hond et al 2002).
Hu (1991a) studied 21 US adults (mean B-Pb 0.29 µmol/L), who had during
1930-1942 suffered from Pb-poisoning as children, and matched referents (B-Pb
0.36 µmol/L). There was a large increase of the risk of hypertension (relative
risk=RR 7.0, CI 1.2-42.3). In 62 US subjects with severe childhood Pb poisoning
(mean initial B-Pb 1,503±771, range 1,000-4,7010 µg/L) and 19 aged-matched
siblings, studied 17-23 years (mean B-Pbs in both groups 74 µg/L) after chelation
therapy, there were no differences in blood pressure (Moel & Sachs 1992).
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Schwartz (1995) made a meta-analysis of 15 studies in men published 1985-
1993. He estimated that an increase of B-Pb from 50 to 100 µg/L was associated
with an increase 1.5 mm Hg in systolic blood pressure.
Steassen et al (1994, 1995 and 1996) have made several other meta-analyses.
In the latest one (Nawrot et al 2002), 31 studies (19 general and 12 occupational
populations; 58,518 subjects), a two-fold rise of B-Pb was associated with a 1.0
(CI +0.5 to +1.4) mm Hg increase of systolic, and a 0.6 (CI +0.4 to +0.8) mm Hg
of diastolic blood pressure, with no sex difference, though the effect in females is
less well documented than in males. The authors concluded that the association
was weak.
In a study of 282 children (age 5.5 years) from a Pb-industry town in Kosovo
(mean B-Pb 373 µg/L) and an “unexposed one (B-Pb 87 µg/L), there were non-
significant associations between adjusted systolic (0.5, CI –0.2 to 1.3 mm Hg/100
µg/L) and diastolic (0.4, CI –0.1 to 0.9 mm Hg) blood pressures, on the one hand,
and B-Pb, on the other (Factor-Litvak et al 1996). Use of twelve B-Pb determi-
nations since birth gave similar results.
Gene-environment interaction
There might be gene-environment interactions: In 798 Korean Pb workers (mean
B-Pb 320, range 40-860 µg/L; tibia-Pb 37.2, range -7 to 338 µg/g bm) and 135
controls (mean B-Pb 53, range 20-100 µg/L; tibia-Pb 5.8, range –11 to 27 µg/g
bm), B-Pb, tibia-Pb and DMSA-chelatable Pb were all predictors of systolic blood
pressure, but only tibia-Pb of diastolic. There was no clear effect modification of
neither ALAD, nor VDR genotype of the effect of Pb (B-Pb and DMSA-chelatable
Pb) on neither blood pressure, nor hypertension (Lee et al 2001a). However, VDR
genotype per se was associated with blood pressure. In accordance with these
results, in 691 US construction workers (mean B-Pb 77.8 µg/L), there was no
difference in blood pressure with ALAD genotype (Smith et al 1995a).
Mechanisms
The mechanism(s) behind the likely association between Pb exposure and blood
pressure is not known. Several possibilities have been proposed: Direct effects on
the excitability and contractibility of the heart, alteration of the compliance of the
vascular smooth muscle tissue (perhaps through interaction with Ca signalling),
altered vascular reactivity to α-adrenergic agents, interference with the renal
synthesis of eicosanoids (resulting in depletion of prostaglandins with enhance-
ment of sodium retention and the pressor response to angiotensin II and vaso-
pressin), effects on the renal ion transport processes, and action on the parts of the
CNS responsible for blood pressure regulation (Loghman-Adham 1997). In US
males, there was an association between B-Pb and excretion of epinephrine (but
not norepinephrine) (Payton et al 1993).
Pb may cause a modification of the renin-angiotensin system. Also, other
effects mediated through kidney toxicity must be considered. Hence, although
there was no association between renal markers of Pb toxicity and blood pressure
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in two studies (Staessen 1995; Nash et al 2003), in a third one there was an
association between B-Pb and serum creatinine concentration (Kim et al 1996b).
Also, reverse causality may exist: hypertension reduces glomerular filtration,
which may decrease urinary Pb excretion and cause a rise of B-Pb. Further,
the variance of blood pressure explained by B-Pb is very minor.
4.4.2.2. Heart disease and stroke
Hypertension is a major risk factor for cardiovascular disease. As said above,
for an individual, the blood pressure effects associated with Pb have limited
importance. However, on a population basis, the effect on cardiovascular disease
is considerable. Thus, a 2 mm Hg reduction of systolic blood pressure would be
expected to result in a 17% reduction of the prevalence of hypertension, a 15%
decrease of the risk of stroke and transient ischemic attacks and a 6% reduction
of the risk of CHD (Mulrow 1999).
Occupational exposure
Studies of HRV have been discussed above (section 4.1.2.2. Autonomous nervous
system).
In a survey of 1,261 New York City typesetters with low exposure to Pb (air
levels <50 µg/m3), there was a slight increase of cerebrovascular deaths (total
cohort: SMR=1.35, CI=0.98-1.82; subjects exposed >30 years: SMR=1.68,
CI=1.18-2.31; based on local rates) (Michaels et al 1991).
In a study of 1,990 US smelter workers (average duration of Pb exposure
9.9 years, the intensity assumed to be high, average 3.1 mg/m3), there was
no significant increases (compared to national rates) of ischemic heart or
cerebrovascular diseases (Steenland et al 1992). The exposures to Cd and As
were reported to be “relatively low” (averages 14 and 113 µg/m3, respectively).
Swedish primary smelter workers, who had died from cardiovascular or
cerebrovascular diseases did not have higher levels if Pb in lung tissue than other
smelter workers (but they differed from unexposed controls) (Gerhardsson &
Nordberg 1993; Gerhardsson et al 1995a).
In 664 male workers in a Swedish secondary smelter handling mainly Pb
batteries, there was increased mortalities from ischemic heart disease (SMR 1.72,
CI 1.20-2.42) and totally (SMR 1.44, CI 1.16-1.79) (Gerhardsson et al 1995b).
However, smoking was not controlled for.
In a study of mortality 1950-1992 among 1,388 workers and laborers in an
Italian primary Pb smelter (air-Pb in 1977-78; GM=47.6, range 1-1,650 µg/m3),
there was no clear increase of total cardiovascular, ischemic heart (SMR=34;
CI=77-115; national rates) or cerebrovascular (SMR=95; CI=77-115) disease
(Cocco et al 1997).
In a case-referent study of Swedish glass-industry workers, there was no
association between cardiovascular death and Pb exposure (Wingren & Axelson
1993).
Among a cohort of 3,979 Pb-exposed Swedish primary-smelter workers,
followed 1955-1987, there was no increase of deaths from cardiovascular disease
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(ischemic heart or cerebrovascular), as compared to the county population
(SMR=0.9, CI=0.8-1.0; mean B-Pb 1950: 3.0 µmol/L; 1987: 1.6 µmol/L)
(Lundström et al 1997). This was also true for the subgroup with the highest
exposure.
In a study of first-time, non-fatal myocardial infarction in Stockholm, there was
no increase of adjusted risk in subjects with a history of occupational Pb exposure
(air-Pb estimated by an occupational hygienist ≥0.04 mg/m3; RR=1.03, CI=0.64-
1.65) (Gustavsson et al 2001).
General population
In 775 middle-aged and elderly US men, bone-Pb (in particular tibia-Pb; mean
22.2 µg/g bm) was associated with ECG-changes (intraventricular block), while
B-Pb (mean 58 µg/L) was not (Cheng et al 1998a).
In a population-based survey of 1,052 Danish men and women born in 1936
and living in Copenhagen, after adjustment for potential confounders (sex,
tobacco use, serum cholesterol, physical activity), B-Pb (means 1976: men: 136,
range 50-600, women 96, 40-390 µg/L) was associated with CHD at follow-up
(Møller & Kristensen 1992). However, after adjustment for potential confounders,
there was only left an association with total deaths.
Further, in the US general population, elevated B-Pb was associated with a
dose-related increase in deaths due to hypertension-related CHD and stroke in
both men and women (Lustberg & Silbergeld 2002). Hence, the RR for
circulatory disease was 1.39 (CI=1.01-1.91), in subjects in the B-Pb range 200-
290 µg/L, as compared with those <100 µg/L. There was a numerical increase
even in the range 100-190 µg/L. The all-cause mortality was also increased in
that range (RR=1.46, CI=1.14-1.86).
In a follow-up study of 454 US children, who had been hospitalized for Pb
poisoning in the period 1923-1966, there were (up to 1991) significantly increases
of all-cause mortality (RR=1.7, CI=1.4-2.2) and cardiovascular (RR=2.1, CI=1.3-
3.2) and cerebrovascular (women: RR=5.5, CI=1.1-15.9) deaths (McDonald &
Potter 1996).
Also, even moderate increases of blood pressure affects the GFR, as indicated
by associations with serum creatinine in a cross-sectional study of the US general
population (NHANES III) (Coresh et al 2001), and – more importantly – in a
prospective study over 12-15 years (Perneger et al 1993).
4.4.3. Summary
As said above (section 4.1.2.2. Autonomous nervous system), there were some
indications of ECG effects (reduced HRV) at B-Pbs of 1.5 µmol/l, or higher
(Table 2).
There is considerable evidence that Pb absorption, at least in predisposed
individuals, may lead to hypertension. Hence, several studies indicated a blood-
pressure effect in Pb workers, although the picture is far from consistent (Table 2).
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There are also clear indications of an effect of Pb on blood pressure at lower
exposures. Thus, in the B-Pb range of the general population (mean B-Pbs 0.4
µmol/L, or higher; Table 2), there was an increase of systolic and/or diastolic
blood pressure by about 1 mm Hg for each doubling of B-Pbs in the low range
(although the picture is not consistent), less at higher.
The available information does not allow firm conclusions on whether the
association between B-Pb and blood pressure is really causal. Thus, epidemiol-
ogical studies of determinants of blood pressure are complicated, since there are
many potential confounding and effect-modifying factors. For example, alcohol
intake may cause confounding. However, in the latest studies, these problems
seem to be reasonably well under control. Still, there is a risk of both residual
confounding and over-adjustment, which may result in over- or under-estimates
of the effect. The problems are well illustrated by the partly diverging results
obtained in analyses of the same data-base. Also, there might be other methodo-
logical problems, in terms of reverse causality, mediated through a blood-pressure
dependent decrease of GFR with reduced Pb excretion.
It is possible that any effect on the blood pressure, at the high exposures in
Pb workers, is associated with Pb-caused kidney damage, although hypertension
seems to occur even in workers without obvious kidney disorder. This mechanism
may be different from the effect at lower exposures, which may mainly be due to
effects on vascular reactivity.
The effect on blood pressure is not a health outcome per se, but is a risk factor
for cardiovascular and cerebrovascular disease. This risk is rather small from
an individual subject risk point of view. However, in a population, it might be
important. Indeed, some (but far from all) studies showed increased risk of
cerebrovascular (perhaps also CHD) in Pb workers. In those studies, the referents
were from the general population. This may be a problem, since there are
indications of an effect already at such low B-Pbs.
In an attempt to calculate the global burden of disease (ischemic heart,
cerbrovascular, hypertensive and other cardiac) because of an effect of Pb on
blood pressure, it was estimated that 2% of the world-wide cardiovascular disease
burden was due to Pb exposure (annually 229,000 deaths and 3.1 million
disability-adjusted life years [DALYs], ie, the sum of years of life lost due
to death and years of life with disability) (Fewtrell et al 2004).
4.5. Endocrine system
4.5.1. State of the art 1991
In 1991 (Skerfving 1992 and 1993), it was concluded, that there were some
indications of various effects of occupational Pb exposure (mean B-Pbs about 1.5-
2.0 µmol/L, or higher) on the hypothalamus-pituitary-thyroid/adrenal axes.
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4.5.2. Update
Male Swedish Pb-smelter workers (mean B-Pb 332, range 83-932 µg/L) did not
differ from unexposed referents (B-Pb 8-62 µg/L) as regards thyroid stimulating
hormone or serum levels of thyroid hormones (basal and after challenge) (Erfurth
et al 2001). Sex hormones are discussed under section 8. Reproduction and effects
in infants/small children.
In 98 Belgian battery-factory workers (mean 510, range 400-750 µg/L) and 85
“controls” (B-Pb 209, range 44-390 µg/L), there were no statistically significant
differences in serum concentrations of follicle-stimulating hormone, thyroid-
stimulating hormone, thyroxine or triiodothyronine (Gennart et al 1992a). Neither
was there any association with the B-Pb.
In a study of Pb smelter workers and referents, there were no significant differ-
ences in hormone concentrations depending upon ALAD genotype (Bergdahl et al
1997a).
In Italian Pb-workers and referents, there was an association between serum
prolactin and B-Pb (median 280, range 60-610 µg/L and 70, 20-210 µg/L,
respectively) (Lucchini et al 2000). Possibly, an effect was present down to about
100 µg/L. Increased prolactin can be ascribed to impaired modulation of pituitary
secretion by the tubero-infundibular dopaminergic system, and may thus be an
early sign of neurotoxicity. Similar results were reported in another study, with
higher B-Pbs (mean 553 µg/L) (Manzo et al 1996), while another one (mean 367
µg/L) (Telisman et al 2000) revealed no such effect.
4.5.3. Summary
There are some indications of various effects of occupational Pb exposure (B-Pb
1.5-2.0 µmol/L) on the hypothalamus-pituitary-thyroid/adrenal axes.
5. Immunotoxicology
5.1. State of the art 1991
In 1991 (Skerfving 1992 and 1993), it was noted, that there was limited infor-
mation on immunotoxic effects of Pb. Possibly, there are various effects on the
humoural and cellular immunity in groups of Pb workers with B-Pbs about 2
µmol/L, or higher. The health implications of some of these effects was not clear,
but an increased sensitivity to infections had been reported in one study.
5..2. Update
Reviews of the immunotoxicology of Pb has been published (Fischbein et al
1993a; McCabe 1994).
Further, some new studies have been published since 1991: Hence, varying
effects on immunoglobulins in serum (Horiguchi et al 1992a; Queiroz et al 1993
and 1994; Undeger et al 1996; Pinkerton et al 1998) and saliva (Queiroz et al
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1994; Pinkerton et al 1998) have been reported in Pb workers. Further, serum
concentrations of C3 complement have been found to be unaffected (Pinkerton et
al 1998).
Moreover, in Pb-exposed workers, varying effects on leucocyte and lymphocyte
subtypes and function have been described (Valentino et al 1991; Fischbein et al
1993b; Queiroz et al 1994; Undeger et al 1996; Sata et al 1997; Pinkerton et al
1998).
There was a slight increase of colds in Japanese Pb-refinery workers, as
compared to referents (Horiguchi et al 1992b).
All these effects have been noted at B-Pb about 2 µmol/L, or higher.
5.3. Summary
There is fairly limited information on immunotoxic effects of Pb. The picture is
not consistent. Some of the inter-study discrepancies may be due to the variations
in exposure intensity and methodologic differences. There is no evidence of a very
marked immunotoxic effect of Pb at the exposure levels studied. However, there
are probably various effects on the humoural and cellular immunities. Their health
implications are not clear, but there are some indications of increased sensitivity
to infections. The information is not easy to interpret in terms of exposure-
response. However, various effects have been reported in groups of Pb workers
with mean B-Pbs about 2 µmol/L, or higher (Table 2).
6. Mutagenicity
6.1. State of the art 1991
In 1991 (Skerfving 1992 and 1993), it was noted, that genotoxic effects
(chromosome aberrations in peripheral lymphocytes) had been reported in Pb
workers exposed at levels corresponding to average B-Pbs of about 2 µmol/L, or
higher. However, the available information was conflicting. Further, the health
significance of such findings was not known.
6.2. Update
In a recent review, it was concluded, that experimental evidence shows that
Pb accumulates in the cell nucleus. There, it may cause clastogenic activity
(induction of chromosomal aberrations, micronuclei and sister chromatid
exchanges) (Silbergeld et al 2000). However, there is only limited evidence
of direct genotoxic or DNA-damaging effects, except for Pb chromate, where
hexavalent chromium is probably the cause. Hence, Pb has mostly been negative
in in-vitro gen-tox assays.
Rather, Pb-induced non-genotoxic/epigenetic mechanisms seem to affect DNA.
Pb exposure may increase the susceptibility to genotoxic agents. Hence, Pb may
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bind to, and deplete, glutathione (a free-radical scavenger) (Hunaiti et al 2000),
interfere with DNA repair (Hartwig 1994) and bind to histones, thus decreasing
their DNA protection (Quintanilla-Vega et al 2000). In accordance with this, there
was a multiplicative effect for co-exposure in occupational settings to Pb (mean
air level 3, range 1.6-50 µg/m3) and cobalt and Cd, as regards induction of DNA
single strand breaks (Hengstler et al 2003).
Pb-induced ALA accumulation can also generate ROS (Silbergeld et al 2000).
Further, experimental evidence shows, that Pb can substitute for Zn in several
proteins that function as transcriptional regulators, including protamines. Pb also
reduces the binding of these proteins to recognition elements in genomic DNA,
which suggests an epigenetic involvement of Pb in altered gene expression.
32 male workers in a Turkish metal powder-production factory (mean B-Pb
138±92 µg/L) and 20 controls (B-Pb 23.7±9.0 µg/L) differed slightly as to sister
chromatid exchange (SCE) frequency in lymphocytes from peripheral blood
(Dönmez e t al 1998). The effect did not seem to be dependent upon age or
smoking.
Among a Bulgarian study, the frequency of micronuclei in peripheral blood
lymphocytes was 2-3 times higher in 22 battery workers (mean B-Pb 2.94, range
0.78-3.94 µmol/L; air-Pb 447, range 130-711 µg/m3) than in 19 “internal” (in the
same factory; B-Pb 1.33, range 0.78-2.40 µmol/L; air-Pb 58, range 22-86 µg/m3)
and 19 “external” (B-Pb 0.88, range 0.72-1.20 µmol/L; air-Pb 73, range 130-711
µg/m3) referents (Vagenlov et al 1998). Further, after the workers had been treated
for 4 months by a “polyvitamin-polymineral complex” drug (composition and
dose not given), there was a dramatic decrease of the effect; however, no un-
treated control group was studied. In a second study, of 103 Pb-workers and
78 controls, there was a gradual increase of binucleated cells with micronuclei in
peripheral blood lymphocytes from a group with <1.20, over 1.20-1.91, and 1.92-
2.88, to >2.88 µmol/L (Vaglenov et al 2001).
120 Slovenian Pb-Zn miners (mean B-Pb 279, range 37-800 µg/L) differed
from two control groups (B-Pb 72±8.4 µg/L) as to the frequencies of structural
chromosomal aberrations, micronuclei and SCEs in lymphocytes from peripheral
blood (Bilban 1998). However, there was no correlation with B-Pb, but only
with radon exposure.
31 Turkish battery workers (mean B-Pb 363, range 222-525 µg/L) differed from
20 matched controls (B-Pb 111, range 81-147 µg/L) in SCE frequency, even at B-
Pbs <400 µg/L, possibly even at <300 µg/L (Duydu et al 2001). There were
correlations between B-Pb and U-ALA (better), on the one hand, and SCEs, on
the other. The authors suspect that ALA generates oxidative stress with DNA
damage.
In 11 Chinese battery workers (median B-Pb 276, range 79-578 µg/L; median
TWA air-Pb 1.22, range 0.19-10.32 µg/m3), the adjusted frequencies of SCEs and
DNA-protein cross links were higher than in 11 controls (B-Pb 33, range 15-70
µg/L) (Wu et al 2002). The air-Pb levels are very high in relation to the B-Pbs.
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6.3. Summary
There is only limited evidence for a direct genotoxic effect of Pb. However, non-
genotoxic/epigenetic mechanisms seem to damage DNA. Hence, Pb may affect
mechanisms handling free radicals and the metabolism of genotoxic xenobiotics,
as well as DNA repair.
Pb has a clastogenic effect, inducing chromosome aberrations, micronuclei and
SCEs. An increased occurrence of such has been shown in peripheral lymphocytes
of Pb workers exposed at levels corresponding to average B-Pbs of about 1.5-2
µmol/L, or higher (Table 2).
All these effects may increase the risk of cancer (see below, section 7. Cancer).
Indeed, it has now become clear, that structural chromosome aberrations – as had
been assumed for a long time – are really associated with an increased risk of later
cancer (Hagmar et al 1998). For micronuclei and SCEs, the picture is less clear.
7. Cancer
7.1. State of the art 1991
Animal experiments have shown a tumourogenic effect of Pb (Skerfving 1992 and
1993). Hence, soluble Pb salts such as Pb acetate and subacetate have produced
kidney and brain tumours, and Pb phosphate kidney tumours, in rodents after oral
or parenteral administration. Synergistic effects exist for the development of
cancer between Pb acetate and oxide, on the one hand, and some organic car-
cinogens, such as benso(a)pyrene and nitrosoamines, on the other. In general,
epidemiological studies did not support a carcinogenic effect of inorganic Pb
in humans, although the exposure in several studies had been high (B-Pb >3
µmol/L); the small increases seen in some studies could well be explained by
confounding.
7.2. Update
The carcinogenicity of Pb has recently been reviewed (Vainio 1997; Landrigan
et al 2000; Silbergeld 2000). In animals, exposure to some inorganic Pb species
are associated with increased risks of carcinogenesis, even at doses which do
not cause organ toxicity. There are also limited indications of transplacental
carcinogenicity. Possible mechanisms of cancer have been discussed above
(Section 6. Mutagenicity).
7.2.1. Occupational exposure
A series of investigations of occupational and other cohorts have been published
since 1991: In a study of 1,990 US smelter workers (average duration of Pb
exposure 9.9 years), there was no significant increases of deaths from total
cancers or lung cancer, but an increase of kidney cancer, which was most
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pronounced in those with high (SMR=2.39, CI=1.03-4.71) and long-time
exposure (Steenland et al 1992).
In a meta-analysis of 10 case-control and cohort studies of humans exposed
to Pb, there was an excess risks of total (RR=1.33, CI=1.18-1.49), stomach
(RR=1.33, CI=1.18-1.49), lung (RR=1.29, CI=1.10-1.50) and bladder (RR=1.41,
CI=1.16-1.71) cancers (Fu & Boffetta 1995). However, no adjustment for
potential confounders was made. In a meta-analysis of 20 populations (out of 92
studies made 1969-98 covering 121 populations), there was no association
between risk of pancreatic cancer and exposure to Pb and Pb compounds
(RR=1.1, CI=0.8-1.5) (Ojajärvi et al 2000).
In 664 male workers in a Swedish secondary smelter, handling mainly Pb
batteries, there was an increased mortality from all malignant neoplasms
(SMR=1.65, CI=1.09-2.44; county rates), but no dose (employment time)-
response relationship (Gerhardsson et al 1995b). In the most exposed quartile,
there was an increased risk of gastrointestinal tract cancers (SMR=2.34, CI=1.07-
4.45).
In a study of workers in a Swedish primary smelter, exposed to Pb and em-
ployed for at least 1 year in 1928-1992, the total deaths from cancers were not
increased (Gerhardsson et al 1997b; Lundström et al 1997; Englyst et al 2001).
However, there were increased risks of lung cancer, both in the total cohort of
3,797 subjects and in the 710 workers who had ever been employed in the Pb
department (SIR=2.42, CI=1.16-4.45; county rates). 85 deceased workers had
increased levels of Pb in their lung tissue, as compared to 25 urban and rural
controls (Gerhardsson & Nordberg 1993). However, the cases also had a
significant exposure to arsenic (As); the concentrations of this element were also
raised (Gerhardsson & Nordberg 1993). The highest Pb levels were recorded in
lung-cancer cases. Increased Pb levels in relation to unexposed controls have also
been recorded in liver, kidney (both associated with time-integrated B-Pb) and
brain (Gerhardsson et al 1995a).
In 20,741 Finnish workers, who had been monitored for B-Pb in 1973-83, there
was a 1.4-fold increase of total cancer incidence, and a 1.8-fold of lung cancer,
among those who ever had a B-Pb ≥1.0 µmol/L (Anttila et al 1995). In a nested
case-referent study (handling potential confounders, eg, smoking), the risk for
lung cancer was increased at concomitant exposure to Pb and diesel exhaust, even
when the B-Pb had only been slightly increased. Further, there was an excess of
gliomas (Anttila et al 1996). Hence, in a nested case-referent study, workers with
B-Pb >1.4 µmol/L had an increased risk, as compared to those with <0.7 µmol/L
(OR=11, CI=1.0-630).
Wong and Harris (2000) found no significantly increased all-cancer mortality
(SMR=103.8, CI=97.1-110.8) in a US cohort of 4,518 battery and 2,300 smelter
workers. However, stomach (SMR=147.4, CI=115-189.8) and lung (SMR=116.4,
CI=103.9-129.9; unadjusted for smoking) cancers were increased, although there
were no exposure-response relationships. No rises of kidney, bladder, CNS,
lymphatic or hematopoetic tumors were observed.
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In studies of Sardinian female (Cocco et al 1994a) and male (Carta et al 1994;
Cocco et al 1994b) Pb- and Zn-mineworkers, there were no increases of total
mortality, but rises of lung cancers. However, no data on Pb exposures were
given. Further, smoking and exposure to polycyclic aromatic hydrocarbons and
As were not fully accounted for. The cancer risk seemed to be associated with
exposure to quartz (increased risk of non-malignant respiratory disease) and radon
daughters.
In a study of cause-specific mortality in 1950-1992 among 1,388 workers
and laborers in an Italian primary Pb smelter (air-Pb in 1977-78; geometric
mean=GM=47.6, range 1-1,650 µg/m3), there was no increase of all cancers
(SMR=69; CI=58-81; national rates) (Cocco et al 1997). Regional rates were
higher, but were only available for 1965 and on (SMR=93; CI=78-110). The
risk of lung cancer was low (SMR=62; CI=43-86 and SMR=82; CI=56-116,
respectively), in spite of the fact that there was an increased risk of pneumo-
coniosis. There was a non-significant increase of kidney cancer (SMR=142;
CI=46-333 and SMR=175; CI=48-449, respectively), and an association between
exposure time and risk (>20 years RR=10.9, CI=1.0-121; adjusted for calendar
year and age). Non-significant increases were reported for cancers of the liver and
biliary tract, bladder and brain. There was concurrent exposure to Cd (28% of
samples >10 µg/m3); the As levels were low (<1 µg/m3).
In a case-referent study of glass-industry workers, there was some association
between death from stomach and colon cancer (but not lung cancer) and the Pb
consumption of the glass work, but there was co-exposure to a multitude of other
elements (Wingren & Axelson 1993). The mean level of Pb in air was 61 µg/m3
in the foundry of a heavy crystal glasswork; oven inlay work resulted in up to 72
µg/m3 in both crystal and semicrystal works (Andersson et al 1990). In 1993,
IARC (IARC 1993) evaluated the manufacture of art glass, glass containers, and
pressware to entail exposures that are probably carcinogenic to humans (Group
2A).
In a job-exposure matrix study of 413,877 Finnish women with blue-collar
occupations in 1970, there was no significant increase of cancer risk associated
with assumed Pb exposure (Wesseling et al 2002).
7.2.2. General populations
In a follow-up study up to 1991, of 454 US children, who had been hospitalized
for Pb poisoning in the period 1923-1966, there was no increase of deaths from
total cancers, but two deaths from pancreatic cancer (RR=10.2, CI=1.1-36.2) and
two from non-Hodgkin´s lymphoma (RR=13.0, CI=1.5-46.9) (McDonald & Potter
1996).
In the US general population (NHANES III), elevated B-Pb was associated
with a dose-related increase in total cancer deaths; RR was 1.68 (CI=1.02-2.78,
adjusted for multiple potential confounding, including smoking) in subjects in the
B-Pb range 200-290 µg/L (as compared to <100 µg/L) (Lustberg & Silbergeld
2002). There was a numerical increase even in the B-Pb range 100-190 µg/L.
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Increased (but statistically non-significant) risks were seen for both lung and non-
lung cancers. Possibly, there was an interaction between B-Pb and smoking.
7.3. Summary
Experiments in rodent have demonstrated a carcinogenic effect of some Pb
compounds, with increased risk of kidney and brain tumours after oral or
parenteral administration. Synergistic effects exist between Pb and some
organic carcinogens.
In a series of epidemiological studies, Pb workers had increased risks of total,
kidney, lung or stomach cancers. Also, there is limited support for a synergism
with other carcinogens. The studied cohorts of Pb workers have had a high
exposure (mean B-Pbs >3 µmol/L), at least in most of the studies. There is some
data indicating that Pb exposure in the general population is associated with
cancer risk. Then, the exposure has been lower.
However, the pattern is not consistent and there are major problems in terms
of confounding, eg, as regards concomitant exposure to As and Cd in the occupa-
tional cohorts. Also, there may be selection bias. Hence, Pb-workers may differ in
many ways besides the Pb exposure. In particular, confounding by smoking is a
problem, which has only occasionally been tackled. Also, they may be physically
fit and may have different diet.
8. Reproduction and effects in infants/small children
8.1. Female
8.1.1. State of the art 1991
In 1991 (Skerfving 1992 and 1993), it was concluded, that exposure to Pb in a
woman during pregnancy causes Pb accumulation in the placenta. Further, Pb
passes the placenta; the B-Pb in cord blood is about 85% of maternal B-Pb.
Pb is embryotoxic/fetotoxic in experimental animals. The information in man
was considered incomplete, but there were indications of several types of effects.
However, there was little information available on occupationally exposed
women.
The information did not firmly support a teratogenic effect (malformations) in
man. However, several studies had shown effects on the fetus, including reduction
of gestational age, birth weigth and disturbance of heme synthesis. Further,
retardation of neurobehavioural development and growth, as well as EEG and
hearing changes, had been reported in infants and children. Slight effects on the
mental and motor development had repeatedly been claimed to be associated with
exposures corresponding to low B-Pbs, prenatally and/or early in life. In spite of
many methodological problems in such studies, there were indications, that effects
may occur even at B-Pbs in the pregnant woman and infant of only 0.5-0.75
µmol/L. However, the fraction of the total variance of the CNS function that
was explained by Pb was marginal.
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Further, it was concluded, that the breast-fed infant may be exposed to
significant amount of Pb, although there is a large inter-individual variation in
milk-Pb. It was noted that the absorption of Pb from the GI tract probably was
enhanced in the lactating woman, that there is probably a mobilization of Pb from
the skeleton during lactation, that the Pb absorption is higher in infants than in
adults, and that the Pb absorption may be enhanced when the Pb is ingested in
milk. Further, the penetration of Pb into the CNS is probably more effective in
infants than in adults. It was not known to what extent the reported effects in
infants/children are due to prenatal exposure, to exposure via milk and/or to
later exposure. Also, the reversibility of the effects was not known.
Moreover, in addition to the effects through germ cells (and placenta and breast
milk), secondary exposure may occur in children of both male and female Pb
workers, as a result of contamination of the infant/child´s environment.
8.1.2. Update
Effects on reproduction (Andrews et al 1994; Landrigan et al 2000) and children
(Lidsky & Schneider 2003; US CDC 2004) have been reviewed. Rice and
Silbergeld (1996), in a review of monkey and human data, concluded that the
CNS effects (behavioural impairment) may be dependent upon the time and
pattern of exposure, that the infant is vulnerable and that the effects seem not to be
reversible.
8.1.2.1. Fertility
In a US study (NHANES III) of sexual maturation in girls and exposure to Pb, B-
Pb was significantly associated with the attainment of pubic hair and menarche,
but not breast development (Wu et al 2003b). For example, at age 12, 68.0% of
girls with B-Pb 7-20 µg/L had reached menarche, 44.3% at 21-49 µg/L and 38.5%
at 50-217 µg/L.
In a Finnish study, there were indications that occupational exposure to Pb in
an exposure-related way increased time to pregnancy (ORs: unexposed=1.0, <0.48
µmol/L=0.93, 0.48-0.99=0.84, ≥1.0=0.80) (Sallmén et al 1995).
8.1.2.2. Lead metabolism during pregnancy and lactation
There is a U-shaped time trend for B-Pb (West et al 1994; Lagerqvist et al 1996;
Rothenberg et al 1994 and 2000; Schnell et al 2000) and P-Pb (Téllez-Rojas et al
2004) during pregnancy. This is because there is first hemodilution, and later
mobilization of Pb from the skeleton (Pires et al 2001; Téllez-Rojo et al 2004),
possibly also increased Pb absorption in the GI tract. In a series of studies,
employing high-precision measurements of Pb isotopic composition in Australian
and immigrant women, it was seen that B-Pb rose by 20% during pregnancy, and
that about 30% of the B-Pb originated from the skeleton (Gulson et al 1997a,
1997b and 1998b). Low Ca intake was associated with high P-Pb (Téllez-Rojo et
al 2004) and B-Pb and patella-Pb (Hernadez-Avila et al 1996). However, when
the Pb load was small, there was no increase of B-Pb (Berglund et al 2000a;
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Vahter et al 2002) or P-Pb (Téllez-Rojo et al 2004). Pb was present in the
placenta, but also passed into the fetus (Lutz et al 1996; Osman et al 2000).
There is a transfere of Pb to the fetus. A significant positive, relatively close
correlation was observed between the B-Pbs in maternal and cord blood in women
from Singapore (Ong et al 1993). It has been claimed that the skeletal Pb is
mobilized to plasma, and that this is particularly available for transfer to the fetus
(Chunang et al 2001). However, as said above (section 3.5. Toxicokinetics), this is
doubtful.
During lactation, there is also an increase of maternal B-Pb. The maternal B-Pb
seems to increase more in women who practice breast-feeding than in others
(Téllez-Rojo et al 2002). In Swedish women (rise of mean from 11 to 18 µg/L),
this was probably due to increased skeletal turnover (as judged from rises of
serum osteocalcin and urinary crosslinked N-terminal telopeptide of type I
collagen=NTx) (Berglund et al 2000a), although bone mineral density did not
correlate with B-Pb (Osterloh & Kelly 1999).
Pb is transferred into milk (reviews: Oskarsson et al 1995; Abadin et al 1997).
In Australia (mean B-Pb 30 µg/L), the milk-Pb was 0.09-3.1 µg/kg, with large
day-to-day variations (Gulson et al 2001). Similar milk-Pb levels have been
reported from northern Sweden (Hallén et al 1995), Austria (Tiran et al 1994), the
US (Pires et al 2001; Soweres et al 2002) and Mexico (Ettinger et al 2004a and
2004b). Much higher concentrations have been reported from Mexico (Namihira
et al 1993), Egypt (Saleh et al 1996) and China (Li et al 2000), partly due to high
exposure, but probably also because of methodological problems. Milk-Pb is
proportional to maternal B-Pb (non-linearily; Namihira et al 1993; Ettinger et al
2004a) and bone-Pb (Ettinger et al 2004a) and skeletal mobilization (Sowers et al
2002). Further, the infant´s B-Pb correlated with maternal B-Pb and milk-Pb
(Ettinger et al 2004b).
During the pregnancy and lactation periods, an average of 0.9-10 µg Pb/day
was mobilized from the skeleton in Australians, more during lactation than in
pregnancy (Gulson et al 1999 and 2000b). There was no increase of maternal GI
Pb absorption rate. Half of the milk-Pb originated from the skeleton, the rest from
the maternal diet (Gulson et al 2001). Possibly, there is some reduction of skeletal
mobilization by Ca supplementation (Hernandez-Avila et al 2003). No less than
79% of the mobilized Pb reached the baby (Gulson et al 2003). As expected, there
is a correlation between the milk-Pb and the infant´s B-Pb (Gulson et al 1998b).
8.1.2.3. Effects in the pregnant woman or embryo/fetus
Among 1,627 US women in their third trimester, an increase of B-Pb from 5th to
95th percentile (90 to 620 µg/L) was associated with a rise in blood pressure (2.8
and 2.4 mm Hg for systolic and diastolic, respectively) in immigrants (almost only
Latin Americans), while no significant increase was seen in nonimmigrants
(Rothenberg et al 1999a). The authors hypothesize that the difference is due to
prior Pb exposure. Indeed, in the same cohort, an increase by 10.7 µg Pb/g bm
in trabecular bone (patella; GM 10.7 µg/g) was associated with a rise of OR for
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hypertension by 1.86 (CI 1.04-3.32) (Rothenberg et al 2002). Cortical tibia-Pb
displayed no such association, possibly because Pb is mobilized mainly from
trabecular bone during pregnancy. However, only a small fraction of the variation
in blood pressure (1% of systolic) was explained by Pb (Rothenberg et al 1999a).
Still, in the US population, such a Pb-associated effect (assuming a causal
relationship) would push a considerable fraction of high normotensive/borderline
hypertensive pregnant women into clear hypertension.
Hertz-Picciotto (2000) made a critical review of the information on maternal
exposure to Pb and risk of spontaneous abortion. She concluded, that most studies
(including Murphy et al 1990; Laudanski et al 1991; Tabacova and Balabaeva
1993; Driscoll 1998) were biased due to small sample sizes, bad ascertainment of
outcome, lack of confounding control and/or deficiencies in exposure assessment
(ecological rather than individual). In a prospective study in Mexico City, most
of these problems were handled (Borja-Aburto et al 1999). Then, a exposure-
response relationship was seen, from women with B-Pb <50 µg/L over the
exposure categories 50-90 (OR=2.3), and 100-140 (OR=5.4) to >150 (OR=12.2)
µg/L (test for trend P<0.03; it is not clear at which level there is a formal
statistical significance).
In a study of preterm labor, there was no indication of an increased risk in
Swedish (mean B-Pb 11 µg/L) and Polish (B-Pb 38 µg/L) women (Fagher et al
1993). Neither did Pb concentrations in the myometrium or placenta (mean 0.3
µg/g dry weight) predict this effect.
In north-west England there were significant associations between Pb in
placentas (mean 2.3 µg/g wet weight), on the one hand, and gestational age of the
newborn, birth weight and head circumference, on the other (Ward et al 1990).
Among 349 African American women, who were sampled in the third trimester
of pregnancy, B-Pbs (mean 63.6, range 27-126 µg/L) were associated with low
gestational age, birth weight (though not fully significantly) and birth length in
relation to weight (West et al 1994), though the information is scarce. However,
B-Pbs were positively associated with serum Ca and phosphorous. Women who
took vitamineral supplement had lower B-Pbs than those who did not, and there
were negative correlations with serum levels of vitamins C and E; however, the
latter may be explained by confounding by life style/vitamin supplement.
Further, in a study of about 200 mother-infant pairs in Mexico City, low
birth weight (Gonzalez-Cossio et al 1997), birth length, head circumference
(Hernandez-Avila et al 2002) and infant weight gain during the first month of life
(Sanin et al 2001) were associated with biomarkers of Pb (mean umbilical cord B-
Pb 67, range 12-216 µg/L; maternal tibia-Pb 9.8 µg/g bm, patella-Pb 14.4 µg/g).
Moreover, B-Pb and bone-Pb were also associated with low scores on a mental
development scale at age 2 years (Gomaa et al 2002). The bone-Pb had an effect
independent of B-Pb, which indicates that exposure during the whole pregnancy
is of importance. There was no significant effect on motor development.
Similar findings of association between B-Pb and birth weight were made
in a study of Norwegian (mean maternal B-Pb 0.06 µmol/L) and Russian (0.14
µmol/L) mother/infant pairs (Odland et al 1999). However, there is an obvious
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risk of confounding. Effects on the size of the infant were also reported from
South Carolina (37% of B-Pb in infants/children >0.48 µmol/L=100 µg/L)
(Recknor et al 1997).
In a study of 199 mother-newborn pairs in Mexico City, an increase of B-Pb at
gestational week 36 from 10 to 350 µg/L (0.05 to 1.68 µmol/L) was associated
with an average reduction of the adjusted head circumference by 1.9 (CI 0.9-3.0)
cm at age 6 months (Rothenberg et al 1999b). Also, at age 36 months, there was
a negative association with the children´s B-Pb at age 12 months.
In 106 Swedish mother-child pairs, there were associations between birth
weight, length and head circumference, on the one hand, and cord-blood B-Pb
(median 54 nmol/L, range 4.3-590 nmol/L), on the other (Osman et al 2000). An
increase of 54 nmol/L corresponded to an adjusted decrease in the infant´s weight
by 100 g and length by 0.5 cm. The maternal B-Pb was almost the same as in cord
blood, which correlated with placenta-Pb (median 26 nmol/kg=5.2 ng/g wet
weight), which, in turn, was associated with the mothers´ wine intake. Further, as
expected, the birth weight was dependent upon the smoking habits of the pregnant
woman. Hence, there is a wealth of possible confounding. Also, there might be
co-precipitation of Ca and Pb in a degenerating placenta.
In a Norwegian study of the reproductive outcome as reflected in the birth
register in offspring of parents who were occupationally exposed to Pb, as judged
from the population census records, offspring to women potentially exposed to Pb
had a significantly increased risk of low birth weight (RR=1.34, CI 1.12-1.60) and
neural tube defects (RR=2.87; CI 1.05-6.38) (Irgens et al 1998). However, the
study is fairly blunt, since job titles (the exact procedure is not described) were
used as a surrogate to measure degree of Pb exposure, which is open to mis-
classification. Further, some of the job titles used were obtained 10 years before
conception. Moreover, there is a risk of confounding by smoking and occupational
exposure to other chemicals. Also, there is a risk of multiple inference, since
many associations were tested. Risk of neural tube defects were also associated
with Pb in drinking water (25% increase for each 10% increase of houses in the
area with >10 µg Pb/L; the origin of Pb was pipes, lined tanks or solder) in
Lancashire, UK, though the risk estimate was reduced by inclusion of
socioeconomic deprivation in the epidemiological model (Bound et al 1997).
The authors speculated that the mechanism was interaction with zinc, which
impairs folate absorption.
In a review of studies on maternal occupation and birth defects, it was
concluded that the associations were equivocal and often controversial (Shi &
Chia 2001). Many reported associations were only suggestive and hampered by
methodological problems. As to Pb, there was almost no valid information.
8.1.2.4. Neurobehavioural and other effects in the offspring
US adults, who had suffered Pb encephalopathia below age 4, were inferior
to controls in cognitive tasks, and they had a lower lifetime occupational status
(White et al 1993). Also, they had higher proportions of spontaneous abortions
and stillbirth, and their children more often had learning disabilities (Hu 1991b).
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In a series of meta-analyses, using data from some of the cross-sectional studies
off school-age children reviewed in 1991 (Skerfving 1992 and 1993), it was
concluded, that a decrease of one IQ point was seen for every 20-40 µg/L change
in B-Pb, with a steeper slope (ie, a greater effect) at high B-Pbs than at low ones;
an increase of B-Pb from 100 to 200 µg/L was associated with a decrease by
approximately 2.6 IQ points (Schwartz 1994). A shortcoming of the analysis was
a lack of analysis of population variation or uncertainty. The analysis showed no
threshold, down to a B-Pb of 10 µg/L. Similar estimates have been reported later,
with a net decrease of 3.4 (CI 1.1-5.0) IQ points at 150 µg/L (WHO 2000b). A
working group of the US CDC (2004) concluded that, while available evidence
did not permit a definite causal interpretation of the observed associations
between higher B-Pbs in the range <100 µg/L and adverse health indicators, the
weight of the available evidence favored, and did not refute, the interpretation that
these associations were, at least partial, causal, though the possibility of residual
confounding and other factors left considerable uncertainty.
Since 1991, a series of additional cross-sectional studies of general populations,
with varying exposure intensities, have been reported [in Denmark (Damm et al
1993; Nielsen et al 2000); New Zealand (Ferguson et al 1993); Germany
(Walkowiak et al 1998); China (Shen et al 1998); NHANES III (Lanphear et al
2000); Croatia (Prpic-Majic et al 2000); Saudi Arabia (Al-Saleh et al 2001);
Mexico (Calderón et al 2001); Pakistan (Rahman et al 2002); Taiwan (Wang et al
2002)]. The studies examined 80-4,853 infants or children, up to age 16. Mean B-
Pb ranged 29.4-973 µg/L. However, taken together they add little to the under-
standing of low exposure to Pb on cognitive functions (Koller et al 2004).
In a cross-sectional study of 301 children (age 11) from Pittsburgh,
Pennsylvania, USA, there was a slight, but statistically significant, association
between tibia-Pb class and assessments of delinquent behavior (Needleman et
al 1996). Curiously, in that study, the IQ was positively correlated with tibia-Pb
(although this effect was entirely due to Afro-Americans). Further, 194 arrested
and adjudicated youths aged 12-18 had higher tibia-Pb than 146 non-delinquent
controls (11.0±32.7 vs 1.5±32.1 µg/g bm) (Needleman et al 2002). The adjusted
OR to have high tibia-Pb was 4.0 (CI 1.4-11.1). In this connection, it may be
mentioned, that in the US, there is an ecological relationship (at county level)
between B-Pb levels and homicide rate (Stretesky & Lynch 2001).
Several prospective studies have been published since the review in 1991
(Skerfving 1992 and 1993).
In the Cincinatti Lead Study, Ohio, USA, there were, in 245 6-year-old
children, significant negative associations between the covariate-adjusted
achievements in a comprehensive neuromotor assessment battery, on the one
hand, and maternal first trimester (mean 0.406 µmol/L), neonatal (0.233 µmol/L)
and postnatal (maximum at 2 years, 0.824 µmol/L) B-Pbs, on the other (Dietrich
et al 1993).
In a prospective study in Boston, Massachusetts, USA, in 48 children, whose B-
Pb had never exceeded 100 µg/L at birth or at age 6, 12, 18, 24, 57 or 120 months,
there was a negative association between adjusted IQ at age 10 and B-Pb,
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although the precise shape of the dose-effect relation remained uncertain
(Bellinger et al 1992 and 1994b; Kim et al 1995b; Bellinger 2000; Bellinger &
Needleman 2003).
Around the smelter in Port Pirie, Australia, B-Pb (GM 83 µg/L at birth) in 375
children was negatively associated with adjusted cognitive performances at 2, 4
and 7 years of age (Baghurst et al 1992; Tong et al 1996, 1998 and 2000). In
connection with a decrease of mean B-Pb from 1.02 µmol/L (212 µg/L) at age 2,
to 0.38 µmol/L (79 µg/L) at age 11-13, there was no significant relationship
between the individual´s B-Pb decrease and its IQ change. The data may indicate
a long-lasting effect of damage caused in the fetus and/or infant.
In the Yugoslavia Prospective Lead Study, IQ at 3, 4, 5, 7 or 10-12 years in 390
children to women living in a smelter (mean B-Pb 309 µg/L at age 10-12) and a
control (B-Pb 61 µg/L) town displayed a negative association with prenatal and
postnatal B-Pb (Factor-Litvak et al 1999; Wasserman et al 2000 and 2003). A
doubling of the average lifetime B-Pb (eg, an increase from 30 to 60 µg/L) was
associated with a decrease of full-scale IQ by 1.6 points. The association with
tibia-Pb (range –14.4 to 193.5 µg/g bm) at age 10-12 was closer than with B-Pb.
In the Mexico City Prospective Lead Study, 112 children were followed
between 3 and 5 years of age (Schnaas et al 2000; Gomaa et al 2002). B-Pbs (-Pb
GM about 100 µg/L) measured in cord blood (eg, 50 to 100 µg/L) was negatively
associated with adjusted intellectual function, while postnatal B-Pbs were not.
This had also been seen in other studies.
In an important study of 172 children in Rochester, New York, USA, in whom
B-Pbs were measured serially between the ages 6 months to 5 years, 101 did not
have a recorded B-Pb >100 µg/L (Canfield et al 2003; additional information in
Koller et al 2004). Strong and significant negative associations between B-Pb and
adjusted IQ (0.74 points per 10 µg/L) were observed at 3 and 5 years. There were
indications that the effect was larger at lower B-Pbs than at higher ones.
In 79 infants from Atlanta, Georgia, USA, memory at age 7 months was
negatively associated with maternal B-Pb (7.2±8.8 µg/L) (Emory et al 2003).
However, the authors urge caution because of the small number of infants.
In a thorough review of some of the recent prospective studies of children, it
was concluded, that even at B-Pbs consistently <100 µg/L, there was intellectual
impairment (Koller et al 2004). However, Pb exposure was believed to account
for only a small amount (1-4%) of the total variation in cognitive ability, social
and parenting factors for 40%, or more.
Critics have questioned the importance of such a small decrements of IQs of
individual children. However, the tests are blunt instruments for detecting subtle
changes in brain function. Further, even small changes of IQ in large numbers of
children will dramatically increase the proportion of children with low (eg, <80),
and decrease the fraction with high (>120).
It should be stressed, that the confounding and effect-modification issues are
very complicated (Bellinger 2000). Hence, over- and/or under-adjustment or
incorrect inference may easily occur. Also, the limits of the precision of analytical
and psychometric measurements increase the uncertainty of any estimate of effect,
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especially at B-Pbs <100-150 µg/L. Hence, if a threshold exists, it is unlikely
to be detected.
In a study of neuropsychological performance in 19-20 year-olds, those who
had had high deciduous tooth-Pb performed less in several tests, while there were
few associations with current patella-Pb or tibia-Pb (Bellinger et al 1994a). Five
children with the ALAD2 genotype had low dentine-Pb and consistently better
performance (for some reason adjusted for dentine-Pb), as compared to 67
children with ALAD1, though the effects were small.
Pb-associated declines in mental development are not reversed by chelation
(Rogan et al 2001; Liu et al 2002). However, conflicting results have been
reported (Ruff et al 1993 and 1996), although that study has been severely
criticized.
In Boston, deciduous dentine-Pb (but not tibia-Pb) was associated with body
mass index (BMI) at age 13 (Kim et al 1995b). In a case-referent study in
Baltimore, Maryland, USA, there were no clear association between estimated
occupational exposure to Pb in the mothers from conception through age 9 months
and strabismus in the offspring (Hakim et al 1991).
8.1.3. Summary
There is some information indicating an effect of Pb on female sexual maturation.
Also, limited information may mean that Pb causes a delay of time-to-pregnancy.
Pb is embryotoxic and fetotoxic in experimental animals. Pb exposure in man is
associated with spontaneous abortion. It seems that such effects may occur
already at B-Pbs about 0.5 µmol/L (Table 2), although there is a risk of con-
founding. The mechanism for inducing pregnancy loss is not clear. Besides pre-
conceptional chromosome damage (in the egg cell or in the testis, see below) or a
direct teratogenic effect on the fetus, interference with the maternal/fetal hormone
environment or developmental toxicity to the embryo/fetus are possible. Also,
vascular effects on the placenta are plausible; elevated blood pressure during
pregnancy means increased risks to both the mother and fetus (reduced birth
weight, abruptio placentae and perinatal mortality).
During pregnancy, Pb is is mobilized from the skeleton of the pregnant woman,
causing an increase of B-Pb. A large part of that amount, and of recently absorbed
Pb is transferred through the placenta into the fetus. The available information
does not support a teratogenic effect (malformations) in man. However, several
studies had shown effects on the fetus, including reduction of gestational age,
birth weight and disturbance of heme synthesis. Associations between Pb ex-
posure and size of the newborn have occasionally been reported at mean B-Pb in
the mothers even <0.1 µmol/L (Table 2). However, again unadjusted confounding
may be a problem. Reduced fetal growth is of particular interest, since it may
predict later cardiovascular, neurologic and metabolic disorders.
Further, retardation of neurobehavioural development and growth, as well as
electrophysiological and hearing changes have in a long series of studies of
infants and children been shown to be associated with B-Pbs in the mother,
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newborn, infant and child. It is not known which period that is most critical.
For example, the in utero exposure is often related to postnatal uptake of Pb.
During lactation, there is also a mobilization of Pb from the skeleton of the
woman. Pb is excreted into the milk. A large fraction of the Pb is absorbed by
the infant and transferred into the fetal CNS.
Although there are many methodological problems in such studies, there were
indications, that effects may occur even at B-Pbs in the pregnant woman and
infant of only 0.5 µmol/L, perhaps even lower (Table 2). Although the effect in
the individual is small, as is the fraction of the total variance of the CNS function
explained by Pb, the effect is definitely adverse. The reversibility of the effects is
not adequately known, but they seem to be at least partly irreversible.
In an attempt to calculate the global burden of disease because of Pb-induced
mild mental retardation, the estimate was 9.8 million DALYs, mostly in the West
Pacific, South East Asia and Central and South America regions (Fewtrell et al
2004).
8.2. Male
8.2.1. State of the art 1991
In 1991 (Skerfving 1992 and 1993), it was concluded that Pb had caused
disturbances of the hypothalamic-pituitary-testis endocrine axis, testis damage
and sperm defects in experimental animal studies. The studies in man were few
and not fully conclusive. However, there were some indications of various effects
of occupational Pb exposure on the hypothalamus-pituitary-testis axis. Moreover,
decreased libido, sperm quality and concentration and other effects on the testis
had been indicated. It seemed reasonable to assume, that B-Pbs of about 2-3
µmol/L, or higher, are associated with both endocrine dysfunction and sperm
changes.
8.2.2. Update
Effects of paternal Pb exposure on reproduction has been reviewed (Tas et al
1996).
8.2.2.1. Endocrine function
122 Chinese Pb workers (mean B-Pb 352, range 96-774 µg/L) had slightly higher
plasma levels of luteinizing (LH) and follicle stimulating (FSH) hormones (but
not testosterone or prolactin) than 49 non-exposed ones (B-Pb 83, range 26-148
µg/L) (Ng et al 1991). In the B-Pb range 100-400 µg/L, the LH and FSH
concentrations increased.
In a study of 98 Pb workers (mean B-Pb 367, range 119-659 µg/L) and 51
unexposed referents (B-Pb 103, 67-208 µg/L), parameters of prostate secretory
function and serum testosterone and estradiol displayed associations with B-Pb
(Telisman et al 2000).
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Male Swedish Pb workers (mean B-Pb 332, range 83-932 µg/L) also displayed
minor changes in their male endocrine function (lower serum levels of FSH levels
after challenge with gonadotrophin-releasing hormone) than unexposed referents
(B-Pb 8-62 µg/L) (Erfurth et al 2001). There were no effects on basal serum levels
of sex-hormone binding globulin or testosterone. The data indicate an effect of Pb
on the pituitary level.
8.2.2.2. Effects on sperms
In five Taiwanese occupationally Pb-exposed battery workers (mean B-Pb
436±112 µg/L), the total semen-Pb was 411±274 µg/L, while in eight controls (B-
Pb 105±77 µg/L), it was 219±165 µg/L (Kuo et al 1997). As in all semen studies,
there was a considerable selection of workers willing to participate.
In a study of 38 battery workers (mean B-Pb 656, range 405-980 µg/L) and 30
referents (235, 176-260 µg/L), there were significant reductions (about 30%) of
sperm count and motility, as well as a decrease of dead and an increase (two
times) of abnormal sperms, but no dose-response relationship within the exposed
group (Lerda 1992). On the other hand, in another battery-worker study (current
B-Pb 280-930 µg/L), there was no association between the Pb exposure and sperm
concentration or count (Robins et al 1997). However, the number of workers with
low B-Pb was limited; hence, the exposure contrast may have been too small.
In a study of 98 Pb workers (mean B-Pb 367, range 119-659 µg/L) and 51
unexposed referents (B-Pb 103, 67-208 µg/L), there were dose-dependent
decreases in sperm concentration, and motile, viable and morphologically normal
sperms, as functions of B-Pb (Telisman et al 2000). B-Pb correlated with semen-
Pb, and on the same level, which is in accordance with findings in Thai battery
workers (Aribarg et al 1996). However, in the latter ones there was no association
between semen-Pb and quality, which was neither the case in Finnish workers
without occupational Pb exposure (Hovatta et al 1998).
In a European study, of 362 male Pb workers (mean B-Pb 310, range 46-
645 µg/L) employed in 10 companies (battery factories, Pb smelter, Cu alloy
foundries) and 141 referent workers (44-198 µg/L), the median sperm
concentration was reduced by 49% in subjects with B-Pb >500 µg/L (Bonde
et al 2002). There seemed to be a threshold at about 440 µg/L. Abnormal sperm
chromatin structure was not related to B-Pb. Neither was there any relation
between time-integrated B-Pb (up to about 5,090 µg/L x year) and effects. A
problem with the study (as in any sperm investigation) was the low participation
rate (18%), which may have caused selection bias. In the 165 workers studied,
there were strong associations between Pb in seminal plasma (average 19 µg/L),
spermatozoa (320 µg/L) and blood (280 µg/L). There was a significant decline of
sperm count and semen volume with rising spermatozoa-Pb, and some indications
of deterioration of sperm chromatin at high concentrations.
In a longitudinal study of 19 Danish battery workers, significant improvements
were seen in the proportion of motile semen cells and in egg penetration parallel
to a decrease of B-Pb from 2.03 to 0.96 µmol/L, but no change of sperm cell
concentration or morphological abnormalities (Viskum et al 1999).
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In 106 smelter workers, the log values of total sperm count was inversely
correlated with B-Pb (mean about 230 µg/L), but this association did not vary
significantly by ALAD genotype, although there was a tendency of lower values in
ALAD1 subjects (Alexander et al 1998). However, the selection was tremendous.
Among 35 Chinese males of the general population attending a andrology
clinic, there was no difference in B-Pb between asthenozoospermic (72±62 µg/L)
and normozoospermic (51±24 µg/L) subjects (Chia et al 1992). The authors
believe (for unclear reasons), that the difference is due to chance.
In 76 Singapore non-occupational exposed males, the mean level of Pb in blood
was 82.6 (range 33.0-184) µg/L and in seminal plasma 12.4 (8.1-19.0) µg/L,
without any correlation (Xu et al 1994). In 221 men, there were no correlations
between sperm density, motility, morphology or semen volume and B-Pb (mean
B-Pb 77.2±31.3 µg/L) or seminal plasma Pb (12.7±2.9 µg/L) (Xu et al 1993). In
56 males, the GM seminal Pb was 7.8 µg/L (CI 4.6-13.1) µg/L (Xu et al 2003).
When seminal Pb was >10 µg/L, there were a reduction of sperm density and
sperm number per ejaculum. However, a weak correlation was seen between
oxidative DNA damage (8-hydroxy deoxyguanosine=8OHdG).
In 64 “apparently healthy men” of a university clinic staff, there was an inverse
association between sperm viability and seminal plasma-Pb (mean 125±80 to
60±20 µg/L in different groups) (Dawson et al 1998). Similar patterns were seen
for Cd and aluminum.
8.2.2.3. Fertility
Among 681 Italian healthy adult males, who submitted a semen sample because of
couple infertility, there was no increase of men who, in a questionnaire, reported
occupations with plausible exposure to Pb (Figà-Talamanca et al 1992). However,
the bluntness of the approach precludes any conclusion.
In a French battery-factory, 229 Pb-exposed male workers (exposure ≥1 year;
mean B-Pb 463±152 µg/L) did not differ with regard to fertility (live births during
an average follow-up time of 4.1 years) from 125 non-exposed ones (B-Pb not
defined!) (Coste et al 1991). ORs adjusted for factors claimed to be potential
confounders (including age and exposure to heat, but not contraceptives) ranged
0.79-1.20 in different B-Pb groups.
In 74 Belgian battery factory workers (mean B-Pb 463, range 240-750 µg/L)
and 138 “unexposed” controls (B-Pb 104, 44-190 µg/L), the probability of a
live birth was somewhat greater in the Pb exposed subjects before the onset of
exposure (adjusted OR=1.31, CI 0.98-1.76), while a decrease in fertility was
observed during the period of exposure (OR=0.65, CI 0.43-0.98) (Gennart et al
1992b). However, none of the variables reflecting exposure duration or intensity
were found to be significantly associated with fertility, although there was a
tendency of decreased fertility with increasing duration of exposure.
Lin et al (1996) examined the standardized fertility ratio (SFR) 1981-92 in
4,256 New York State workers exposed to Pb, as compared to 748 bus drivers.
There was no association between B-Pb (mean 372±110 µg/L) and fertility.
However, in Pb workers employed for >5 years, the likelihood of having a
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child was reduced, irrespective of B-Pb (adjusted SFR=0.38; CI=0.23-0.61). The
authors pledge careful interpretation, since there is a possibility of confounding
(eg, by marital status).
In 251 Italian Pb-workers and 119 controls, the time to pregnancy was shorter
(sic!) among the exposed subjects (although non-significantly longer among the
most heavily exposed ones), and the number of children greater (Apostoli et al
2000). However, the participation rate was low. Among Finnish Pb-exposed men,
there was an exposure-associated decrease of SFR (B-Pbs <0.5 µmol/L=1.0, 0.5-
0.9=0.92, 1.0-1.4=0.89, 1.5-1.8=0.58, ≥1.9=0.83) (Sallmén et al 1992 and 2000).
8.2.2.4. Effects on the embryo/fetus/offspring
In a review of epidemiological studies of paternal Pb exposure on risk of
spontaneous abortion, it was concluded, that there were indications of such an
effect (Anttila & Sallmén 1995). Issues surrounding male-mediated reproductive
toxicity for Pb have been more thoroughly reviewed by Apostoli et al (1998).
Further, in a general review of paternal exposures and birth defects, it was con-
cluded that in painters and painters and printers – occupation with a potential
exposure to Pb, though not exceptionally high - run an increased risk (Chia &
Shi 2002).
In a study of Norwegian printers, there were increased risks of early preterm
birth (exposure to Pb: adjusted OR= 2.0, CI=0.5-8.7; Pb and solvents: OR=8.6,
CI=2.7-27.3) and perinatal deaths (Pb: OR=2.4, CI=1.2-4.9), as compared to
national rates (Kristensen et al 1993). Paternal exposure had little impact on birth
weight, intrauterine growth or total and specific birth defects. There is an obviuos
risk of confounding, eg, by life style factors.
In a case-referent study in Baltimore, US, there was a gradual rise of the risk of
low birth weight by increasing paternal occupational Pb exposure 6 months prior
and during pregnancy (interview; classification by industrial hygienist) (Min et al
1996). In the most heavily exposed group, the adjusted OR was 4.72 (CI=1.10-
20.23; 10 out of 12 of the fathers were painters). Pb seemed to affect both
intrauterine growth and preterm birth. Adjustment was made for maternal
smoking, but there is a clear risk of confounding.
In a study of occupations in fathers of 268,109 children borne in Cumbria, UK,
1950-89, a hypothesis that Pb-exposure had affected the testosterone levels, and
thus the sex distribution of the children, could not be verified (Dickinson & Parker
1994). However, the Pb exposure in the studied occupations (professional drivers)
was probably low.
In a study of the offspring of US firemen, who had an assumed exposure to Pb
during firefighting, there was an increased risk of malformations (septal defects of
the heart) (Olshan et al 1990). In a case-referent study in Baltimore, Maryland,
USA, there were no clear association between estimated occupational exposure to
Pb in the fathers (from conception through age 9 months) and strabismus in the
offspring (Hakim et al 1991). Both studies have very weak data on Pb exposure
and obvious risks of confounding.
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In a large US study of cardiovascular malformations, paternal Pb soldering
during 6 months preceding pregnancy (as reported in an interview), was
associated with pulmonary atresia (Correa-Villaseñor et al 1993). However, such
soldering causes only low air-Pb levels. Also, paint stripping (causing organic
solvent exposure) correlated with coarctation of the aorta and ventricular septal
defects.
In a study of male printers, potentially exposed to Pb (compositors, monotype
casters and stereotyping workers; B-Pb may have been as high as 1.5-3 µmol/L),
there was no significant increase of cancers in their offspring (Kristensen &
Andersen 1992).
In a Norwegian study of the reproductive outcome as reflected in the birth
register in offspring of parents who were occupationally exposed to Pb, as judged
from the population census records, offspring to fathers potentially exposed to Pb
had no increased risk for any of the analysed birth defects (Irgens et al 1998).
Surprisingly, and opposite to exposed women (above), there was a decreased
risk of low birth weight (RR=0.91, CI 0.86-0.96).
The studies of malformations and cancers among offspring are open to
methodological problems, since the father´s occupation was often obtained from
birth certificates and job titles (sometimes 10 years before conception) were used
as a surrogate to measure degree of Pb exposure, which is open to misclas-
sification. Moreover, there is a risk of confounding by smoking and alcohol,
exposure to other chemicals and maternal exposure. Also, multiple comparisons
were made.
8.2.3. Summary
In experimental animals Pb exposure may cause effects on the male endocrine
system, as well as on the testis and sperms. In Pb-workers, semen-Pb is correlated
with B-Pb.
Pb workers have shown disturbances of the hypothalamic-pituitary-testis
endocrine axis and sperm quality. Some data may also indicate decreased libido
and decreased fertility, as well as increased risk of spontaneous abortion and
decreased birth weight in their offspring. Some of these effects (in particular
endocrine, sperm and fertility effects) have been reported at mean B-Pbs as low as
1.5-2.0 µmol/L (Table 2). However, there are methodological problems in most
studies, especially as regards selection (very low participation rate and
confounding).
9. Needs for further research
In spite of centuries of investigations into the toxicology of Pb, there is a large
number of theoretically and practically important questions which are still
unsolved. Here, only a few ones will be mentioned.
The mechanism of Pb toxicity is still not well understood. Pb competes with Zn
in proteins (ALAD and others). Also, it interferes with Ca turnover in several
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ways. Hence, there are numerous possibilities for toxic interference. More infor-
mation is needed on which aspects that are really crucial for different effects.
There is a controversy on whether the endogenous exposure from bone-Pb is a
particular risk because it affects P-Pb, which in turn hits the target organs. This
important issue should be solved.
The information on exposure-response relationships for many of the effects is
incomplete. Hence, more information is needed.
Further, while a series of routes to perform deterministic risk assessments have
been tried, there is a lack of probabilistic ones, which might contribute more
reliable and detailed estimates (Bridges et al 2003). In only a couple of papers
(WHO 2000b; Murata et al 2003) has a probabilistic approach been used.
10. Discussion and assessment
10.1. State of the art 1991
In 1991 (Skerfving 1992 and 1993), it was noted, that exposure to Pb may affect
many functions in the body: the nervous system, blood, kidney, cardiovascular,
endocrine, and immuno systems and female and male reproduction and the GI
tract. Also, there was evidence of mutagenicity and some indications of cancer.
It was stressed that there were many problems with interpretation of the
available information. Most studies were cross-sectional, which means that there
might have been a selection. Also, even in the most ambitious analyses, there was
a risk of residual confounding. Moreover, information on history of exposure was
missing. Further, many of the reported effects were subclinical and their relation-
ship to clinically relevant disease was unclear. Also, there was only rarely detailed
information on the low-exposure part of the exposure-response curve, which is a
problem, since the potential lowest observed adverse effect level (LOAEL) is
close to the “background”.
It was noted, that there are sensitive groups. Hence, there seemed to be a sex
difference in the metabolism of Pb. Further, Fe and Ca deficiencies, which are
more prevalent in women than in males, will increase the GI absorption of Pb.
Such deficiency is particularly prevalent during pregnancy, Ca deficiency during
pregnancy and lactation. Moreover, disturbance of heme metabolism is more
pronounced in women than in males. There were some indications that subjects
with certain types of porphyrias are particularly sensitive to Pb. Also, subjects
with “non-Pb” anemias, hypertension, kidney disease, disorders of the nervous
system and – possibly – some immunodeficiencies were assumed to be
particularly vulnerable.
For almost all information on exposure-response was the exposure information
in terms of B-Pb. It was concluded that sensitive adult subjects could suffer slight
- but potentially adverse - effects on the CNS and PNS and kidney at an average
B-Pb in a group of exposed subjects of about 1.5-2.0 µmol/L, or higher. Sperms
were believed to be affected at about 2 µmol/L. It was considered likely that
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fetuses suffer effects on the CNS at even lower exposures, perhaps already at 0.5-
0.75 µmol/L in the pregnant woman. There were some indications of effects on
the blood pressure at similarly low exposures.
It was estimated, that an average B-Pb of 1.5 µmol/L in subjects with a low
“background” exposure (as in Sweden) would be reached at an air level in the
occupational setting of about 27, 0.75 µmol/L at about 13 µg/m3.
It was concluded, that some chemical forms of Pb were animal carcinogens and
that there were some indications of mutagenicity in man, but no firm support for
carcinogenicity in man.
10.2. Update
Since 1991 an enormous amount of new information has been published. Pb is
certainly the by far most extensively studied toxic agent. Large Pb-worker and
general populations have been investigated. Then, some types of effects have been
reported in general population strata with low exposures, indeed in the range of
the referent groups in many studies of Pb workers. This is a problem.
Also, explanations of the formerly intriguing differences in sensitivity have
begun to appear in terms of gene-environment interactions, mainly as regards
ALAD genotype. ALAD2 has a higher binding capacity for Pb, so that such subjects
seem to have a higher B-Pb at the same exposure intensity (at least when it is not
low). However, in spite of their higher B-Pb, they may be protected from at least
some adverse effects, and may tolerate higher exposure. These phenomena may
induce selection at the work place. Hence, if B-Pb is surveyed, ALAD2 subjects
are more likely to be removed. On the other hand, if there is no such surveillance,
ALAD1 subjects may quit selectively because of early symptoms. Moreover, the
prevalences of the genes differ between races, making it less obvious to use
information from other parts of the world for evaluation of risks for Caucasians.
Pre-employment screening for ALAD genotype has been proposed. However,
this seems premature.
Moreover, while selection and confounding are often addressed, effect
modification has rarely been considered (Bellinger 2000), especially not in meta-
analyses. This has become all the more critical, when genetic influence on the
toxicity is realised.
One problem is that most studies do only allow conclusions about differences
between groups with varying exposure; hence, it is not possible to define a no
observed adverse effect level (NOAEL) or LOAEL. Also, the number of occu-
pationally exposed subjects have often been low. On the other hand, when discrete
exposure measures (B-Pb) are used in large populations, effects may be shown at
low exposures, but then at a low rate.
At the same time, very sensitive methods have been employed. Then, the
question whether the effects should really be considered adverse (ie, indicating a
health risk, and thus a basis for risk assessment) becomes more complicated.
There is still far too little information on the relationship between air-Pb and
effects. Hence, biomarkers have to be used. However, the choice of biomarkers to
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define the exposure may seem less obvious than earlier. Hence, in the last decade,
the use of in vivo determination of skeletal Pb has exploded. Thus, bone-Pb has
sometimes shown relations to effects, when B-Pb has not. This has been taken as
an indicator that the endogenous exposure is of particular importance for the
exposure of target organs (Hu & Hernandez-Avila 2002). However, it might as
well be an illustration of the well-known limitations of B-Pb (saturation at high
exposure).
Some information relating effects to P-Pb has occurred. P-Pb may have advan-
tages over B-Pb. However, P-Pb data are still too limited to make it possible to
use it in a risk assessment. As to U-Pb, there are several problems, in particular at
low exposure; also, the information on exposure-response is limited and mostly
obsolete. Further, chelatable Pb (after dosing of EDTA or DMSA, which differ),
in spite of the fact that there is quite a lot of information as regards some effects,
is not possible to use in practice, mainly because it is too complicated for risk
surveillance.
Thus, because of the wealth of information, we still have to use B-Pb, keeping
its limitations in mind. An important - and still mostly unsolved - problem, is the
time aspect of the toxic effects. Hence, it is possible that the current B-Pb is less
interesting than the time-integrated/cumulated B-Pb (or bone-Pb, which is related
to it) or the peak B-Pb. Further, the reversibility of most of the critical effects is
not known. It is perfectly clear, that some effects (kidney damage by heavy
exposure during childhood) stays for life, in spite of reduction of exposure,
but it is possible that others – at least partly - disappear.
From the above review of effects on different organs, it is clear that the focus,
from the point of view of the occupational setting, should be on two discrete
effects: Toxicity in the fetus and/or breast-fed infant, and on the blood pressure. In
the general population, neurotoxicity in children must also be considered. These
effects are adverse. It is not possible to define an overall NOAEL or LOAEL. It
might well be, that in some areas of the world, a considerable fraction of the
general population suffers effects. However, it is also clear, that the fraction of the
variance explained by Pb then is low. On an individual level, the effect of Pb on
disorders and disease processes may be subtle. However, on the population level,
Pb exposure may contribute an important fraction to the mortality associated with
theses disease processes.
10.3. Conclusion
A summary of the B-Pbs associated with various adverse and non-adverse effects
is given in Table 2.
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Table 2. Overall summary of information on at which lowest blood concentrations
(average in studied populations; µmol/L) various adverse, slight effects of lead have been
reported with some consistency. ? = Limited data, inconsistent results and/or possible/
probable confounding. - = Not relevant or not sufficiently studied.
                     Population
         General
Organ Effect  Occupational   Adults   Children
Nervous system
Central Encephalopathia1 >4.0 >4.0 >4.0
Slight symptoms 1.5-2.0 - -
Neurobehavioural 1.5-2.0 - <0.52
Peripheral Symptoms 1.5 - -
Neurophysiological 1.5 - -
Complex effects Evoked potentials 1.5 - -
Posture 1.5 - -
Hearing - - 0.5
Autonomous Heart rate variability 1.5 - -
Blood Anemia1 >3.0 >3.0 >3.0
Hemoglobin concentration 2.0-2.5 - -
Heme metabolism 0.1-0.3 - -
Nucleotide metabolism ≈0.3 - -
Kidneys Tubular 1.5 - 0.5?
Glomerular 2.0? 0.5? 0.5?
Cardiovascular Blood pressure 1.5-2.0? 0.4 1.8?
Heart rate variability 1.5 - -
Endocrine system3 Hypothalamus/pituitary/
thyroid/adrenal axes
1.5-2.0 - -
Immune system Immunosuppression 2.0 - -
Mutagenicity Chromosome aberrations,
Micronuclei, SCEs
1.5-2.0 - -
Cancer Kidney, lung4 ? - -
Reproduction
Female Abortion ? 5 0.5? -
Fetal growth - 0.1? -
Neurobehavioural - - <0.52
Male Endocrine function 1.5 - -
Sperm quality 2.0 - -
Fertility 2.0? - -
Gastro-intestinal
tract1
Obstipation, abdominal pain >3.0 >3.0 >3.0
1 See Skerfving 1992 and 1993.
2 Uncertainty whether effects are mainly due to exposure in utero or after birth.
3 Except for reproduction.
4 Uncertain.
5 Levels not clear, probably high.
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The CNS of the fetus and the breast-fed infant seems to be affected already at
a mean B-Pb in the pregnant/lactating woman of 0.5 µmol/L, probably even much
lower (Table 2). In the last decade, the importance of the mobilization of Pb from
the skeleton of the pregnant and lactating women has become perfectly clear. This
is a major source of exposure of the offspring. Considering its sensitivity, Pb
exposure in girls and fertile women should be as low as possible. Hence, before
menopause, women should not be exposed in the workplace.
Effects on blood pressure in general populations have been shown at average B-
Pbs about 0.4 µmol/L (Table 2). Effects on the kidney may perhaps start already
at a mean B-Pb of 0.5 µmol/L, a level present in many general populations.
However, there is better evidence for slight effects on the kidney at a mean B-
Pb of 1.5 µmol/L (Table 2), which is a level often present in Pb-workers, and in
the general population in some areas with high Pb exposure. Adverse effects on
the nervous and endocrine systems and male reproduction may occur at a mean
B-Pb of 1.5-2.0 µmol/L.
There is some evidence of mutagenicity (clastogenicity) and effects on the
immune system at a mean B-Pb of 1.5-2.0 µmol/L (Table 2). Adverse effects on
blood formation seem to start at about 2.0-2.5, on the GI tract at about 3 µmol/L.
Because of the dramatic decrease of B-Pb in the general population in many
areas (to about 0.2 µmol/L in the average adult Swedish male), it may be argued
that the space for occupational exposure has increased somewhat.
It is not easy to translate these B-Pbs into Pb concentrations in air. Part of
the uptake in occupational settings occurs via oral ingestion. Further, it is clear
that there is a wide difference between Pb species with varying solubilitie and
particle sizes. Also, the “background” exposure (which is low in Sweden, in an
international perspective) and the endogenous exposure from skeletal Pb depots,
caused by earlier exposure, must be considered. However, from the data presented
above (section 3.5. Toxicokinetics), it seems that the average worker would just
not reach 1.5 µmol/L if exposed to 200 µg/m3 of Pb with low solubility (sulphide
[solubility 0.86 mg/L] [CRC 1989], dust from crystal glass, etc) or to about 30
µg/m3 with high solubility (sulphate [42.5 mg/L], nitrate [376,500 mg/L], etc),
assuming small particle sizes (Figure 6). The metabolic models give the same
picture.
Several human studies indicate limited evidence that Pb is carcinogenic in man,
but definite proof is lacking. Pb chromate and arsenate are carcinogenic in man,
but that is not due to the Pb moiety.
11. Exposure standards and classifications
11.1. Occupational exposure limits
The present Swedish OEL is 50 µg/m3 for respirable dust and 100 µg/m3 for total
dust (Swedish NBOSH 2000). As to biological exposure/risk monitoring, Pb work
is considered to be present when samples from at least one out of ten workers
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show a B-Pb ≥0.8 µmol/L (Swedish NBOSH 1992). Such workers shall be
surveyed medically (occupational and medical history, physical examination,
blood pressure and blood hemoglobin and Pb and urinary protein concentrations).
Such periodical examination of Pb workers shall be organized within 1 month
after start of work, and then each third month (if ≤1.5 µmol/L three times each
sixth month). A worker with >2.5 (women <50 years >1.5, since Pb is classified
as a reproductive toxin) µmol/L, is not allowed to work with Pb until the B-Pb is
<2.0 (<1.2) µmol/L. The same applies to workers who have >2.0 (>1.2) µmol/L at
three consecutive examinations. Pregnant and lactating women are not allowed to
work with Pb. Chromates (including Pb chromate) and inorganic As compounds
(including Pb arsenate) are classified as carcinogens.
The OEL in the European Union is 150 µg/m3 (EU 1998a). Medical surveys
shall be made if the air-Pb is >75 µg/m3 (TWA during a 40-hour week) or if the
B-Pb is >400 µg/L in an individual worker. However, the Scientific Committee on
Occupational Exposure Limits (EU SCOEL, in press) has recommended an OEL
of 100 µg/m3 (fumes and dust) and a biological limit value for B-Pb of 300 µg/L
(for both males and females). It is noted, that it is not easy to set an OEL for
airborne Pb, since a considerable fraction of the Pb is ingested orally. Further, the
B-Pb is not seen as entirely protective for the offspring of working women; no
threshold for potential CNS effects in newborn and infants could be identified.
In Norway (Norwegian Directory of the Labour Inspectorate 2003) and
Denmark (Danish Labour Inspectorate 2002), the OEL is 0.05, in Finland 0.1
(Finnish Social Wellfare and Health Agency 2002), and in the United Kingdom
0.15 (UK Health and Safety Executive 2002) mg/m3.
In Germany, the air limit (Maximale Arbeitsplatzkonzentration; MAK) is 0.1
mg/m3 (for Pb and its inorganic compounds, except Pb arsenate and chromate;
excursion factor 2 for a maximum of 15 min, maximum four per shift with an
interval of 1 h) and the biological limit value (Biologischer Arbeitsstofftoleranz-
wert; BAT) 400 µg/L. A BAT of 100 µg/L for women <45 years has been
proposed, based on the background load in the general population (Deutsche
Forschungsgemeinschaft 2003). Pb was classified as animal carcinogen and
potentially fetotoxic.
In the US, ACGIH (2001 and 2003) has given a threshold limit value (TLV) for
Pb and its inorganic compounds of 0.05 mg/m3 and consider them to be confirmed
animal carcinogens with unknown relevance to humans. Pb chromate has the
same TLV, but is listed as a suspected human carcinogen. Pb arsenate has a TLV
of 0.15 mg/m3 as the total compound, in order to also protect from the toxic
effects of As. The recommended Biological Exposure Index (BEI) for elemental
and inorganic Pb is 300 µg/L blood, with a special warning, that women with a B-
Pb >100 µg/L are at risk of delivering a child with a B-Pb over the US CDC
(1997) guideline of 100 µg/L, which should not be exceeded.
The US OSHA (1998) permissible exposure limit is 50 µg/m3 (action limit 30
µg/m3). There is a requirement for monitoring of B-Pb, medical surveillance and
reduction of exposure when the worker B-Pbs are ≥400 µg/L; at ≥600 µg/L the
worker should be removed from exposure. There are no additional restrictions for
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women. It may be mentioned, that in the US, the current goal of the Department
of Health and Human Services is to eliminate all occupational exposures resulting
in B-Pb >250 µg/L (1.2 µmol/L).
In Japan, the OEL is 0.1 mg/m3 and the occupational exposure limit based on
biological monitoring 400 µg/L (Japan Society for Occupational Health 2002).
11.2. Other assessments
11.2.1. Environmental exposure
In the US, the Centers for Disease Control and Prevention in 1991 identified a
goal to reduce children´s B-Pb below 100 µg/L (US CDC 1991). Interventions
for individual children were recommended at levels of 150 µg/L and above.
The WHO B-Pb level of concern is 200 µg/L (WHO/ICPS 1995). Later, a
critical B-Pb level of 100 µg/L was given (WHO 2000a).
In Germany, as to “human biological monitoring values” for B-Pb for the
general population, no risk was assumed at 100 µg/L in children <12 years and
women in the reproductive age, and 150 µg/L in men >45 years, increased risk
of adverse effects at 150 and 250 µg/L, respectively (Ewers et al 1999).
The EU (1999) ambient air quality guideline for Pb is 0.5 µg/m3 on an annual
basis. This is to be met 2005; in the immediate vicinity of specific industrial
sources, the value is 1 µg/m3 until 2010. In the US, the ambient air quality
standard is 1.5 µg/m3 (quarterly average) (US EPA 2003). The level 0.5 µg/m3
has been adopted by Sweden (Ministry of the Environment 2001).
A provisional tolerable weekly intake (PTWI) of 25 µg/kg bw through food and
drinking water has been established for all age groups by the Joint FAO/WHO
Expert Committee on Food Additives (JEFCA 1999; WHO 2000b).
The tolerable concentration of Pb in drinking water in the EU (1998b) and
Sweden is 10 µg/L (National Swedish Food Agency 2001). This is based on a
health-based guideline value for bottle-fed infants (provisional tolerated weekly
intake 25 µg/kg bw=3.5 µg/kg bw/day; bw 5 kg; 50% allocation to water; 0.75
L/day; rounded figure) (WHO 2003).
11.2.2. Cancer and reproduction
International Agency of Research on Cancer (IARC 1987), on the basis of animal
experiments, determined that Pb is possibly a human carcinogen (Group 2B).
A series of inorganic Pb species have been classified as having (Repr1), or
possibly having (Repr3), effects on fertility (R60, R62) and the human embryo/
fetus/offspring (R6, R63) by the EU and Sweden (KemI 2001).
Pb acetate, Pb chromate, Pb chromate molybdenum sulphate, Pb chromate
sulphate and Pb hydrogen arsenate have been classified as possibly carcinogenic
to man (Canc3; R40) by the EU and Sweden (KemI 2001).
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12. Summary
Pb is certainly the most extensively studied toxic agent. Occupational exposure
occurs in a wide variety of settings. However, the exposure levels have decreased
considerably in the last decades. There is also exposure in the general environ-
ment. For many years, the US ATSDR (1999) has considered Pb to be the toxicant
that poses the greatest risk. After the ban of Pb addition to petrol, there has been a
dramatic decrease of the exposure in several parts of the world. From an inter-
national perspective, Swedes have a low exposure.
Exposure to Pb is most often assessed by biological monitoring, mainly often
by determination of B-Pb. This index has limitations, especially since there is
saturation at high exposure. P-Pb has advantages, but the experience is too meagre
yet. Pb is accumulated in the skeleton, where the concentration reflects long-term
uptake, and where it may be determined by in vivo methods.
At Pb exposure, there are toxic effects on the CNS and PNS, the blood
(including inhibition of heme synthesis, which will also affect all other cells), the
kidney, the cardiovascular, endocrine, immune systems and the GI tract. There
are also effects on male reproduction (sperm quality).
Pb passes the placenta barrier and may cause toxic effects on the nervous
system of fetuses. Slight (but adverse) effects on the mental development of
infants have repeatedly been reported at a mean B-Pb of 0.5 µmol/L, or even less,
in the pregnant woman. As Pb is accumulated in the skeleton, mobilized during
pregnancy and lactation, and is transferred to the fetus/infant, premenopausal
women are a group of great concern.
Epidemiological studies of exposure-response relationships for slight toxic
effects of Pb suffer methodological problems, eg, in terms of selection bias and
confounding. However, they permit conclusions on the relationships between
different effects and B-Pb.
The current average B-Pb in adult Swedish males is about 0.2 µmol/L, lower in
women, adolescents and children.
Effects on the heme synthesis occur at the B-Pbs in general populations with
low exposure. There are indications of slight effects on the blood pressure right
down to a mean B-Pb of about 0.4 µmol/L. On a population basis, this may mean
an increased risk of coronary heart and cerebrovascular diseases.
There is evidence for slight effects on the kidney at a mean B-Pb of 1.5 µmol/L,
which is a level often present in Pb workers, as well as in the general population
in some areas of the world with high Pb exposure. Adverse effects on the nervous
and male reproduction may also occur at a mean B-Pb of 1.5 µmol/L.
There is some evidence of mutagenicity (clastogenicity) and effects on the
endocrine and immune systems at a mean B-Pb of 1.5-2.0 µmol/L. Adverse
effects on blood formation seem to start at about 2.0-2.5, on the GI tract at about
3 µmol/L.
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The average worker would just not reach 1.5 µmol/L if exposed to 200 µg/m3 of
Pb with low solubility (sulphide, dust from crystal glass, etc), or to about 30
µg/m3 with high (sulphate, nitrate, etc), assuming small particle sizes.
Pb is carcinogenic in animal experiments, but there is only limited evidence for
carcinogenicity in humans.
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13. Summary in Swedish
Av alla toxiska substanser är bly utan tvekan den mest undersökta. Yrkesmässig
exponering för bly förekommer i många olika arbetsmiljöer. Exponeringsnivåerna
har emellertid minskat väsentligt det senaste årtiondet. Exponering förekommer
även i omgivningsmiljön. I många år ansåg amerikanska myndigheter att bly var
den toxiska substans som utgjorde den största risken för hälsan (US ASTDR
1999). Efter det att blytillsatser i bensin förbjöds, har det i stora delar av världen
skett en dramatisk minskning av exponeringen för bly. I ett internationellt
perspektiv har vi i Sverige låga exponeringsnivåer för bly.
Blyexponering uppskattas oftast med biologisk exponeringsmätning, vanligast
är att mäta halten bly i blodet. Emellertid har detta mått begränsningar, bl.a.
mättas blodbly vid högre exponeringar. Att i stället mäta bly i plasma har vissa
fördelar men erfarenheten av detta exponeringsmått är än så länge begränsad. Bly
ackumuleras i skelettet och skeletthalten som kan mätas med in vivo-metoder
speglar långtidsexponeringen.
Blyexponering kan orsaka effekter på centrala och perifera nervsystemet, blodet
(inkluderat hämning av hemsyntesen vilket också påverkar alla celler i kroppen),
njurarna, mag-tarm-kanalen, hjärt-kärl- och immunsystemet samt det endokrina
systemet. Effekter ses också på det manliga fortplantningssystemet (spermie
kvalitén).
Bly passerar placentabarriären och kan skada nervsystemet hos fostret. Lätta,
men ändock skadliga, effekter på den mentala utvecklingen hos barn har rappor-
terats i ett flertal studier när modern under graviditeten haft en medelhalt av
blodbly på 0,5 µmol/L, kanske även t.o.m. lägre. Eftersom bly ackumuleras i
ben, frigörs under graviditet och amning och transporteras till fostret/det diande
spädbarnet, utgör flickor och fertila kvinnor en grupp som är speciellt viktig att
ta hänsyn till med tanke på effekter på avkomman.
Epidemiologiska studier av dos-responssamband för lätta toxiska effekter av bly
är behäftade med metodologiska problem, t.ex. selektionsbias och confounding.
Det går dock att dra slutsatser om förhållandet mellan blodblyhalt och olika
effekter.
Hos svenska män är för närvarande medelvärdet för blodbly ca 0,2 µmol/L.
Medelvärdet är lägre hos kvinnor, ungdomar och barn.
Hemsyntesen påverkas vid halter av blodbly som förekommer vid låg
exponering i den allmänna befolkningen. Det finns tecken på att blodtrycket
påverkas vid medelblodblyhalter ända ner till 0,4 µmol/L. På populationsbasis
kan detta innebära en ökad risk för hjärt-kärlsjukdom.
Det finns belägg för att lätta effekter på njurarna uppträder vid en medel-
blodblyhalt på 1,5 µmol/L. Detta är en blodblynivå man ofta finner hos
blyarbetare och i den allmänna befolkningen i områden av världen med hög
blyexponering. Skadliga effekter på nervsystemet och manlig fortplantnings-
förmåga uppträder också vid en blyblodhalt på 1,5 µmol/L.
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Det finns en del belägg för att bly är mutagent (klastogent) och att effekter på
det endokrina systemet och immunsystemet uppträder vid en medelblodblyhalt
på 1,5-2,0 µmol/L. Skadliga effekter på blodbildningen och på mag-tarmkanalen
verkar börja uppträda vid en blodblyhalt på 2,0-2,5 respektive 3 µmol/L.
Det har uppskattats att personer som är yrkesmässigt exponerade för
blyföreningar med liten partikelstorlek (≤1 µm) och låg vattenlöslighet (t.ex.
sulfid, damm från kristallglas m.m.) sällan uppnår en blodblyhalt på 1,5 µmol/L
vid en luftexponering på 200 µg/m3. Motsvarande luftvärde för blyföreningar
med hög vattenlöslighet (t.ex. sulfat, nitrat, etc.) är 30 µg/m3.
Bly är carcinogent på försöksdjur, men endast begränsade belägg för carcino-
genicitet hos människa föreligger.
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